# PeptideScanner evidence objects: Liraglutide

Every published version of the records placed with Liraglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/liraglutide.json. Selected public evidence only; not medical advice.

- Objects: 169
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00318461-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT00318461

> PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00318461-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00318461-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00318461-liraglutide-v1
- Content SHA-256: `3ccd4f96e4e10f9db68cbf8d6fb8996b3866c934043c670c36062ccd85fea58d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00318461 ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

### Sources

<a id="source-ctg-observation-nct00318461-2017-03-07-b420376245a1"></a>
- **ClinicalTrials.gov record NCT00318461 · retained source version 2017-03-07:b420376245a19be08a4635d7fd337be76cd7ec699d0ec5c178d5cba831a84916** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00318461) (`ctg-observation-nct00318461-2017-03-07-b420376245a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00318461." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00318461-liraglutide-v1 SHA-256: 3ccd4f96e4e10f9db68cbf8d6fb8996b3866c934043c670c36062ccd85fea58d.

---

<a id="clinicaltrials-gov-nct00422058-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT00422058

> PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00422058-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00422058-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00422058-liraglutide-v1
- Content SHA-256: `88e38d77e3102f340164feb1f7aabc7b11691bec85a6d18a21671f0c6945180a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00422058 ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`](#source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa))

### Sources

<a id="source-ctg-observation-nct00422058-2017-11-01-d2810fdb94aa"></a>
- **ClinicalTrials.gov record NCT00422058 · retained source version 2017-11-01:d2810fdb94aaad83aa65edb19700814dd2561b3d9e562d1099bb77a78ed0c4e1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00422058) (`ctg-observation-nct00422058-2017-11-01-d2810fdb94aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00422058." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00422058-liraglutide-v1 SHA-256: 88e38d77e3102f340164feb1f7aabc7b11691bec85a6d18a21671f0c6945180a.

---

<a id="clinicaltrials-gov-nct00781937-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT00781937

> PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00781937-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00781937-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00781937-liraglutide-v1
- Content SHA-256: `d950faf638d6ad36f3fe5d42d95f4fbed0ddce8438d82df834d01b73b3002412`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00781937 ([`ctg-observation-nct00781937-2017-11-01-77658bf61c38`](#source-ctg-observation-nct00781937-2017-11-01-77658bf61c38))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00781937-2017-11-01-77658bf61c38`](#source-ctg-observation-nct00781937-2017-11-01-77658bf61c38))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00781937-2017-11-01-77658bf61c38`](#source-ctg-observation-nct00781937-2017-11-01-77658bf61c38))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00781937-2017-11-01-77658bf61c38`](#source-ctg-observation-nct00781937-2017-11-01-77658bf61c38))

### Sources

<a id="source-ctg-observation-nct00781937-2017-11-01-77658bf61c38"></a>
- **ClinicalTrials.gov record NCT00781937 · retained source version 2017-11-01:77658bf61c38a1ec4b24b61c09680fa751389a69f50a5142a04ded8d93246d28** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00781937) (`ctg-observation-nct00781937-2017-11-01-77658bf61c38`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00781937." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00781937-liraglutide-v1 SHA-256: d950faf638d6ad36f3fe5d42d95f4fbed0ddce8438d82df834d01b73b3002412.

---

<a id="clinicaltrials-gov-nct00873223-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT00873223

> PeptideScanner retained ClinicalTrials.gov record NCT00873223 at 2026-07-30T21:25:36.788Z. Its registry update date was 2017-01-26, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00873223-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00873223-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00873223-liraglutide-v1
- Content SHA-256: `a6c6651eb9534fdd001e190faa7725b664ca4a3a86fe99322049dae7f62620ca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00873223 ([`ctg-observation-nct00873223-2017-01-26-e763c897968f`](#source-ctg-observation-nct00873223-2017-01-26-e763c897968f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00873223 at 2026-07-30T21:25:36.788Z. Its registry update date was 2017-01-26, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00873223-2017-01-26-e763c897968f`](#source-ctg-observation-nct00873223-2017-01-26-e763c897968f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00873223 at 2026-07-30T21:25:36.788Z. Its registry update date was 2017-01-26, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00873223-2017-01-26-e763c897968f`](#source-ctg-observation-nct00873223-2017-01-26-e763c897968f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00873223-2017-01-26-e763c897968f`](#source-ctg-observation-nct00873223-2017-01-26-e763c897968f))

### Sources

<a id="source-ctg-observation-nct00873223-2017-01-26-e763c897968f"></a>
- **ClinicalTrials.gov record NCT00873223 · retained source version 2017-01-26:e763c897968f46969c83f36e1c7c2a66ac5008d7d9a1e569e329b17203ae3984** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00873223) (`ctg-observation-nct00873223-2017-01-26-e763c897968f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00873223." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00873223-liraglutide-v1 SHA-256: a6c6651eb9534fdd001e190faa7725b664ca4a3a86fe99322049dae7f62620ca.

---

<a id="clinicaltrials-gov-nct00978393-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT00978393

> PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00978393-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-07-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00978393-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00978393-liraglutide-v1
- Content SHA-256: `ca32f96f8d427c86db0ba0a9f4d02e11a9d693058284716951fd3228e6e6a678`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00978393 ([`ctg-observation-nct00978393-2017-07-27-fed03f0455b8`](#source-ctg-observation-nct00978393-2017-07-27-fed03f0455b8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00978393-2017-07-27-fed03f0455b8`](#source-ctg-observation-nct00978393-2017-07-27-fed03f0455b8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00978393-2017-07-27-fed03f0455b8`](#source-ctg-observation-nct00978393-2017-07-27-fed03f0455b8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00978393-2017-07-27-fed03f0455b8`](#source-ctg-observation-nct00978393-2017-07-27-fed03f0455b8))

### Sources

<a id="source-ctg-observation-nct00978393-2017-07-27-fed03f0455b8"></a>
- **ClinicalTrials.gov record NCT00978393 · retained source version 2017-07-27:fed03f0455b8d4679da32a76c225d8335cd0985a666c1739a6acd19ef3b33bbd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00978393) (`ctg-observation-nct00978393-2017-07-27-fed03f0455b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00978393." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct00978393-liraglutide-v1 SHA-256: ca32f96f8d427c86db0ba0a9f4d02e11a9d693058284716951fd3228e6e6a678.

---

<a id="clinicaltrials-gov-nct01128894-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01128894

> PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01128894-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01128894-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01128894-liraglutide-v1
- Content SHA-256: `27664c2edc1a59740f70e2070de1b6cebdfc0a2e1a6fcaa283771746c075d4e0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01128894 ([`ctg-observation-nct01128894-2017-02-23-b22edff3f045`](#source-ctg-observation-nct01128894-2017-02-23-b22edff3f045))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01128894-2017-02-23-b22edff3f045`](#source-ctg-observation-nct01128894-2017-02-23-b22edff3f045))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01128894-2017-02-23-b22edff3f045`](#source-ctg-observation-nct01128894-2017-02-23-b22edff3f045))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01128894-2017-02-23-b22edff3f045`](#source-ctg-observation-nct01128894-2017-02-23-b22edff3f045))

### Sources

<a id="source-ctg-observation-nct01128894-2017-02-23-b22edff3f045"></a>
- **ClinicalTrials.gov record NCT01128894 · retained source version 2017-02-23:b22edff3f04587639a619ae511638e98572862b18bd2b46559d68a3bd329c59a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01128894) (`ctg-observation-nct01128894-2017-02-23-b22edff3f045`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01128894." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01128894-liraglutide-v1 SHA-256: 27664c2edc1a59740f70e2070de1b6cebdfc0a2e1a6fcaa283771746c075d4e0.

---

<a id="clinicaltrials-gov-nct01179048-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01179048

> PeptideScanner retained ClinicalTrials.gov record NCT01179048 at 2026-07-30T20:48:52.462Z. Its registry update date was 2019-07-17, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01179048-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01179048-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01179048-liraglutide-v1
- Content SHA-256: `ad33109ef77397c84c4601b6184db920a956ae26afaef18b62fbd304575b4528`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01179048 ([`ctg-observation-nct01179048-2019-07-17-757a7acb706b`](#source-ctg-observation-nct01179048-2019-07-17-757a7acb706b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01179048 at 2026-07-30T20:48:52.462Z. Its registry update date was 2019-07-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01179048-2019-07-17-757a7acb706b`](#source-ctg-observation-nct01179048-2019-07-17-757a7acb706b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01179048 at 2026-07-30T20:48:52.462Z. Its registry update date was 2019-07-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01179048-2019-07-17-757a7acb706b`](#source-ctg-observation-nct01179048-2019-07-17-757a7acb706b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01179048-2019-07-17-757a7acb706b`](#source-ctg-observation-nct01179048-2019-07-17-757a7acb706b))

### Sources

<a id="source-ctg-observation-nct01179048-2019-07-17-757a7acb706b"></a>
- **ClinicalTrials.gov record NCT01179048 · retained source version 2019-07-17:757a7acb706b5ed2990269c6fb648ec18f4b0647228738eedfcdabe7882917f4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01179048) (`ctg-observation-nct01179048-2019-07-17-757a7acb706b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01179048." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01179048-liraglutide-v1 SHA-256: ad33109ef77397c84c4601b6184db920a956ae26afaef18b62fbd304575b4528.

---

<a id="clinicaltrials-gov-nct01237119-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01237119

> PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01237119-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-03-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01237119-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01237119-liraglutide-v1
- Content SHA-256: `3ad188efae7ffe77effcbb6d6f4913f306249e1d5ba14d3920616a57796fc02d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01237119 ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

### Sources

<a id="source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438"></a>
- **ClinicalTrials.gov record NCT01237119 · retained source version 2016-03-23:9fc751a5d438338bbd956465199469975b22c82ed8b16150659175b3a0748cab** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01237119) (`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01237119." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01237119-liraglutide-v1 SHA-256: 3ad188efae7ffe77effcbb6d6f4913f306249e1d5ba14d3920616a57796fc02d.

---

<a id="clinicaltrials-gov-nct01270789-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01270789

> PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01270789-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-09-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01270789-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01270789-liraglutide-v1
- Content SHA-256: `b86403fc5bed30af14a783c6c186933c38500d53fd192592084cd5a0f172b924`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01270789 ([`ctg-observation-nct01270789-2014-09-12-230d15b7d87e`](#source-ctg-observation-nct01270789-2014-09-12-230d15b7d87e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01270789-2014-09-12-230d15b7d87e`](#source-ctg-observation-nct01270789-2014-09-12-230d15b7d87e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01270789-2014-09-12-230d15b7d87e`](#source-ctg-observation-nct01270789-2014-09-12-230d15b7d87e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01270789-2014-09-12-230d15b7d87e`](#source-ctg-observation-nct01270789-2014-09-12-230d15b7d87e))

### Sources

<a id="source-ctg-observation-nct01270789-2014-09-12-230d15b7d87e"></a>
- **ClinicalTrials.gov record NCT01270789 · retained source version 2014-09-12:230d15b7d87ef3b93939c45da59592d603ceefbecd3fe72ebc1cdcd11d92d2b8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01270789) (`ctg-observation-nct01270789-2014-09-12-230d15b7d87e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01270789." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01270789-liraglutide-v1 SHA-256: b86403fc5bed30af14a783c6c186933c38500d53fd192592084cd5a0f172b924.

---

<a id="clinicaltrials-gov-nct01272219-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01272219

> PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01272219-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01272219-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01272219-liraglutide-v1
- Content SHA-256: `7c1b0fa062377e796df446215ead4a2155e413e39d62571bdde0fdf00ade04b3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01272219 ([`ctg-observation-nct01272219-2018-01-19-74eba383d010`](#source-ctg-observation-nct01272219-2018-01-19-74eba383d010))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01272219-2018-01-19-74eba383d010`](#source-ctg-observation-nct01272219-2018-01-19-74eba383d010))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01272219-2018-01-19-74eba383d010`](#source-ctg-observation-nct01272219-2018-01-19-74eba383d010))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01272219-2018-01-19-74eba383d010`](#source-ctg-observation-nct01272219-2018-01-19-74eba383d010))

### Sources

<a id="source-ctg-observation-nct01272219-2018-01-19-74eba383d010"></a>
- **ClinicalTrials.gov record NCT01272219 · retained source version 2018-01-19:74eba383d01030af9817920ff0cf5fe7fc9165c5a709a50a00ec7299b8980021** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01272219) (`ctg-observation-nct01272219-2018-01-19-74eba383d010`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01272219." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01272219-liraglutide-v1 SHA-256: 7c1b0fa062377e796df446215ead4a2155e413e39d62571bdde0fdf00ade04b3.

---

<a id="clinicaltrials-gov-nct01394341-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01394341

> PeptideScanner retained ClinicalTrials.gov record NCT01394341 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-10-09, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01394341-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-10-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01394341-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01394341-liraglutide-v1
- Content SHA-256: `778333bebdb81da1654904a24fdedf8801f579b1fe98c0b8ccbe695ae7a394f0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01394341 ([`ctg-observation-nct01394341-2013-10-09-ca5621ff0462`](#source-ctg-observation-nct01394341-2013-10-09-ca5621ff0462))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01394341 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-10-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01394341-2013-10-09-ca5621ff0462`](#source-ctg-observation-nct01394341-2013-10-09-ca5621ff0462))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01394341 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-10-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01394341-2013-10-09-ca5621ff0462`](#source-ctg-observation-nct01394341-2013-10-09-ca5621ff0462))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01394341-2013-10-09-ca5621ff0462`](#source-ctg-observation-nct01394341-2013-10-09-ca5621ff0462))

### Sources

<a id="source-ctg-observation-nct01394341-2013-10-09-ca5621ff0462"></a>
- **ClinicalTrials.gov record NCT01394341 · retained source version 2013-10-09:ca5621ff0462e68b365da3604649f5e9c0b0e7bf1c5b364909b4cd8db2d2f8b6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01394341) (`ctg-observation-nct01394341-2013-10-09-ca5621ff0462`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01394341." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01394341-liraglutide-v1 SHA-256: 778333bebdb81da1654904a24fdedf8801f579b1fe98c0b8ccbe695ae7a394f0.

---

<a id="clinicaltrials-gov-nct01469351-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01469351

> PeptideScanner retained ClinicalTrials.gov record NCT01469351 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-04-19, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01469351-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-04-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01469351-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01469351-liraglutide-v1
- Content SHA-256: `c2f6cbb30aa9a5839016b4e06e419fafbd48d06377f4f4bf422e4ca3a443c2c1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01469351 ([`ctg-observation-nct01469351-2013-04-19-8d88e45d00f2`](#source-ctg-observation-nct01469351-2013-04-19-8d88e45d00f2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01469351 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-04-19, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01469351-2013-04-19-8d88e45d00f2`](#source-ctg-observation-nct01469351-2013-04-19-8d88e45d00f2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01469351 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-04-19, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01469351-2013-04-19-8d88e45d00f2`](#source-ctg-observation-nct01469351-2013-04-19-8d88e45d00f2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01469351-2013-04-19-8d88e45d00f2`](#source-ctg-observation-nct01469351-2013-04-19-8d88e45d00f2))

### Sources

<a id="source-ctg-observation-nct01469351-2013-04-19-8d88e45d00f2"></a>
- **ClinicalTrials.gov record NCT01469351 · retained source version 2013-04-19:8d88e45d00f23cd6c6a6cccf34bf8109b04c9ed75844aca223ed52c7d331fa77** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01469351) (`ctg-observation-nct01469351-2013-04-19-8d88e45d00f2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01469351." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01469351-liraglutide-v1 SHA-256: c2f6cbb30aa9a5839016b4e06e419fafbd48d06377f4f4bf422e4ca3a443c2c1.

---

<a id="clinicaltrials-gov-nct01507272-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01507272

> PeptideScanner retained ClinicalTrials.gov record NCT01507272 at 2026-07-30T21:25:36.818Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01507272-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01507272-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01507272-liraglutide-v1
- Content SHA-256: `e6931aff8908209518a1e96fa8a1253001d1effd6fcf9aa424f16b43a0d7b44a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01507272 ([`ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b`](#source-ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01507272 at 2026-07-30T21:25:36.818Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b`](#source-ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01507272 at 2026-07-30T21:25:36.818Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b`](#source-ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b`](#source-ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b))

### Sources

<a id="source-ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b"></a>
- **ClinicalTrials.gov record NCT01507272 · retained source version 2017-01-24:ba5c9fc2ec1b6b9f2c697c6aba6c84ab1e0f7803802148bfe28f471c8fe45232** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01507272) (`ctg-observation-nct01507272-2017-01-24-ba5c9fc2ec1b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01507272." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01507272-liraglutide-v1 SHA-256: e6931aff8908209518a1e96fa8a1253001d1effd6fcf9aa424f16b43a0d7b44a.

---

<a id="clinicaltrials-gov-nct01507337-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01507337

> PeptideScanner retained ClinicalTrials.gov record NCT01507337 at 2026-07-30T21:25:36.779Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01507337-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01507337-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01507337-liraglutide-v1
- Content SHA-256: `bcd5905090383ea15e87782531b43367e3f23106c9851f79611352e865bc548c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01507337 ([`ctg-observation-nct01507337-2017-01-24-f9f76cedece0`](#source-ctg-observation-nct01507337-2017-01-24-f9f76cedece0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01507337 at 2026-07-30T21:25:36.779Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01507337-2017-01-24-f9f76cedece0`](#source-ctg-observation-nct01507337-2017-01-24-f9f76cedece0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01507337 at 2026-07-30T21:25:36.779Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01507337-2017-01-24-f9f76cedece0`](#source-ctg-observation-nct01507337-2017-01-24-f9f76cedece0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01507337-2017-01-24-f9f76cedece0`](#source-ctg-observation-nct01507337-2017-01-24-f9f76cedece0))

### Sources

<a id="source-ctg-observation-nct01507337-2017-01-24-f9f76cedece0"></a>
- **ClinicalTrials.gov record NCT01507337 · retained source version 2017-01-24:f9f76cedece0d8d04231e9559687b729a50f49e2bef97fe11b0b38104256d139** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01507337) (`ctg-observation-nct01507337-2017-01-24-f9f76cedece0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01507337." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01507337-liraglutide-v1 SHA-256: bcd5905090383ea15e87782531b43367e3f23106c9851f79611352e865bc548c.

---

<a id="clinicaltrials-gov-nct01507389-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01507389

> PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01507389-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-12-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01507389-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01507389-liraglutide-v1
- Content SHA-256: `1b4d9df5a3818e7f3e53323a60878ade1839db66ca319f2e43b8b147fc427a73`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01507389 ([`ctg-observation-nct01507389-2014-12-09-353803c40d60`](#source-ctg-observation-nct01507389-2014-12-09-353803c40d60))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01507389-2014-12-09-353803c40d60`](#source-ctg-observation-nct01507389-2014-12-09-353803c40d60))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01507389-2014-12-09-353803c40d60`](#source-ctg-observation-nct01507389-2014-12-09-353803c40d60))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01507389-2014-12-09-353803c40d60`](#source-ctg-observation-nct01507389-2014-12-09-353803c40d60))

### Sources

<a id="source-ctg-observation-nct01507389-2014-12-09-353803c40d60"></a>
- **ClinicalTrials.gov record NCT01507389 · retained source version 2014-12-09:353803c40d602451ca59d7571d02a1b457569155cad32d95d33240ec7b486e99** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01507389) (`ctg-observation-nct01507389-2014-12-09-353803c40d60`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01507389." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01507389-liraglutide-v1 SHA-256: 1b4d9df5a3818e7f3e53323a60878ade1839db66ca319f2e43b8b147fc427a73.

---

<a id="clinicaltrials-gov-nct01508806-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01508806

> PeptideScanner retained ClinicalTrials.gov record NCT01508806 at 2026-07-30T21:25:36.763Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01508806-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01508806-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01508806-liraglutide-v1
- Content SHA-256: `c7bde8ddb1e938575057638227d05c362e0ec2f2b45f9f36b754df196e30ff95`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01508806 ([`ctg-observation-nct01508806-2017-01-24-97d797b15e37`](#source-ctg-observation-nct01508806-2017-01-24-97d797b15e37))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01508806 at 2026-07-30T21:25:36.763Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01508806-2017-01-24-97d797b15e37`](#source-ctg-observation-nct01508806-2017-01-24-97d797b15e37))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01508806 at 2026-07-30T21:25:36.763Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01508806-2017-01-24-97d797b15e37`](#source-ctg-observation-nct01508806-2017-01-24-97d797b15e37))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01508806-2017-01-24-97d797b15e37`](#source-ctg-observation-nct01508806-2017-01-24-97d797b15e37))

### Sources

<a id="source-ctg-observation-nct01508806-2017-01-24-97d797b15e37"></a>
- **ClinicalTrials.gov record NCT01508806 · retained source version 2017-01-24:97d797b15e3700ac3ceafb7632c62bbd3acb591b2228362426b5f1542441cb8d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01508806) (`ctg-observation-nct01508806-2017-01-24-97d797b15e37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01508806." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01508806-liraglutide-v1 SHA-256: c7bde8ddb1e938575057638227d05c362e0ec2f2b45f9f36b754df196e30ff95.

---

<a id="clinicaltrials-gov-nct01515592-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01515592

> PeptideScanner retained ClinicalTrials.gov record NCT01515592 at 2026-07-30T21:25:36.784Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01515592-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01515592-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01515592-liraglutide-v1
- Content SHA-256: `eb71d1038e4ee8bc37e2b5a96b0c87852396b3874ca74f0282426b0ad41a7a8b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01515592 ([`ctg-observation-nct01515592-2017-01-25-5190b0a4576a`](#source-ctg-observation-nct01515592-2017-01-25-5190b0a4576a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01515592 at 2026-07-30T21:25:36.784Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01515592-2017-01-25-5190b0a4576a`](#source-ctg-observation-nct01515592-2017-01-25-5190b0a4576a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01515592 at 2026-07-30T21:25:36.784Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01515592-2017-01-25-5190b0a4576a`](#source-ctg-observation-nct01515592-2017-01-25-5190b0a4576a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01515592-2017-01-25-5190b0a4576a`](#source-ctg-observation-nct01515592-2017-01-25-5190b0a4576a))

### Sources

<a id="source-ctg-observation-nct01515592-2017-01-25-5190b0a4576a"></a>
- **ClinicalTrials.gov record NCT01515592 · retained source version 2017-01-25:5190b0a4576a182e28cca27b2f2ce984374fd53137a11b77dbcd9d864d4e53dd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01515592) (`ctg-observation-nct01515592-2017-01-25-5190b0a4576a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01515592." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01515592-liraglutide-v1 SHA-256: eb71d1038e4ee8bc37e2b5a96b0c87852396b3874ca74f0282426b0ad41a7a8b.

---

<a id="clinicaltrials-gov-nct01516255-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01516255

> PeptideScanner retained ClinicalTrials.gov record NCT01516255 at 2026-07-30T21:25:36.817Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01516255-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01516255-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01516255-liraglutide-v1
- Content SHA-256: `7139ad3e2c2d6176348d03d8bb2d484f1baeaf0af5168aca4b4292dace3f34a4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01516255 ([`ctg-observation-nct01516255-2017-01-25-1643013dc184`](#source-ctg-observation-nct01516255-2017-01-25-1643013dc184))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01516255 at 2026-07-30T21:25:36.817Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01516255-2017-01-25-1643013dc184`](#source-ctg-observation-nct01516255-2017-01-25-1643013dc184))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01516255 at 2026-07-30T21:25:36.817Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01516255-2017-01-25-1643013dc184`](#source-ctg-observation-nct01516255-2017-01-25-1643013dc184))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01516255-2017-01-25-1643013dc184`](#source-ctg-observation-nct01516255-2017-01-25-1643013dc184))

### Sources

<a id="source-ctg-observation-nct01516255-2017-01-25-1643013dc184"></a>
- **ClinicalTrials.gov record NCT01516255 · retained source version 2017-01-25:1643013dc1848011bc889b694dcdad3b713bd35e00743a90791977243702f141** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01516255) (`ctg-observation-nct01516255-2017-01-25-1643013dc184`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01516255." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01516255-liraglutide-v1 SHA-256: 7139ad3e2c2d6176348d03d8bb2d484f1baeaf0af5168aca4b4292dace3f34a4.

---

<a id="clinicaltrials-gov-nct01518101-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01518101

> PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01518101-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01518101-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01518101-liraglutide-v1
- Content SHA-256: `b58f11af914a9dcc7ef484ac6e3129e03a27d8b423f2ac1db42a1c7a045948aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01518101 ([`ctg-observation-nct01518101-2017-02-27-bd9eb8d39449`](#source-ctg-observation-nct01518101-2017-02-27-bd9eb8d39449))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01518101-2017-02-27-bd9eb8d39449`](#source-ctg-observation-nct01518101-2017-02-27-bd9eb8d39449))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01518101-2017-02-27-bd9eb8d39449`](#source-ctg-observation-nct01518101-2017-02-27-bd9eb8d39449))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01518101-2017-02-27-bd9eb8d39449`](#source-ctg-observation-nct01518101-2017-02-27-bd9eb8d39449))

### Sources

<a id="source-ctg-observation-nct01518101-2017-02-27-bd9eb8d39449"></a>
- **ClinicalTrials.gov record NCT01518101 · retained source version 2017-02-27:bd9eb8d39449fddcb66779cf6be4093d8057f96969b54c1c6339f7bce6d15c43** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01518101) (`ctg-observation-nct01518101-2017-02-27-bd9eb8d39449`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01518101." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01518101-liraglutide-v1 SHA-256: b58f11af914a9dcc7ef484ac6e3129e03a27d8b423f2ac1db42a1c7a045948aa.

---

<a id="clinicaltrials-gov-nct01518166-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01518166

> PeptideScanner retained ClinicalTrials.gov record NCT01518166 at 2026-07-30T21:25:36.824Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01518166-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01518166-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01518166-liraglutide-v1
- Content SHA-256: `c5e49fa21545a00db61b1865fbe895c276d1928be395ab743531a1a7e2bcb1b4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01518166 ([`ctg-observation-nct01518166-2017-01-25-04dde5850c09`](#source-ctg-observation-nct01518166-2017-01-25-04dde5850c09))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01518166 at 2026-07-30T21:25:36.824Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01518166-2017-01-25-04dde5850c09`](#source-ctg-observation-nct01518166-2017-01-25-04dde5850c09))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01518166 at 2026-07-30T21:25:36.824Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01518166-2017-01-25-04dde5850c09`](#source-ctg-observation-nct01518166-2017-01-25-04dde5850c09))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01518166-2017-01-25-04dde5850c09`](#source-ctg-observation-nct01518166-2017-01-25-04dde5850c09))

### Sources

<a id="source-ctg-observation-nct01518166-2017-01-25-04dde5850c09"></a>
- **ClinicalTrials.gov record NCT01518166 · retained source version 2017-01-25:04dde5850c093493c2d8fefcc11e058d34df90b8f668378deec5bf760473ab80** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01518166) (`ctg-observation-nct01518166-2017-01-25-04dde5850c09`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01518166." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01518166-liraglutide-v1 SHA-256: c5e49fa21545a00db61b1865fbe895c276d1928be395ab743531a1a7e2bcb1b4.

---

<a id="clinicaltrials-gov-nct01550653-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01550653

> PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01550653-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-02-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01550653-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01550653-liraglutide-v1
- Content SHA-256: `42085c05c41f6a407473f7ad93ea11b2b61ecfac3bd5b814083a560066e014f7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01550653 ([`ctg-observation-nct01550653-2014-02-27-fad07de5b84a`](#source-ctg-observation-nct01550653-2014-02-27-fad07de5b84a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01550653-2014-02-27-fad07de5b84a`](#source-ctg-observation-nct01550653-2014-02-27-fad07de5b84a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01550653-2014-02-27-fad07de5b84a`](#source-ctg-observation-nct01550653-2014-02-27-fad07de5b84a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01550653-2014-02-27-fad07de5b84a`](#source-ctg-observation-nct01550653-2014-02-27-fad07de5b84a))

### Sources

<a id="source-ctg-observation-nct01550653-2014-02-27-fad07de5b84a"></a>
- **ClinicalTrials.gov record NCT01550653 · retained source version 2014-02-27:fad07de5b84adafc181135b4dda6da3f9c21a6957f74ab95a3a7e5f15abeaf89** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01550653) (`ctg-observation-nct01550653-2014-02-27-fad07de5b84a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01550653." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01550653-liraglutide-v1 SHA-256: 42085c05c41f6a407473f7ad93ea11b2b61ecfac3bd5b814083a560066e014f7.

---

<a id="clinicaltrials-gov-nct01557166-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01557166

> PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01557166-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01557166-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01557166-liraglutide-v1
- Content SHA-256: `0a8d7bc2d9af221ab8cd80a48cc426fbe8280c159bf8ce46cff856968a3b0825`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01557166 ([`ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f`](#source-ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f`](#source-ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f`](#source-ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f`](#source-ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f))

### Sources

<a id="source-ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f"></a>
- **ClinicalTrials.gov record NCT01557166 · retained source version 2017-11-01:4e45e8c8e99f6fedd74c5842223d9e1e8de19c0f3971512846806ca04fd0cb50** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01557166) (`ctg-observation-nct01557166-2017-11-01-4e45e8c8e99f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01557166." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01557166-liraglutide-v1 SHA-256: 0a8d7bc2d9af221ab8cd80a48cc426fbe8280c159bf8ce46cff856968a3b0825.

---

<a id="clinicaltrials-gov-nct01562678-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01562678

> PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01562678-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01562678-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01562678-liraglutide-v1
- Content SHA-256: `211eab51598451fd813dcb397896fede50794806a641260384b3eb7ae52f63ae`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01562678 ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

### Sources

<a id="source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01"></a>
- **ClinicalTrials.gov record NCT01562678 · retained source version 2017-05-31:efb992e7bc017434de2693218744adccc275ddc2fc4b46456849c25581ebc697** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01562678) (`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01562678." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01562678-liraglutide-v1 SHA-256: 211eab51598451fd813dcb397896fede50794806a641260384b3eb7ae52f63ae.

---

<a id="clinicaltrials-gov-nct01620463-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01620463

> PeptideScanner retained ClinicalTrials.gov record NCT01620463 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01620463-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01620463-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01620463-liraglutide-v1
- Content SHA-256: `f954f3bf82d8bd2c89d711ab11e3abbffce0ce1143db669d5ea671b813318f5c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01620463 ([`ctg-observation-nct01620463-2017-01-24-2c1e472d7c97`](#source-ctg-observation-nct01620463-2017-01-24-2c1e472d7c97))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01620463 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01620463-2017-01-24-2c1e472d7c97`](#source-ctg-observation-nct01620463-2017-01-24-2c1e472d7c97))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01620463 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01620463-2017-01-24-2c1e472d7c97`](#source-ctg-observation-nct01620463-2017-01-24-2c1e472d7c97))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01620463-2017-01-24-2c1e472d7c97`](#source-ctg-observation-nct01620463-2017-01-24-2c1e472d7c97))

### Sources

<a id="source-ctg-observation-nct01620463-2017-01-24-2c1e472d7c97"></a>
- **ClinicalTrials.gov record NCT01620463 · retained source version 2017-01-24:2c1e472d7c97605cbbac5f3e77300ad750a160e43c0f434d88745378f92adc09** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01620463) (`ctg-observation-nct01620463-2017-01-24-2c1e472d7c97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01620463." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01620463-liraglutide-v1 SHA-256: f954f3bf82d8bd2c89d711ab11e3abbffce0ce1143db669d5ea671b813318f5c.

---

<a id="clinicaltrials-gov-nct01620476-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01620476

> PeptideScanner retained ClinicalTrials.gov record NCT01620476 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01620476-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01620476-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01620476-liraglutide-v1
- Content SHA-256: `708055e7a5d4f94a2ca24f7319d5bd52f66fccf847877afb669dede8f382b959`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01620476 ([`ctg-observation-nct01620476-2017-01-25-24daea539ca2`](#source-ctg-observation-nct01620476-2017-01-25-24daea539ca2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01620476 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01620476-2017-01-25-24daea539ca2`](#source-ctg-observation-nct01620476-2017-01-25-24daea539ca2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01620476 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01620476-2017-01-25-24daea539ca2`](#source-ctg-observation-nct01620476-2017-01-25-24daea539ca2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01620476-2017-01-25-24daea539ca2`](#source-ctg-observation-nct01620476-2017-01-25-24daea539ca2))

### Sources

<a id="source-ctg-observation-nct01620476-2017-01-25-24daea539ca2"></a>
- **ClinicalTrials.gov record NCT01620476 · retained source version 2017-01-25:24daea539ca2713b198fedf83e9a2548c26fb098f4f3fbfdd0cbddc77cbf6f80** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01620476) (`ctg-observation-nct01620476-2017-01-25-24daea539ca2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01620476." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01620476-liraglutide-v1 SHA-256: 708055e7a5d4f94a2ca24f7319d5bd52f66fccf847877afb669dede8f382b959.

---

<a id="clinicaltrials-gov-nct01695109-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01695109

> PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01695109-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-09-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01695109-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01695109-liraglutide-v1
- Content SHA-256: `9215fc707af83eee04304ae851c47f82f26d50ac53ac7e6f52680755c3ebdc90`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01695109 ([`ctg-observation-nct01695109-2012-09-27-0280d0fd2daf`](#source-ctg-observation-nct01695109-2012-09-27-0280d0fd2daf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01695109-2012-09-27-0280d0fd2daf`](#source-ctg-observation-nct01695109-2012-09-27-0280d0fd2daf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01695109-2012-09-27-0280d0fd2daf`](#source-ctg-observation-nct01695109-2012-09-27-0280d0fd2daf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01695109-2012-09-27-0280d0fd2daf`](#source-ctg-observation-nct01695109-2012-09-27-0280d0fd2daf))

### Sources

<a id="source-ctg-observation-nct01695109-2012-09-27-0280d0fd2daf"></a>
- **ClinicalTrials.gov record NCT01695109 · retained source version 2012-09-27:0280d0fd2daff69e2af80f9cfd9ad8593edc40b9b2d901228d4d25c9fbae6261** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01695109) (`ctg-observation-nct01695109-2012-09-27-0280d0fd2daf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01695109." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01695109-liraglutide-v1 SHA-256: 9215fc707af83eee04304ae851c47f82f26d50ac53ac7e6f52680755c3ebdc90.

---

<a id="clinicaltrials-gov-nct01739049-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01739049

> PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01739049-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01739049-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01739049-liraglutide-v1
- Content SHA-256: `893e32a1361658548ad8ed6867fac71e8ac27bafe6fc5948c553aaa69f1189d3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01739049 ([`ctg-observation-nct01739049-2017-05-04-745f3f9e48ef`](#source-ctg-observation-nct01739049-2017-05-04-745f3f9e48ef))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01739049-2017-05-04-745f3f9e48ef`](#source-ctg-observation-nct01739049-2017-05-04-745f3f9e48ef))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01739049-2017-05-04-745f3f9e48ef`](#source-ctg-observation-nct01739049-2017-05-04-745f3f9e48ef))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01739049-2017-05-04-745f3f9e48ef`](#source-ctg-observation-nct01739049-2017-05-04-745f3f9e48ef))

### Sources

<a id="source-ctg-observation-nct01739049-2017-05-04-745f3f9e48ef"></a>
- **ClinicalTrials.gov record NCT01739049 · retained source version 2017-05-04:745f3f9e48efd8b314d6e4db8ae7fbdaae22bbed922f484fb474a2346bf46501** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01739049) (`ctg-observation-nct01739049-2017-05-04-745f3f9e48ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01739049." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01739049-liraglutide-v1 SHA-256: 893e32a1361658548ad8ed6867fac71e8ac27bafe6fc5948c553aaa69f1189d3.

---

<a id="clinicaltrials-gov-nct01755572-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01755572

> PeptideScanner retained ClinicalTrials.gov record NCT01755572 at 2026-07-30T21:43:54.457Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01755572-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01755572-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01755572-liraglutide-v1
- Content SHA-256: `cb997c9bf5303292a69936d8d50bf9f2ec09b290532fb3f70be87ee5fdf458f4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01755572 ([`ctg-observation-nct01755572-2015-03-25-0ac1d367f022`](#source-ctg-observation-nct01755572-2015-03-25-0ac1d367f022))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01755572 at 2026-07-30T21:43:54.457Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01755572-2015-03-25-0ac1d367f022`](#source-ctg-observation-nct01755572-2015-03-25-0ac1d367f022))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01755572 at 2026-07-30T21:43:54.457Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01755572-2015-03-25-0ac1d367f022`](#source-ctg-observation-nct01755572-2015-03-25-0ac1d367f022))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01755572-2015-03-25-0ac1d367f022`](#source-ctg-observation-nct01755572-2015-03-25-0ac1d367f022))

### Sources

<a id="source-ctg-observation-nct01755572-2015-03-25-0ac1d367f022"></a>
- **ClinicalTrials.gov record NCT01755572 · retained source version 2015-03-25:0ac1d367f0227eaa842a4adac9c98382639563cf57a0895bcb685bbaa11ecf65** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01755572) (`ctg-observation-nct01755572-2015-03-25-0ac1d367f022`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01755572." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01755572-liraglutide-v1 SHA-256: cb997c9bf5303292a69936d8d50bf9f2ec09b290532fb3f70be87ee5fdf458f4.

---

<a id="clinicaltrials-gov-nct01779362-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01779362

> PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01779362-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01779362-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01779362-liraglutide-v1
- Content SHA-256: `3c1f81cbcb0e3d4d16e03c5a72954c72649ca867a5d7364628534c24bac7492a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01779362 ([`ctg-observation-nct01779362-2023-05-11-a17f7f312725`](#source-ctg-observation-nct01779362-2023-05-11-a17f7f312725))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01779362-2023-05-11-a17f7f312725`](#source-ctg-observation-nct01779362-2023-05-11-a17f7f312725))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01779362-2023-05-11-a17f7f312725`](#source-ctg-observation-nct01779362-2023-05-11-a17f7f312725))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01779362-2023-05-11-a17f7f312725`](#source-ctg-observation-nct01779362-2023-05-11-a17f7f312725))

### Sources

<a id="source-ctg-observation-nct01779362-2023-05-11-a17f7f312725"></a>
- **ClinicalTrials.gov record NCT01779362 · retained source version 2023-05-11:a17f7f3127250b4ab9905778ca5b40117fd9ea6add47e7e456712c10fc0dc01d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01779362) (`ctg-observation-nct01779362-2023-05-11-a17f7f312725`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01779362." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01779362-liraglutide-v1 SHA-256: 3c1f81cbcb0e3d4d16e03c5a72954c72649ca867a5d7364628534c24bac7492a.

---

<a id="clinicaltrials-gov-nct01782261-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01782261

> PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01782261-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-10-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01782261-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01782261-liraglutide-v1
- Content SHA-256: `22dc7618393da8de660107d8bd10e6f6684a116eac802c76a6b9fb20549b4181`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01782261 ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

### Sources

<a id="source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a"></a>
- **ClinicalTrials.gov record NCT01782261 · retained source version 2016-10-11:faa1f2f8ee8a6d6651fd6333f3ca3379db5c92bb34f08120775d077c97b7ba1e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01782261) (`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01782261." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01782261-liraglutide-v1 SHA-256: 22dc7618393da8de660107d8bd10e6f6684a116eac802c76a6b9fb20549b4181.

---

<a id="clinicaltrials-gov-nct01785043-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01785043

> PeptideScanner retained ClinicalTrials.gov record NCT01785043 at 2026-07-30T21:41:27.766Z. Its registry update date was 2015-09-15, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01785043-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-09-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01785043-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01785043-liraglutide-v1
- Content SHA-256: `c271fa0d9bff2384648593f4560c257e40127c216d2ae28817047f6e0c085f22`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01785043 ([`ctg-observation-nct01785043-2015-09-15-8049d827dab7`](#source-ctg-observation-nct01785043-2015-09-15-8049d827dab7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01785043 at 2026-07-30T21:41:27.766Z. Its registry update date was 2015-09-15, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01785043-2015-09-15-8049d827dab7`](#source-ctg-observation-nct01785043-2015-09-15-8049d827dab7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01785043 at 2026-07-30T21:41:27.766Z. Its registry update date was 2015-09-15, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01785043-2015-09-15-8049d827dab7`](#source-ctg-observation-nct01785043-2015-09-15-8049d827dab7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01785043-2015-09-15-8049d827dab7`](#source-ctg-observation-nct01785043-2015-09-15-8049d827dab7))

### Sources

<a id="source-ctg-observation-nct01785043-2015-09-15-8049d827dab7"></a>
- **ClinicalTrials.gov record NCT01785043 · retained source version 2015-09-15:8049d827dab7923a5164ffc999e66aae83aa82088aa62f505dc2d7a7796e3253** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01785043) (`ctg-observation-nct01785043-2015-09-15-8049d827dab7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01785043." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01785043-liraglutide-v1 SHA-256: c271fa0d9bff2384648593f4560c257e40127c216d2ae28817047f6e0c085f22.

---

<a id="clinicaltrials-gov-nct01899430-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01899430

> PeptideScanner retained ClinicalTrials.gov record NCT01899430 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01899430-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01899430-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01899430-liraglutide-v1
- Content SHA-256: `e18c449673f36db05ce5b6cef9a7fb77258556c5807eab77fd214d3dd015404e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01899430 ([`ctg-observation-nct01899430-2013-07-15-79c2feec2f49`](#source-ctg-observation-nct01899430-2013-07-15-79c2feec2f49))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01899430 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01899430-2013-07-15-79c2feec2f49`](#source-ctg-observation-nct01899430-2013-07-15-79c2feec2f49))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01899430 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01899430-2013-07-15-79c2feec2f49`](#source-ctg-observation-nct01899430-2013-07-15-79c2feec2f49))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01899430-2013-07-15-79c2feec2f49`](#source-ctg-observation-nct01899430-2013-07-15-79c2feec2f49))

### Sources

<a id="source-ctg-observation-nct01899430-2013-07-15-79c2feec2f49"></a>
- **ClinicalTrials.gov record NCT01899430 · retained source version 2013-07-15:79c2feec2f49e0a566f7b1330898a69698a2976785e020f1fb8cc24d19d7681e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01899430) (`ctg-observation-nct01899430-2013-07-15-79c2feec2f49`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01899430." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01899430-liraglutide-v1 SHA-256: e18c449673f36db05ce5b6cef9a7fb77258556c5807eab77fd214d3dd015404e.

---

<a id="clinicaltrials-gov-nct01911468-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT01911468

> PeptideScanner retained ClinicalTrials.gov record NCT01911468 at 2026-07-30T21:55:56.619Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01911468-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01911468-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01911468-liraglutide-v1
- Content SHA-256: `aeb76dfa8983cd2983d413959f2ee8cce9124300a99d0530ae9d1fabf20eefa6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01911468 ([`ctg-observation-nct01911468-2013-07-30-7f46e88daee6`](#source-ctg-observation-nct01911468-2013-07-30-7f46e88daee6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01911468 at 2026-07-30T21:55:56.619Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01911468-2013-07-30-7f46e88daee6`](#source-ctg-observation-nct01911468-2013-07-30-7f46e88daee6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01911468 at 2026-07-30T21:55:56.619Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01911468-2013-07-30-7f46e88daee6`](#source-ctg-observation-nct01911468-2013-07-30-7f46e88daee6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01911468-2013-07-30-7f46e88daee6`](#source-ctg-observation-nct01911468-2013-07-30-7f46e88daee6))

### Sources

<a id="source-ctg-observation-nct01911468-2013-07-30-7f46e88daee6"></a>
- **ClinicalTrials.gov record NCT01911468 · retained source version 2013-07-30:7f46e88daee66713aca11945cf3c8d95c26dfdf220323c77134720e239bd22b1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01911468) (`ctg-observation-nct01911468-2013-07-30-7f46e88daee6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01911468." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct01911468-liraglutide-v1 SHA-256: aeb76dfa8983cd2983d413959f2ee8cce9124300a99d0530ae9d1fabf20eefa6.

---

<a id="clinicaltrials-gov-nct02060383-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02060383

> PeptideScanner retained ClinicalTrials.gov record NCT02060383 at 2026-07-30T20:52:10.194Z. Its registry update date was 2019-05-29, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02060383-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-05-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02060383-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02060383-liraglutide-v1
- Content SHA-256: `dd6b8a6d0e73a58149ff845e49756bacf33c2fb04402a6053e2d4e16e2b8269b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02060383 ([`ctg-observation-nct02060383-2019-05-29-dca004c9a746`](#source-ctg-observation-nct02060383-2019-05-29-dca004c9a746))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02060383 at 2026-07-30T20:52:10.194Z. Its registry update date was 2019-05-29, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02060383-2019-05-29-dca004c9a746`](#source-ctg-observation-nct02060383-2019-05-29-dca004c9a746))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02060383 at 2026-07-30T20:52:10.194Z. Its registry update date was 2019-05-29, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02060383-2019-05-29-dca004c9a746`](#source-ctg-observation-nct02060383-2019-05-29-dca004c9a746))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02060383-2019-05-29-dca004c9a746`](#source-ctg-observation-nct02060383-2019-05-29-dca004c9a746))

### Sources

<a id="source-ctg-observation-nct02060383-2019-05-29-dca004c9a746"></a>
- **ClinicalTrials.gov record NCT02060383 · retained source version 2019-05-29:dca004c9a746c75526907b14a858ee6263ff8427bc127959116bea69360ad2a3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02060383) (`ctg-observation-nct02060383-2019-05-29-dca004c9a746`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02060383." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02060383-liraglutide-v1 SHA-256: dd6b8a6d0e73a58149ff845e49756bacf33c2fb04402a6053e2d4e16e2b8269b.

---

<a id="clinicaltrials-gov-nct02140983-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02140983

> PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02140983-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02140983-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02140983-liraglutide-v1
- Content SHA-256: `a7be72ec7c00574466ff825ecd35de89892c4d7abe2feffdbd19c1573956d4a0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02140983 ([`ctg-observation-nct02140983-2018-01-25-e0509000d364`](#source-ctg-observation-nct02140983-2018-01-25-e0509000d364))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02140983-2018-01-25-e0509000d364`](#source-ctg-observation-nct02140983-2018-01-25-e0509000d364))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02140983-2018-01-25-e0509000d364`](#source-ctg-observation-nct02140983-2018-01-25-e0509000d364))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02140983-2018-01-25-e0509000d364`](#source-ctg-observation-nct02140983-2018-01-25-e0509000d364))

### Sources

<a id="source-ctg-observation-nct02140983-2018-01-25-e0509000d364"></a>
- **ClinicalTrials.gov record NCT02140983 · retained source version 2018-01-25:e0509000d364d2c3ff151607b7bed1bf85ce15ad2e6f8b7190e3465caad40135** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02140983) (`ctg-observation-nct02140983-2018-01-25-e0509000d364`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02140983." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02140983-liraglutide-v1 SHA-256: a7be72ec7c00574466ff825ecd35de89892c4d7abe2feffdbd19c1573956d4a0.

---

<a id="clinicaltrials-gov-nct02315001-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02315001

> PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02315001-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-05-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02315001-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02315001-liraglutide-v1
- Content SHA-256: `61a8b74c62a3b5bc6979efe958e9541dc37aae9951b359a35fce26890e57835b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02315001 ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

### Sources

<a id="source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35"></a>
- **ClinicalTrials.gov record NCT02315001 · retained source version 2015-05-20:c8b22fe0af3557d5f12f6c331ba0293f7c849252a4c3b2bae3c173c3fe639190** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02315001) (`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02315001." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02315001-liraglutide-v1 SHA-256: 61a8b74c62a3b5bc6979efe958e9541dc37aae9951b359a35fce26890e57835b.

---

<a id="clinicaltrials-gov-nct02321878-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02321878

> PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02321878-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02321878-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02321878-liraglutide-v1
- Content SHA-256: `2cc497a7af6fd6043365020825874e3e05a7c72a8d4d2286f7d5f4a6a7323b37`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02321878 ([`ctg-observation-nct02321878-2017-09-01-e3db641cd662`](#source-ctg-observation-nct02321878-2017-09-01-e3db641cd662))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02321878-2017-09-01-e3db641cd662`](#source-ctg-observation-nct02321878-2017-09-01-e3db641cd662))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02321878-2017-09-01-e3db641cd662`](#source-ctg-observation-nct02321878-2017-09-01-e3db641cd662))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02321878-2017-09-01-e3db641cd662`](#source-ctg-observation-nct02321878-2017-09-01-e3db641cd662))

### Sources

<a id="source-ctg-observation-nct02321878-2017-09-01-e3db641cd662"></a>
- **ClinicalTrials.gov record NCT02321878 · retained source version 2017-09-01:e3db641cd6626922a6cac4f3a023e58aa408ae2eea2e3e08cca2580276188c7a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02321878) (`ctg-observation-nct02321878-2017-09-01-e3db641cd662`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02321878." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02321878-liraglutide-v1 SHA-256: 2cc497a7af6fd6043365020825874e3e05a7c72a8d4d2286f7d5f4a6a7323b37.

---

<a id="clinicaltrials-gov-nct02351232-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02351232

> PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02351232-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02351232-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02351232-liraglutide-v1
- Content SHA-256: `8329cdd9b51e1a169fed30ecddbe5dc857c4ffc42407e87140ae1d8445e421f0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02351232 ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`](#source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc))

### Sources

<a id="source-ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc"></a>
- **ClinicalTrials.gov record NCT02351232 · retained source version 2020-02-12:fe99ba38e8cc44e33a06fca36070c9172d4a7d532881288e92e21e1af07dba9e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02351232) (`ctg-observation-nct02351232-2020-02-12-fe99ba38e8cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02351232." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02351232-liraglutide-v1 SHA-256: 8329cdd9b51e1a169fed30ecddbe5dc857c4ffc42407e87140ae1d8445e421f0.

---

<a id="clinicaltrials-gov-nct02403284-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02403284

> PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02403284-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-07-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02403284-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02403284-liraglutide-v1
- Content SHA-256: `3b1a9b4c9944535956d521de94c69fcb98f011e1701fe92d6fcb670c17735d17`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02403284 ([`ctg-observation-nct02403284-2024-07-22-90a4e9505765`](#source-ctg-observation-nct02403284-2024-07-22-90a4e9505765))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02403284-2024-07-22-90a4e9505765`](#source-ctg-observation-nct02403284-2024-07-22-90a4e9505765))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02403284-2024-07-22-90a4e9505765`](#source-ctg-observation-nct02403284-2024-07-22-90a4e9505765))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02403284-2024-07-22-90a4e9505765`](#source-ctg-observation-nct02403284-2024-07-22-90a4e9505765))

### Sources

<a id="source-ctg-observation-nct02403284-2024-07-22-90a4e9505765"></a>
- **ClinicalTrials.gov record NCT02403284 · retained source version 2024-07-22:90a4e95057651a84d3489d6fed2d94efb69fd812b17646ab588fdf1737959723** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02403284) (`ctg-observation-nct02403284-2024-07-22-90a4e9505765`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02403284." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02403284-liraglutide-v1 SHA-256: 3b1a9b4c9944535956d521de94c69fcb98f011e1701fe92d6fcb670c17735d17.

---

<a id="clinicaltrials-gov-nct02473809-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02473809

> PeptideScanner retained ClinicalTrials.gov record NCT02473809 at 2026-07-30T21:10:03.006Z. Its registry update date was 2018-09-26, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02473809-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-09-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02473809-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02473809-liraglutide-v1
- Content SHA-256: `b174766517ad49588e66a52a23c5947dfc10f264e845c831ef45b7032f83ddf9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02473809 ([`ctg-observation-nct02473809-2018-09-26-04fbab7db3e4`](#source-ctg-observation-nct02473809-2018-09-26-04fbab7db3e4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02473809 at 2026-07-30T21:10:03.006Z. Its registry update date was 2018-09-26, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02473809-2018-09-26-04fbab7db3e4`](#source-ctg-observation-nct02473809-2018-09-26-04fbab7db3e4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02473809 at 2026-07-30T21:10:03.006Z. Its registry update date was 2018-09-26, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02473809-2018-09-26-04fbab7db3e4`](#source-ctg-observation-nct02473809-2018-09-26-04fbab7db3e4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02473809-2018-09-26-04fbab7db3e4`](#source-ctg-observation-nct02473809-2018-09-26-04fbab7db3e4))

### Sources

<a id="source-ctg-observation-nct02473809-2018-09-26-04fbab7db3e4"></a>
- **ClinicalTrials.gov record NCT02473809 · retained source version 2018-09-26:04fbab7db3e4d10ac809f27c3e7e39022c831841b4788ba3c68868b56ca50c17** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02473809) (`ctg-observation-nct02473809-2018-09-26-04fbab7db3e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02473809." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02473809-liraglutide-v1 SHA-256: b174766517ad49588e66a52a23c5947dfc10f264e845c831ef45b7032f83ddf9.

---

<a id="clinicaltrials-gov-nct02488057-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02488057

> PeptideScanner retained ClinicalTrials.gov record NCT02488057 at 2026-07-30T20:47:16.573Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02488057-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-08-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02488057-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02488057-liraglutide-v1
- Content SHA-256: `447cd89d06a1db09984a75627dd243fdfca1349f023bcced01f7c6110b674aef`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02488057 ([`ctg-observation-nct02488057-2019-08-28-c95d6da833d6`](#source-ctg-observation-nct02488057-2019-08-28-c95d6da833d6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02488057 at 2026-07-30T20:47:16.573Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02488057-2019-08-28-c95d6da833d6`](#source-ctg-observation-nct02488057-2019-08-28-c95d6da833d6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02488057 at 2026-07-30T20:47:16.573Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02488057-2019-08-28-c95d6da833d6`](#source-ctg-observation-nct02488057-2019-08-28-c95d6da833d6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02488057-2019-08-28-c95d6da833d6`](#source-ctg-observation-nct02488057-2019-08-28-c95d6da833d6))

### Sources

<a id="source-ctg-observation-nct02488057-2019-08-28-c95d6da833d6"></a>
- **ClinicalTrials.gov record NCT02488057 · retained source version 2019-08-28:c95d6da833d60de5d050ee7ab5f1a659083e01e064a83c857095ebd435cf2446** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02488057) (`ctg-observation-nct02488057-2019-08-28-c95d6da833d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02488057." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02488057-liraglutide-v1 SHA-256: 447cd89d06a1db09984a75627dd243fdfca1349f023bcced01f7c6110b674aef.

---

<a id="clinicaltrials-gov-nct02527200-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02527200

> PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02527200-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02527200-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02527200-liraglutide-v1
- Content SHA-256: `a74583f72d227f325f6f302902f6edb3b2dc05e2b301c2b63dffcb590a8ef373`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02527200 ([`ctg-observation-nct02527200-2023-07-06-31628d773ac4`](#source-ctg-observation-nct02527200-2023-07-06-31628d773ac4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02527200-2023-07-06-31628d773ac4`](#source-ctg-observation-nct02527200-2023-07-06-31628d773ac4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02527200-2023-07-06-31628d773ac4`](#source-ctg-observation-nct02527200-2023-07-06-31628d773ac4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02527200-2023-07-06-31628d773ac4`](#source-ctg-observation-nct02527200-2023-07-06-31628d773ac4))

### Sources

<a id="source-ctg-observation-nct02527200-2023-07-06-31628d773ac4"></a>
- **ClinicalTrials.gov record NCT02527200 · retained source version 2023-07-06:31628d773ac40366d7a952004bb978f2cd44010d3d5f0bf6e618ebdf33e393a4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02527200) (`ctg-observation-nct02527200-2023-07-06-31628d773ac4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02527200." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02527200-liraglutide-v1 SHA-256: a74583f72d227f325f6f302902f6edb3b2dc05e2b301c2b63dffcb590a8ef373.

---

<a id="clinicaltrials-gov-nct02545738-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02545738

> PeptideScanner retained ClinicalTrials.gov record NCT02545738 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-08-10, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02545738-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02545738-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02545738-liraglutide-v1
- Content SHA-256: `932c8349606932d7faafec853b1cb967c5c5dbf10ee0b74d899708d2e3603034`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02545738 ([`ctg-observation-nct02545738-2016-08-10-2f7146c9d816`](#source-ctg-observation-nct02545738-2016-08-10-2f7146c9d816))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02545738 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-08-10, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02545738-2016-08-10-2f7146c9d816`](#source-ctg-observation-nct02545738-2016-08-10-2f7146c9d816))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02545738 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-08-10, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02545738-2016-08-10-2f7146c9d816`](#source-ctg-observation-nct02545738-2016-08-10-2f7146c9d816))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02545738-2016-08-10-2f7146c9d816`](#source-ctg-observation-nct02545738-2016-08-10-2f7146c9d816))

### Sources

<a id="source-ctg-observation-nct02545738-2016-08-10-2f7146c9d816"></a>
- **ClinicalTrials.gov record NCT02545738 · retained source version 2016-08-10:2f7146c9d81688f92d3ee649d7aca82d0e720b97e25fb9c38da577cdeee735e1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02545738) (`ctg-observation-nct02545738-2016-08-10-2f7146c9d816`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02545738." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02545738-liraglutide-v1 SHA-256: 932c8349606932d7faafec853b1cb967c5c5dbf10ee0b74d899708d2e3603034.

---

<a id="clinicaltrials-gov-nct02616003-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02616003

> PeptideScanner retained ClinicalTrials.gov record NCT02616003 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02616003-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02616003-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02616003-liraglutide-v1
- Content SHA-256: `5e63b86d79601065b446feb89ecb5a32cf6a97a3c14b305ba036a1be7022d46d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02616003 ([`ctg-observation-nct02616003-2021-03-23-9055868e27a5`](#source-ctg-observation-nct02616003-2021-03-23-9055868e27a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02616003 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02616003-2021-03-23-9055868e27a5`](#source-ctg-observation-nct02616003-2021-03-23-9055868e27a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02616003 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02616003-2021-03-23-9055868e27a5`](#source-ctg-observation-nct02616003-2021-03-23-9055868e27a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02616003-2021-03-23-9055868e27a5`](#source-ctg-observation-nct02616003-2021-03-23-9055868e27a5))

### Sources

<a id="source-ctg-observation-nct02616003-2021-03-23-9055868e27a5"></a>
- **ClinicalTrials.gov record NCT02616003 · retained source version 2021-03-23:9055868e27a5257f4124d554f19043a7533e2b5fe11e59a18608bf94cf742886** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02616003) (`ctg-observation-nct02616003-2021-03-23-9055868e27a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02616003." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02616003-liraglutide-v1 SHA-256: 5e63b86d79601065b446feb89ecb5a32cf6a97a3c14b305ba036a1be7022d46d.

---

<a id="clinicaltrials-gov-nct02647944-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02647944

> PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02647944-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02647944-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02647944-liraglutide-v1
- Content SHA-256: `9c05901a524935abe7c4ae13b6283a16f2288eadaac2dea44441cd10820edcb6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02647944 ([`ctg-observation-nct02647944-2017-10-27-a59df329c86b`](#source-ctg-observation-nct02647944-2017-10-27-a59df329c86b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02647944-2017-10-27-a59df329c86b`](#source-ctg-observation-nct02647944-2017-10-27-a59df329c86b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02647944-2017-10-27-a59df329c86b`](#source-ctg-observation-nct02647944-2017-10-27-a59df329c86b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02647944-2017-10-27-a59df329c86b`](#source-ctg-observation-nct02647944-2017-10-27-a59df329c86b))

### Sources

<a id="source-ctg-observation-nct02647944-2017-10-27-a59df329c86b"></a>
- **ClinicalTrials.gov record NCT02647944 · retained source version 2017-10-27:a59df329c86b93f34110565c06ba1f0781a8ad02e474138bb2e0a44c24e5b703** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02647944) (`ctg-observation-nct02647944-2017-10-27-a59df329c86b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02647944." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02647944-liraglutide-v1 SHA-256: 9c05901a524935abe7c4ae13b6283a16f2288eadaac2dea44441cd10820edcb6.

---

<a id="clinicaltrials-gov-nct02650206-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02650206

> PeptideScanner retained ClinicalTrials.gov record NCT02650206 at 2026-07-30T20:26:41.666Z. Its registry update date was 2020-06-09, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02650206-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-06-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02650206-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02650206-liraglutide-v1
- Content SHA-256: `dfe590145c2762665071327f9cce0514a189a643366fa45795dbbdc64db03cd9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02650206 ([`ctg-observation-nct02650206-2020-06-09-d287e60cdf48`](#source-ctg-observation-nct02650206-2020-06-09-d287e60cdf48))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02650206 at 2026-07-30T20:26:41.666Z. Its registry update date was 2020-06-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02650206-2020-06-09-d287e60cdf48`](#source-ctg-observation-nct02650206-2020-06-09-d287e60cdf48))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02650206 at 2026-07-30T20:26:41.666Z. Its registry update date was 2020-06-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02650206-2020-06-09-d287e60cdf48`](#source-ctg-observation-nct02650206-2020-06-09-d287e60cdf48))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02650206-2020-06-09-d287e60cdf48`](#source-ctg-observation-nct02650206-2020-06-09-d287e60cdf48))

### Sources

<a id="source-ctg-observation-nct02650206-2020-06-09-d287e60cdf48"></a>
- **ClinicalTrials.gov record NCT02650206 · retained source version 2020-06-09:d287e60cdf4847498ee60a650c943919d43c13e3b884c821b2ee64e9fdea5453** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02650206) (`ctg-observation-nct02650206-2020-06-09-d287e60cdf48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02650206." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02650206-liraglutide-v1 SHA-256: dfe590145c2762665071327f9cce0514a189a643366fa45795dbbdc64db03cd9.

---

<a id="clinicaltrials-gov-nct02717858-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02717858

> PeptideScanner retained ClinicalTrials.gov record NCT02717858 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-28, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02717858-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02717858-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02717858-liraglutide-v1
- Content SHA-256: `6e28d29fb08cc07f05a72b0b10fe587ed704d5286d3396225b68bb127b4ee7cc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02717858 ([`ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd`](#source-ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02717858 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-28, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd`](#source-ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02717858 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-28, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd`](#source-ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd`](#source-ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd))

### Sources

<a id="source-ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd"></a>
- **ClinicalTrials.gov record NCT02717858 · retained source version 2018-06-28:0e48f4fef8fd8e9127f10e5de37fece0a62d0a57f71f9663f844db8c0acf2fbc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02717858) (`ctg-observation-nct02717858-2018-06-28-0e48f4fef8fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02717858." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02717858-liraglutide-v1 SHA-256: 6e28d29fb08cc07f05a72b0b10fe587ed704d5286d3396225b68bb127b4ee7cc.

---

<a id="clinicaltrials-gov-nct02765399-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02765399

> PeptideScanner retained ClinicalTrials.gov record NCT02765399 at 2026-07-30T19:40:58.914Z. Its registry update date was 2022-04-12, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02765399-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02765399-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02765399-liraglutide-v1
- Content SHA-256: `3a1b870f18e9be36e7e0625272c88af14bd4ad4e7bfc9dcfa28743fe83a5fee9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02765399 ([`ctg-observation-nct02765399-2022-04-12-34c234debd69`](#source-ctg-observation-nct02765399-2022-04-12-34c234debd69))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02765399 at 2026-07-30T19:40:58.914Z. Its registry update date was 2022-04-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02765399-2022-04-12-34c234debd69`](#source-ctg-observation-nct02765399-2022-04-12-34c234debd69))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02765399 at 2026-07-30T19:40:58.914Z. Its registry update date was 2022-04-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02765399-2022-04-12-34c234debd69`](#source-ctg-observation-nct02765399-2022-04-12-34c234debd69))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02765399-2022-04-12-34c234debd69`](#source-ctg-observation-nct02765399-2022-04-12-34c234debd69))

### Sources

<a id="source-ctg-observation-nct02765399-2022-04-12-34c234debd69"></a>
- **ClinicalTrials.gov record NCT02765399 · retained source version 2022-04-12:34c234debd69195589394e820a3501f4ae0c5a702a63b1606e3f38992d5570b8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02765399) (`ctg-observation-nct02765399-2022-04-12-34c234debd69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02765399." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02765399-liraglutide-v1 SHA-256: 3a1b870f18e9be36e7e0625272c88af14bd4ad4e7bfc9dcfa28743fe83a5fee9.

---

<a id="clinicaltrials-gov-nct02911818-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02911818

> PeptideScanner retained ClinicalTrials.gov record NCT02911818 at 2026-07-30T20:52:10.188Z. Its registry update date was 2019-05-07, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02911818-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-05-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02911818-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02911818-liraglutide-v1
- Content SHA-256: `3a8a30ea269adc01acdc66d35e95eb1ba0a82c4f6c45b93650e1bb70240d8029`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02911818 ([`ctg-observation-nct02911818-2019-05-07-df7cafc81a9c`](#source-ctg-observation-nct02911818-2019-05-07-df7cafc81a9c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02911818 at 2026-07-30T20:52:10.188Z. Its registry update date was 2019-05-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02911818-2019-05-07-df7cafc81a9c`](#source-ctg-observation-nct02911818-2019-05-07-df7cafc81a9c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02911818 at 2026-07-30T20:52:10.188Z. Its registry update date was 2019-05-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02911818-2019-05-07-df7cafc81a9c`](#source-ctg-observation-nct02911818-2019-05-07-df7cafc81a9c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02911818-2019-05-07-df7cafc81a9c`](#source-ctg-observation-nct02911818-2019-05-07-df7cafc81a9c))

### Sources

<a id="source-ctg-observation-nct02911818-2019-05-07-df7cafc81a9c"></a>
- **ClinicalTrials.gov record NCT02911818 · retained source version 2019-05-07:df7cafc81a9c9f2726b3dbf4d8160fa69da9d905cf3df68b3b273c75a928088e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02911818) (`ctg-observation-nct02911818-2019-05-07-df7cafc81a9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02911818." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02911818-liraglutide-v1 SHA-256: 3a8a30ea269adc01acdc66d35e95eb1ba0a82c4f6c45b93650e1bb70240d8029.

---

<a id="clinicaltrials-gov-nct02918279-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02918279

> PeptideScanner retained ClinicalTrials.gov record NCT02918279 at 2026-07-30T20:29:13.572Z. Its registry update date was 2020-04-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02918279-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-04-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02918279-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02918279-liraglutide-v1
- Content SHA-256: `11abc284c2afde80dccea45325009183d13cb8d499993d5b2dcf8b4d0bcbee83`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02918279 ([`ctg-observation-nct02918279-2020-04-27-aede943f7fa6`](#source-ctg-observation-nct02918279-2020-04-27-aede943f7fa6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02918279 at 2026-07-30T20:29:13.572Z. Its registry update date was 2020-04-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02918279-2020-04-27-aede943f7fa6`](#source-ctg-observation-nct02918279-2020-04-27-aede943f7fa6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02918279 at 2026-07-30T20:29:13.572Z. Its registry update date was 2020-04-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02918279-2020-04-27-aede943f7fa6`](#source-ctg-observation-nct02918279-2020-04-27-aede943f7fa6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02918279-2020-04-27-aede943f7fa6`](#source-ctg-observation-nct02918279-2020-04-27-aede943f7fa6))

### Sources

<a id="source-ctg-observation-nct02918279-2020-04-27-aede943f7fa6"></a>
- **ClinicalTrials.gov record NCT02918279 · retained source version 2020-04-27:aede943f7fa62e410f3e6ee7bd17bba398cc81b33a92fbef1afc40e3764c29de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02918279) (`ctg-observation-nct02918279-2020-04-27-aede943f7fa6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02918279." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02918279-liraglutide-v1 SHA-256: 11abc284c2afde80dccea45325009183d13cb8d499993d5b2dcf8b4d0bcbee83.

---

<a id="clinicaltrials-gov-nct02944500-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02944500

> PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02944500-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02944500-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02944500-liraglutide-v1
- Content SHA-256: `a623bb4991e11210d0745a77d18b7939d4bb074b2c6f9f4565194b1203d089ae`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02944500 ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

### Sources

<a id="source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92"></a>
- **ClinicalTrials.gov record NCT02944500 · retained source version 2026-05-01:2ab184f58b92a10a2d09128f3081f01713ff9c38f68bd2ddb16824bed4b684ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02944500) (`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02944500." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02944500-liraglutide-v1 SHA-256: a623bb4991e11210d0745a77d18b7939d4bb074b2c6f9f4565194b1203d089ae.

---

<a id="clinicaltrials-gov-nct02953665-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02953665

> PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02953665-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02953665-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02953665-liraglutide-v1
- Content SHA-256: `c6657f47bcdc927a7aaaf5ed85a1686a1dbb7ffc23db0c96eb4c2d165d70b3ea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02953665 ([`ctg-observation-nct02953665-2024-03-07-70c05accc476`](#source-ctg-observation-nct02953665-2024-03-07-70c05accc476))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02953665-2024-03-07-70c05accc476`](#source-ctg-observation-nct02953665-2024-03-07-70c05accc476))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02953665-2024-03-07-70c05accc476`](#source-ctg-observation-nct02953665-2024-03-07-70c05accc476))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02953665-2024-03-07-70c05accc476`](#source-ctg-observation-nct02953665-2024-03-07-70c05accc476))

### Sources

<a id="source-ctg-observation-nct02953665-2024-03-07-70c05accc476"></a>
- **ClinicalTrials.gov record NCT02953665 · retained source version 2024-03-07:70c05accc476d640e9f6a45fecba5b3cbbd2e0b39bd51d90cdd4acb055fcacfa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02953665) (`ctg-observation-nct02953665-2024-03-07-70c05accc476`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02953665." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02953665-liraglutide-v1 SHA-256: c6657f47bcdc927a7aaaf5ed85a1686a1dbb7ffc23db0c96eb4c2d165d70b3ea.

---

<a id="clinicaltrials-gov-nct02967757-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT02967757

> PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02967757-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02967757-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02967757-liraglutide-v1
- Content SHA-256: `4059969c562ae78bd4a939d1838afab0e68ccdd15060fdca9567f51e2fb95787`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02967757 ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`](#source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049))

### Sources

<a id="source-ctg-observation-nct02967757-2023-01-20-9aa28cc08049"></a>
- **ClinicalTrials.gov record NCT02967757 · retained source version 2023-01-20:9aa28cc0804923e16a352891245c5aed5fdf4a02a78a77211879d3ccb2d08e54** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02967757) (`ctg-observation-nct02967757-2023-01-20-9aa28cc08049`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02967757." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct02967757-liraglutide-v1 SHA-256: 4059969c562ae78bd4a939d1838afab0e68ccdd15060fdca9567f51e2fb95787.

---

<a id="clinicaltrials-gov-nct03036800-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03036800

> PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03036800-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-08-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03036800-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03036800-liraglutide-v1
- Content SHA-256: `7c8bcbf33ea3ff0abdbfdc12cfd7247f8c26858485ccc8a89a57f9637767b96f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03036800 ([`ctg-observation-nct03036800-2024-08-13-2fc0e382c31a`](#source-ctg-observation-nct03036800-2024-08-13-2fc0e382c31a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03036800-2024-08-13-2fc0e382c31a`](#source-ctg-observation-nct03036800-2024-08-13-2fc0e382c31a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03036800-2024-08-13-2fc0e382c31a`](#source-ctg-observation-nct03036800-2024-08-13-2fc0e382c31a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03036800-2024-08-13-2fc0e382c31a`](#source-ctg-observation-nct03036800-2024-08-13-2fc0e382c31a))

### Sources

<a id="source-ctg-observation-nct03036800-2024-08-13-2fc0e382c31a"></a>
- **ClinicalTrials.gov record NCT03036800 · retained source version 2024-08-13:2fc0e382c31a9ea146deedcb4758499c638c94c10ad86fbb200fdf4cd8c0df99** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03036800) (`ctg-observation-nct03036800-2024-08-13-2fc0e382c31a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03036800." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03036800-liraglutide-v1 SHA-256: 7c8bcbf33ea3ff0abdbfdc12cfd7247f8c26858485ccc8a89a57f9637767b96f.

---

<a id="clinicaltrials-gov-nct03068065-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03068065

> PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03068065-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03068065-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03068065-liraglutide-v1
- Content SHA-256: `0d5f103308025e54c414d779e2c26c23d2604ecf9f0cd13aa871b3b5a0d0eb2d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03068065 ([`ctg-observation-nct03068065-2017-03-01-2482c0808ba7`](#source-ctg-observation-nct03068065-2017-03-01-2482c0808ba7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03068065-2017-03-01-2482c0808ba7`](#source-ctg-observation-nct03068065-2017-03-01-2482c0808ba7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03068065-2017-03-01-2482c0808ba7`](#source-ctg-observation-nct03068065-2017-03-01-2482c0808ba7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03068065-2017-03-01-2482c0808ba7`](#source-ctg-observation-nct03068065-2017-03-01-2482c0808ba7))

### Sources

<a id="source-ctg-observation-nct03068065-2017-03-01-2482c0808ba7"></a>
- **ClinicalTrials.gov record NCT03068065 · retained source version 2017-03-01:2482c0808ba7879f335f794f2f618c46cf0e25d9fea3ea9472d4f9f114fa65ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03068065) (`ctg-observation-nct03068065-2017-03-01-2482c0808ba7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03068065." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03068065-liraglutide-v1 SHA-256: 0d5f103308025e54c414d779e2c26c23d2604ecf9f0cd13aa871b3b5a0d0eb2d.

---

<a id="clinicaltrials-gov-nct03158805-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03158805

> PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03158805-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03158805-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03158805-liraglutide-v1
- Content SHA-256: `cfa57b5212cabc6a7f2c4a4c40b35652df8e67df911e84ae94204c44af51dcc9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03158805 ([`ctg-observation-nct03158805-2025-03-12-c34ca92f848a`](#source-ctg-observation-nct03158805-2025-03-12-c34ca92f848a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03158805-2025-03-12-c34ca92f848a`](#source-ctg-observation-nct03158805-2025-03-12-c34ca92f848a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03158805-2025-03-12-c34ca92f848a`](#source-ctg-observation-nct03158805-2025-03-12-c34ca92f848a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03158805-2025-03-12-c34ca92f848a`](#source-ctg-observation-nct03158805-2025-03-12-c34ca92f848a))

### Sources

<a id="source-ctg-observation-nct03158805-2025-03-12-c34ca92f848a"></a>
- **ClinicalTrials.gov record NCT03158805 · retained source version 2025-03-12:c34ca92f848a73e5ed06931e8e9a1500d50ae600a4c47f205b0faea2474719e9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03158805) (`ctg-observation-nct03158805-2025-03-12-c34ca92f848a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03158805." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03158805-liraglutide-v1 SHA-256: cfa57b5212cabc6a7f2c4a4c40b35652df8e67df911e84ae94204c44af51dcc9.

---

<a id="clinicaltrials-gov-nct03374956-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03374956

> PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03374956-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03374956-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03374956-liraglutide-v1
- Content SHA-256: `c50798edff1699e38dff943566ac57094af0e7f2067a198a16690505d0a4bb19`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03374956 ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

### Sources

<a id="source-ctg-observation-nct03374956-2023-07-18-339e221e46e4"></a>
- **ClinicalTrials.gov record NCT03374956 · retained source version 2023-07-18:339e221e46e42c79e8bc5a011202507dc12637bd22eba26a877a62009a6ed5a9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03374956) (`ctg-observation-nct03374956-2023-07-18-339e221e46e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03374956." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03374956-liraglutide-v1 SHA-256: c50798edff1699e38dff943566ac57094af0e7f2067a198a16690505d0a4bb19.

---

<a id="clinicaltrials-gov-nct03466021-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03466021

> PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03466021-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03466021-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03466021-liraglutide-v1
- Content SHA-256: `6f47c595b39466679be02db6ffb9bc087d3059bed42372177fc570e7d61cd594`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03466021 ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03466021-2021-03-16-252ec0730220`](#source-ctg-observation-nct03466021-2021-03-16-252ec0730220))

### Sources

<a id="source-ctg-observation-nct03466021-2021-03-16-252ec0730220"></a>
- **ClinicalTrials.gov record NCT03466021 · retained source version 2021-03-16:252ec0730220066aba86678666fd29420fe59adc3285d317c67d5c02dc87e64b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03466021) (`ctg-observation-nct03466021-2021-03-16-252ec0730220`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03466021." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03466021-liraglutide-v1 SHA-256: 6f47c595b39466679be02db6ffb9bc087d3059bed42372177fc570e7d61cd594.

---

<a id="clinicaltrials-gov-nct03479762-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03479762

> PeptideScanner retained ClinicalTrials.gov record NCT03479762 at 2026-07-30T19:32:59.846Z. Its registry update date was 2022-11-25, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03479762-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03479762-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03479762-liraglutide-v1
- Content SHA-256: `3080e24dc430d7b4fd7349dd44a81776ec478e0080265b63876457c8c9eee60d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03479762 ([`ctg-observation-nct03479762-2022-11-25-4b96658deba6`](#source-ctg-observation-nct03479762-2022-11-25-4b96658deba6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03479762 at 2026-07-30T19:32:59.846Z. Its registry update date was 2022-11-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03479762-2022-11-25-4b96658deba6`](#source-ctg-observation-nct03479762-2022-11-25-4b96658deba6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03479762 at 2026-07-30T19:32:59.846Z. Its registry update date was 2022-11-25, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03479762-2022-11-25-4b96658deba6`](#source-ctg-observation-nct03479762-2022-11-25-4b96658deba6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03479762-2022-11-25-4b96658deba6`](#source-ctg-observation-nct03479762-2022-11-25-4b96658deba6))

### Sources

<a id="source-ctg-observation-nct03479762-2022-11-25-4b96658deba6"></a>
- **ClinicalTrials.gov record NCT03479762 · retained source version 2022-11-25:4b96658deba689511c75d7d6bd060ec8eee3b6feacc86b9d1ea3dba1c62591fd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03479762) (`ctg-observation-nct03479762-2022-11-25-4b96658deba6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03479762." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03479762-liraglutide-v1 SHA-256: 3080e24dc430d7b4fd7349dd44a81776ec478e0080265b63876457c8c9eee60d.

---

<a id="clinicaltrials-gov-nct03619330-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03619330

> PeptideScanner retained ClinicalTrials.gov record NCT03619330 at 2026-07-30T21:10:02.994Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03619330-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03619330-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03619330-liraglutide-v1
- Content SHA-256: `06a2c7c0f0852f336319da5b2134ad32a052aed380f1536f160cbb2ae9cc4007`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03619330 ([`ctg-observation-nct03619330-2018-08-07-98a0e87b932b`](#source-ctg-observation-nct03619330-2018-08-07-98a0e87b932b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03619330 at 2026-07-30T21:10:02.994Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03619330-2018-08-07-98a0e87b932b`](#source-ctg-observation-nct03619330-2018-08-07-98a0e87b932b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03619330 at 2026-07-30T21:10:02.994Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03619330-2018-08-07-98a0e87b932b`](#source-ctg-observation-nct03619330-2018-08-07-98a0e87b932b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03619330-2018-08-07-98a0e87b932b`](#source-ctg-observation-nct03619330-2018-08-07-98a0e87b932b))

### Sources

<a id="source-ctg-observation-nct03619330-2018-08-07-98a0e87b932b"></a>
- **ClinicalTrials.gov record NCT03619330 · retained source version 2018-08-07:98a0e87b932bb9738bb4ab39f93fd76ac666760f316ec42121b3c2d4919a732d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03619330) (`ctg-observation-nct03619330-2018-08-07-98a0e87b932b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03619330." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03619330-liraglutide-v1 SHA-256: 06a2c7c0f0852f336319da5b2134ad32a052aed380f1536f160cbb2ae9cc4007.

---

<a id="clinicaltrials-gov-nct03672812-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03672812

> PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03672812-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03672812-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03672812-liraglutide-v1
- Content SHA-256: `d60f4565c86dc31c99ff001e8a3c2b789ccf5fa41318b68647cd69c0593ffe03`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03672812 ([`ctg-observation-nct03672812-2024-03-05-fb7401b1f18d`](#source-ctg-observation-nct03672812-2024-03-05-fb7401b1f18d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03672812-2024-03-05-fb7401b1f18d`](#source-ctg-observation-nct03672812-2024-03-05-fb7401b1f18d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03672812-2024-03-05-fb7401b1f18d`](#source-ctg-observation-nct03672812-2024-03-05-fb7401b1f18d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03672812-2024-03-05-fb7401b1f18d`](#source-ctg-observation-nct03672812-2024-03-05-fb7401b1f18d))

### Sources

<a id="source-ctg-observation-nct03672812-2024-03-05-fb7401b1f18d"></a>
- **ClinicalTrials.gov record NCT03672812 · retained source version 2024-03-05:fb7401b1f18d62afe048a85c6a417c4776a8d8912d92ee79d5e83a407df8a35b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03672812) (`ctg-observation-nct03672812-2024-03-05-fb7401b1f18d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03672812." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03672812-liraglutide-v1 SHA-256: d60f4565c86dc31c99ff001e8a3c2b789ccf5fa41318b68647cd69c0593ffe03.

---

<a id="clinicaltrials-gov-nct03737240-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03737240

> PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03737240-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03737240-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03737240-liraglutide-v1
- Content SHA-256: `0de1bcaefd8a1a06e4243a6cc626809bb137a09ec60a317054d670583e52ea52`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03737240 ([`ctg-observation-nct03737240-2023-09-08-1098278c21cf`](#source-ctg-observation-nct03737240-2023-09-08-1098278c21cf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03737240-2023-09-08-1098278c21cf`](#source-ctg-observation-nct03737240-2023-09-08-1098278c21cf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03737240-2023-09-08-1098278c21cf`](#source-ctg-observation-nct03737240-2023-09-08-1098278c21cf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03737240-2023-09-08-1098278c21cf`](#source-ctg-observation-nct03737240-2023-09-08-1098278c21cf))

### Sources

<a id="source-ctg-observation-nct03737240-2023-09-08-1098278c21cf"></a>
- **ClinicalTrials.gov record NCT03737240 · retained source version 2023-09-08:1098278c21cf701af83f2e8ed9043a559eadff4282f4b46f0d0581d2d13b3134** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03737240) (`ctg-observation-nct03737240-2023-09-08-1098278c21cf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03737240." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03737240-liraglutide-v1 SHA-256: 0de1bcaefd8a1a06e4243a6cc626809bb137a09ec60a317054d670583e52ea52.

---

<a id="clinicaltrials-gov-nct03795701-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03795701

> PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03795701-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-12-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03795701-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03795701-liraglutide-v1
- Content SHA-256: `2c145180e0f952adc422e42123cc4ec423d5462aa6d2c5bf4d790cdfc340af22`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03795701 ([`ctg-observation-nct03795701-2023-12-04-4c6f297d949d`](#source-ctg-observation-nct03795701-2023-12-04-4c6f297d949d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03795701-2023-12-04-4c6f297d949d`](#source-ctg-observation-nct03795701-2023-12-04-4c6f297d949d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03795701-2023-12-04-4c6f297d949d`](#source-ctg-observation-nct03795701-2023-12-04-4c6f297d949d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03795701-2023-12-04-4c6f297d949d`](#source-ctg-observation-nct03795701-2023-12-04-4c6f297d949d))

### Sources

<a id="source-ctg-observation-nct03795701-2023-12-04-4c6f297d949d"></a>
- **ClinicalTrials.gov record NCT03795701 · retained source version 2023-12-04:4c6f297d949d6b4f99cdcc166d4ddd480d0c2fca6e407e3372b20aa99c07411f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03795701) (`ctg-observation-nct03795701-2023-12-04-4c6f297d949d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03795701." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03795701-liraglutide-v1 SHA-256: 2c145180e0f952adc422e42123cc4ec423d5462aa6d2c5bf4d790cdfc340af22.

---

<a id="clinicaltrials-gov-nct03856632-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03856632

> PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03856632-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03856632-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03856632-liraglutide-v1
- Content SHA-256: `0996a56e0602c361450ea2adf01aea23cc993e1052e7b7d3ead8b91776db98a5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03856632 ([`ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc`](#source-ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc`](#source-ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc`](#source-ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc`](#source-ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc))

### Sources

<a id="source-ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc"></a>
- **ClinicalTrials.gov record NCT03856632 · retained source version 2026-05-01:1f8eb2a9d3bcc1e748e2d5612992b515bc965540821b142ac204bcaf5ab738c7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03856632) (`ctg-observation-nct03856632-2026-05-01-1f8eb2a9d3bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03856632." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03856632-liraglutide-v1 SHA-256: 0996a56e0602c361450ea2adf01aea23cc993e1052e7b7d3ead8b91776db98a5.

---

<a id="clinicaltrials-gov-nct03883412-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03883412

> PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03883412-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-12
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03883412-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03883412-liraglutide-v1
- Content SHA-256: `3a56b031e20b951333fb8c5b0a8f123d4824a5802fec6d0d4d5b739e670287d7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03883412 ([`ctg-observation-nct03883412-2026-08-12-71b4a7b41434`](#source-ctg-observation-nct03883412-2026-08-12-71b4a7b41434))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03883412-2026-08-12-71b4a7b41434`](#source-ctg-observation-nct03883412-2026-08-12-71b4a7b41434))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03883412-2026-08-12-71b4a7b41434`](#source-ctg-observation-nct03883412-2026-08-12-71b4a7b41434))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03883412-2026-08-12-71b4a7b41434`](#source-ctg-observation-nct03883412-2026-08-12-71b4a7b41434))

### Sources

<a id="source-ctg-observation-nct03883412-2026-08-12-71b4a7b41434"></a>
- **ClinicalTrials.gov record NCT03883412 · retained source version 2026-08-12:71b4a7b4143414f41ec8a4fb62a8a5e2522df79b187a5d4266769c5ecaaca41e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03883412) (`ctg-observation-nct03883412-2026-08-12-71b4a7b41434`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03883412." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03883412-liraglutide-v1 SHA-256: 3a56b031e20b951333fb8c5b0a8f123d4824a5802fec6d0d4d5b739e670287d7.

---

<a id="clinicaltrials-gov-nct03936049-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT03936049

> PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03936049-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03936049-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03936049-liraglutide-v1
- Content SHA-256: `7452de8d79f91de8da65af8cfa3f1ad216b61fb8505e8827cd6dd94376c0e486`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03936049 ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

### Sources

<a id="source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d"></a>
- **ClinicalTrials.gov record NCT03936049 · retained source version 2023-07-27:70e1dcd6b30df121b0c5e008c061993fb8eb3775c1a42ef9e8586166ef23d17b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03936049) (`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03936049." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct03936049-liraglutide-v1 SHA-256: 7452de8d79f91de8da65af8cfa3f1ad216b61fb8505e8827cd6dd94376c0e486.

---

<a id="clinicaltrials-gov-nct04466566-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT04466566

> PeptideScanner retained ClinicalTrials.gov record NCT04466566 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04466566-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-28
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04466566-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04466566-liraglutide-v1
- Content SHA-256: `ac08d35ee3faf958608cbf3a9088c9798c00ec2de5e31033c2edb4dbfb4276c1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04466566 ([`ctg-observation-nct04466566-2026-10-28-4589c5a340a9`](#source-ctg-observation-nct04466566-2026-10-28-4589c5a340a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04466566 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04466566-2026-10-28-4589c5a340a9`](#source-ctg-observation-nct04466566-2026-10-28-4589c5a340a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04466566 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04466566-2026-10-28-4589c5a340a9`](#source-ctg-observation-nct04466566-2026-10-28-4589c5a340a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04466566-2026-10-28-4589c5a340a9`](#source-ctg-observation-nct04466566-2026-10-28-4589c5a340a9))

### Sources

<a id="source-ctg-observation-nct04466566-2026-10-28-4589c5a340a9"></a>
- **ClinicalTrials.gov record NCT04466566 · retained source version 2026-10-28:4589c5a340a9b4a0539b84cd34e3edf66306b04f6d10c77b1966eee032c43651** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04466566) (`ctg-observation-nct04466566-2026-10-28-4589c5a340a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04466566." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04466566-liraglutide-v1 SHA-256: ac08d35ee3faf958608cbf3a9088c9798c00ec2de5e31033c2edb4dbfb4276c1.

---

<a id="clinicaltrials-gov-nct04575844-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT04575844

> PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04575844-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04575844-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04575844-liraglutide-v1
- Content SHA-256: `094838d7e35c946452f987c34a568d29db7c42ff88bd73bcb08f6f5287f1b5e8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04575844 ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

### Sources

<a id="source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b"></a>
- **ClinicalTrials.gov record NCT04575844 · retained source version 2026-05-06:d301f90b0d5be92254aa2e6906ecb93e099fc1c8c96ed61c93b1ff7ba0bc9943** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04575844) (`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04575844." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04575844-liraglutide-v1 SHA-256: 094838d7e35c946452f987c34a568d29db7c42ff88bd73bcb08f6f5287f1b5e8.

---

<a id="clinicaltrials-gov-nct04605861-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT04605861

> PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04605861-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-06-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04605861-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04605861-liraglutide-v1
- Content SHA-256: `b5121a405f0ce5ba5aee8407a71d0710da555205c017fa448bcdc460d0871e1e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04605861 ([`ctg-observation-nct04605861-2023-06-07-71d70816a63f`](#source-ctg-observation-nct04605861-2023-06-07-71d70816a63f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04605861-2023-06-07-71d70816a63f`](#source-ctg-observation-nct04605861-2023-06-07-71d70816a63f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04605861-2023-06-07-71d70816a63f`](#source-ctg-observation-nct04605861-2023-06-07-71d70816a63f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04605861-2023-06-07-71d70816a63f`](#source-ctg-observation-nct04605861-2023-06-07-71d70816a63f))

### Sources

<a id="source-ctg-observation-nct04605861-2023-06-07-71d70816a63f"></a>
- **ClinicalTrials.gov record NCT04605861 · retained source version 2023-06-07:71d70816a63f82406a10dd2655b965273cce8913580682a60f5b056dc06eefdd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04605861) (`ctg-observation-nct04605861-2023-06-07-71d70816a63f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04605861." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04605861-liraglutide-v1 SHA-256: b5121a405f0ce5ba5aee8407a71d0710da555205c017fa448bcdc460d0871e1e.

---

<a id="clinicaltrials-gov-nct04775082-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT04775082

> PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04775082-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04775082-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04775082-liraglutide-v1
- Content SHA-256: `0237aa0c73eaa30534eebede71501c953cf85cb359690531089cad24ee978f0d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04775082 ([`ctg-observation-nct04775082-2026-07-09-b565460c570f`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04775082-2026-07-09-b565460c570f`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04775082-2026-07-09-b565460c570f`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04775082-2026-07-09-b565460c570f`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f))

### Sources

<a id="source-ctg-observation-nct04775082-2026-07-09-b565460c570f"></a>
- **ClinicalTrials.gov record NCT04775082 · retained source version 2026-07-09:b565460c570f54691038370a4ed8849b5613367537a68460b01624478cd31cfe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04775082) (`ctg-observation-nct04775082-2026-07-09-b565460c570f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04775082." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04775082-liraglutide-v1 SHA-256: 0237aa0c73eaa30534eebede71501c953cf85cb359690531089cad24ee978f0d.

---

<a id="clinicaltrials-gov-nct04775082-liraglutide-v2"></a>

## ClinicalTrials.gov record NCT04775082

> PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04775082-liraglutide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04775082-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04775082-liraglutide-v2
- Content SHA-256: `c1981455d8680a87f39c74f8f0caf52a3f5ded58154d7a29c0ee145fe4fe1888`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04775082 ([`ctg-observation-nct04775082-2026-07-09-b565460c570f-r2`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04775082-2026-07-09-b565460c570f-r2`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04775082-2026-07-09-b565460c570f-r2`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04775082-2026-07-09-b565460c570f-r2`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f-r2))

### Sources

<a id="source-ctg-observation-nct04775082-2026-07-09-b565460c570f-r2"></a>
- **ClinicalTrials.gov record NCT04775082 · retained source version 2026-11-16:76f5393c2feb9bc0c30a792786461560044658fb99e6e94992bd2440ad4ce177** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04775082) (`ctg-observation-nct04775082-2026-07-09-b565460c570f-r2`)

### Correction lineage

updated on 2026-11-16: ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct04775082-2026-07-09-b565460c570f-r2`](#source-ctg-observation-nct04775082-2026-07-09-b565460c570f-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04775082." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04775082-liraglutide-v2 SHA-256: c1981455d8680a87f39c74f8f0caf52a3f5ded58154d7a29c0ee145fe4fe1888.

---

<a id="clinicaltrials-gov-nct04881110-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT04881110

> PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04881110-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04881110-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04881110-liraglutide-v1
- Content SHA-256: `2256b66e98fdbafa5813cd8303c426c02b11085060f2dd415188f669768e803d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04881110 ([`ctg-observation-nct04881110-2025-03-03-430db87b849d`](#source-ctg-observation-nct04881110-2025-03-03-430db87b849d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04881110-2025-03-03-430db87b849d`](#source-ctg-observation-nct04881110-2025-03-03-430db87b849d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04881110-2025-03-03-430db87b849d`](#source-ctg-observation-nct04881110-2025-03-03-430db87b849d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04881110-2025-03-03-430db87b849d`](#source-ctg-observation-nct04881110-2025-03-03-430db87b849d))

### Sources

<a id="source-ctg-observation-nct04881110-2025-03-03-430db87b849d"></a>
- **ClinicalTrials.gov record NCT04881110 · retained source version 2025-03-03:430db87b849dfeeab0cbfc6362b977187972ec221f2cb6c55f812e42611c44e1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04881110) (`ctg-observation-nct04881110-2025-03-03-430db87b849d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04881110." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04881110-liraglutide-v1 SHA-256: 2256b66e98fdbafa5813cd8303c426c02b11085060f2dd415188f669768e803d.

---

<a id="clinicaltrials-gov-nct04883346-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT04883346

> PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04883346-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04883346-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04883346-liraglutide-v1
- Content SHA-256: `7fbf442aee5303aa265e9b4876c3dfddf54e09d9599d4e06f5b0026e05ab8098`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04883346 ([`ctg-observation-nct04883346-2024-11-20-67f263748e10`](#source-ctg-observation-nct04883346-2024-11-20-67f263748e10))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04883346-2024-11-20-67f263748e10`](#source-ctg-observation-nct04883346-2024-11-20-67f263748e10))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04883346-2024-11-20-67f263748e10`](#source-ctg-observation-nct04883346-2024-11-20-67f263748e10))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04883346-2024-11-20-67f263748e10`](#source-ctg-observation-nct04883346-2024-11-20-67f263748e10))

### Sources

<a id="source-ctg-observation-nct04883346-2024-11-20-67f263748e10"></a>
- **ClinicalTrials.gov record NCT04883346 · retained source version 2024-11-20:67f263748e102c9ec54f5ed3cbce1d91cdcf951e33ce667e4107286d2d470172** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04883346) (`ctg-observation-nct04883346-2024-11-20-67f263748e10`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04883346." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct04883346-liraglutide-v1 SHA-256: 7fbf442aee5303aa265e9b4876c3dfddf54e09d9599d4e06f5b0026e05ab8098.

---

<a id="clinicaltrials-gov-nct05153590-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT05153590

> PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05153590-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05153590-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05153590-liraglutide-v1
- Content SHA-256: `ec0e431a6ebaf390a4356b06b7fe2e7efd60a3538e17d6ab3eb14bf433009da2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05153590 ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

### Sources

<a id="source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515"></a>
- **ClinicalTrials.gov record NCT05153590 · retained source version 2022-11-17:0b7ff7017515244ab1b98512492af60a8a4838ad0398b1aa71a49875e29f9657** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05153590) (`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05153590." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05153590-liraglutide-v1 SHA-256: ec0e431a6ebaf390a4356b06b7fe2e7efd60a3538e17d6ab3eb14bf433009da2.

---

<a id="clinicaltrials-gov-nct05313529-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT05313529

> PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05313529-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-06
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05313529-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05313529-liraglutide-v1
- Content SHA-256: `dcbb899c7324829c7fc95eebf5c5038a159796bcbe9c54e5eff85c67a57cd9ff`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05313529 ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

### Sources

<a id="source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621"></a>
- **ClinicalTrials.gov record NCT05313529 · retained source version 2026-08-06:c58d3b45f621f60f25ac9f31cb95bf9db424252032dd2b6f30977f0590a43db4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05313529) (`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05313529." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05313529-liraglutide-v1 SHA-256: dcbb899c7324829c7fc95eebf5c5038a159796bcbe9c54e5eff85c67a57cd9ff.

---

<a id="clinicaltrials-gov-nct05681299-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT05681299

> PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05681299-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05681299-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05681299-liraglutide-v1
- Content SHA-256: `614ad2617931d52869f428b479000955ed2ef330943cdc1564938b0e02d52171`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05681299 ([`ctg-observation-nct05681299-2026-03-04-bed1d964a9df`](#source-ctg-observation-nct05681299-2026-03-04-bed1d964a9df))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05681299-2026-03-04-bed1d964a9df`](#source-ctg-observation-nct05681299-2026-03-04-bed1d964a9df))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05681299-2026-03-04-bed1d964a9df`](#source-ctg-observation-nct05681299-2026-03-04-bed1d964a9df))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05681299-2026-03-04-bed1d964a9df`](#source-ctg-observation-nct05681299-2026-03-04-bed1d964a9df))

### Sources

<a id="source-ctg-observation-nct05681299-2026-03-04-bed1d964a9df"></a>
- **ClinicalTrials.gov record NCT05681299 · retained source version 2026-03-04:bed1d964a9dfe82c45fbfb9322dae8e7cde730ec1a45893edec81fcea32039a2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05681299) (`ctg-observation-nct05681299-2026-03-04-bed1d964a9df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05681299." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05681299-liraglutide-v1 SHA-256: 614ad2617931d52869f428b479000955ed2ef330943cdc1564938b0e02d52171.

---

<a id="clinicaltrials-gov-nct05965908-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT05965908

> PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05965908-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05965908-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05965908-liraglutide-v1
- Content SHA-256: `67111eb5eadfe4d7746b1c04c349c4e41de8bb19619bebf3b63ddcf902800a64`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05965908 ([`ctg-observation-nct05965908-2026-03-06-00023c271ec2`](#source-ctg-observation-nct05965908-2026-03-06-00023c271ec2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05965908-2026-03-06-00023c271ec2`](#source-ctg-observation-nct05965908-2026-03-06-00023c271ec2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05965908-2026-03-06-00023c271ec2`](#source-ctg-observation-nct05965908-2026-03-06-00023c271ec2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05965908-2026-03-06-00023c271ec2`](#source-ctg-observation-nct05965908-2026-03-06-00023c271ec2))

### Sources

<a id="source-ctg-observation-nct05965908-2026-03-06-00023c271ec2"></a>
- **ClinicalTrials.gov record NCT05965908 · retained source version 2026-03-06:00023c271ec208ba5a3873f65d5a6a89e967d536e9bfdc4c4f53d74aea6f5a87** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05965908) (`ctg-observation-nct05965908-2026-03-06-00023c271ec2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05965908." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct05965908-liraglutide-v1 SHA-256: 67111eb5eadfe4d7746b1c04c349c4e41de8bb19619bebf3b63ddcf902800a64.

---

<a id="clinicaltrials-gov-nct06099067-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT06099067

> PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06099067-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-08-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06099067-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct06099067-liraglutide-v1
- Content SHA-256: `3c439fb16f5e5af564f9eb85be1f02885c190eebcce97bc0ae9c30be153c8474`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06099067 ([`ctg-observation-nct06099067-2024-08-30-1a5494f81129`](#source-ctg-observation-nct06099067-2024-08-30-1a5494f81129))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct06099067-2024-08-30-1a5494f81129`](#source-ctg-observation-nct06099067-2024-08-30-1a5494f81129))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct06099067-2024-08-30-1a5494f81129`](#source-ctg-observation-nct06099067-2024-08-30-1a5494f81129))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06099067-2024-08-30-1a5494f81129`](#source-ctg-observation-nct06099067-2024-08-30-1a5494f81129))

### Sources

<a id="source-ctg-observation-nct06099067-2024-08-30-1a5494f81129"></a>
- **ClinicalTrials.gov record NCT06099067 · retained source version 2024-08-30:1a5494f811295efa74946662494d3e84fa95b2815245373f7f2a2cbd0c58d83f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06099067) (`ctg-observation-nct06099067-2024-08-30-1a5494f81129`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06099067." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct06099067-liraglutide-v1 SHA-256: 3c439fb16f5e5af564f9eb85be1f02885c190eebcce97bc0ae9c30be153c8474.

---

<a id="clinicaltrials-gov-nct06283641-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT06283641

> PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06283641-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06283641-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct06283641-liraglutide-v1
- Content SHA-256: `35933ed4fb6a653ae59c73e866857ac664fdc72ec66da9cbc890e8fce205f9bf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06283641 ([`ctg-observation-nct06283641-2026-01-09-8066c6420ae5`](#source-ctg-observation-nct06283641-2026-01-09-8066c6420ae5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct06283641-2026-01-09-8066c6420ae5`](#source-ctg-observation-nct06283641-2026-01-09-8066c6420ae5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct06283641-2026-01-09-8066c6420ae5`](#source-ctg-observation-nct06283641-2026-01-09-8066c6420ae5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06283641-2026-01-09-8066c6420ae5`](#source-ctg-observation-nct06283641-2026-01-09-8066c6420ae5))

### Sources

<a id="source-ctg-observation-nct06283641-2026-01-09-8066c6420ae5"></a>
- **ClinicalTrials.gov record NCT06283641 · retained source version 2026-01-09:8066c6420ae5b9605b36d64514d0da0ade250bd632b43f58e71e9acd7bf6e040** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06283641) (`ctg-observation-nct06283641-2026-01-09-8066c6420ae5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06283641." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct06283641-liraglutide-v1 SHA-256: 35933ed4fb6a653ae59c73e866857ac664fdc72ec66da9cbc890e8fce205f9bf.

---

<a id="clinicaltrials-gov-nct06976619-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT06976619

> PeptideScanner retained ClinicalTrials.gov record NCT06976619 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06976619-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-19
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06976619-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct06976619-liraglutide-v1
- Content SHA-256: `bc269cbe7ddaf334d501a990a732be0392b1b0e9c209b0c15855ddc90391b8be`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06976619 ([`ctg-observation-nct06976619-2026-10-19-b888f351eb41`](#source-ctg-observation-nct06976619-2026-10-19-b888f351eb41))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06976619 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct06976619-2026-10-19-b888f351eb41`](#source-ctg-observation-nct06976619-2026-10-19-b888f351eb41))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06976619 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct06976619-2026-10-19-b888f351eb41`](#source-ctg-observation-nct06976619-2026-10-19-b888f351eb41))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06976619-2026-10-19-b888f351eb41`](#source-ctg-observation-nct06976619-2026-10-19-b888f351eb41))

### Sources

<a id="source-ctg-observation-nct06976619-2026-10-19-b888f351eb41"></a>
- **ClinicalTrials.gov record NCT06976619 · retained source version 2026-10-19:b888f351eb4189c9e953948ff276a6af11fcf63e0c66460f6589099dc650a2e5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06976619) (`ctg-observation-nct06976619-2026-10-19-b888f351eb41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06976619." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct06976619-liraglutide-v1 SHA-256: bc269cbe7ddaf334d501a990a732be0392b1b0e9c209b0c15855ddc90391b8be.

---

<a id="clinicaltrials-gov-nct07029009-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT07029009

> PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07029009-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07029009-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct07029009-liraglutide-v1
- Content SHA-256: `b8c6f662ca80fdee12bbe2773b7c9e8ef61ecc56a1009def57291f449b1c0645`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07029009 ([`ctg-observation-nct07029009-2025-12-17-bb3755c07710`](#source-ctg-observation-nct07029009-2025-12-17-bb3755c07710))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct07029009-2025-12-17-bb3755c07710`](#source-ctg-observation-nct07029009-2025-12-17-bb3755c07710))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct07029009-2025-12-17-bb3755c07710`](#source-ctg-observation-nct07029009-2025-12-17-bb3755c07710))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07029009-2025-12-17-bb3755c07710`](#source-ctg-observation-nct07029009-2025-12-17-bb3755c07710))

### Sources

<a id="source-ctg-observation-nct07029009-2025-12-17-bb3755c07710"></a>
- **ClinicalTrials.gov record NCT07029009 · retained source version 2025-12-17:bb3755c0771079f42200d2d2390051aa7a4d4abd5b472d688da3e9a3fbac31af** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07029009) (`ctg-observation-nct07029009-2025-12-17-bb3755c07710`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07029009." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct07029009-liraglutide-v1 SHA-256: b8c6f662ca80fdee12bbe2773b7c9e8ef61ecc56a1009def57291f449b1c0645.

---

<a id="clinicaltrials-gov-nct07225829-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT07225829

> PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07225829-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07225829-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct07225829-liraglutide-v1
- Content SHA-256: `03282673ff27020b29a1b91e032366ca02c5eebee070c9cdd19b733af8f685ac`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07225829 ([`ctg-observation-nct07225829-2026-07-27-1bf477b28bc4`](#source-ctg-observation-nct07225829-2026-07-27-1bf477b28bc4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct07225829-2026-07-27-1bf477b28bc4`](#source-ctg-observation-nct07225829-2026-07-27-1bf477b28bc4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct07225829-2026-07-27-1bf477b28bc4`](#source-ctg-observation-nct07225829-2026-07-27-1bf477b28bc4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07225829-2026-07-27-1bf477b28bc4`](#source-ctg-observation-nct07225829-2026-07-27-1bf477b28bc4))

### Sources

<a id="source-ctg-observation-nct07225829-2026-07-27-1bf477b28bc4"></a>
- **ClinicalTrials.gov record NCT07225829 · retained source version 2026-07-27:1bf477b28bc4e2f46d9894551b54c0f70bb8663c535dadd3fdd96d22fb9a1792** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07225829) (`ctg-observation-nct07225829-2026-07-27-1bf477b28bc4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07225829." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct07225829-liraglutide-v1 SHA-256: 03282673ff27020b29a1b91e032366ca02c5eebee070c9cdd19b733af8f685ac.

---

<a id="clinicaltrials-gov-nct07913685-liraglutide-v1"></a>

## ClinicalTrials.gov record NCT07913685

> PeptideScanner retained ClinicalTrials.gov record NCT07913685 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07913685-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-03
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07913685-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct07913685-liraglutide-v1
- Content SHA-256: `0dc5be478e6aaa17d212b1c480eb00af7f06bcef206290603be40118cb659f33`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07913685 ([`ctg-observation-nct07913685-2026-11-03-80901fb8385a`](#source-ctg-observation-nct07913685-2026-11-03-80901fb8385a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07913685 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct07913685-2026-11-03-80901fb8385a`](#source-ctg-observation-nct07913685-2026-11-03-80901fb8385a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07913685 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct07913685-2026-11-03-80901fb8385a`](#source-ctg-observation-nct07913685-2026-11-03-80901fb8385a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07913685-2026-11-03-80901fb8385a`](#source-ctg-observation-nct07913685-2026-11-03-80901fb8385a))

### Sources

<a id="source-ctg-observation-nct07913685-2026-11-03-80901fb8385a"></a>
- **ClinicalTrials.gov record NCT07913685 · retained source version 2026-11-03:80901fb8385a411d1a2b00724af441de5d1a6cdff0fa56794dfd9df4f8e1b660** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07913685) (`ctg-observation-nct07913685-2026-11-03-80901fb8385a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07913685." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#clinicaltrials-gov-nct07913685-liraglutide-v1 SHA-256: 0dc5be478e6aaa17d212b1c480eb00af7f06bcef206290603be40118cb659f33.

---

<a id="dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-v1"></a>

## Liraglutide DailyMed SPL version 3

> DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-26
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-v1
- Content SHA-256: `8f699532edfd2210c31f7090bc0616510e93861d7f0de380e94062cbe86734b4`

### Claims and source pins

#### Headline

Liraglutide DailyMed SPL version 3 ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history))

#### Summary

DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history))

### Sources

<a id="source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history"></a>
- **DailyMed SPL SET ID 22c86976-9657-4dd0-8fff-0c3f3f08357c · SPL version 3 · published 2026-02-26 · retained ZIP SHA-256 46fd6d808082199ec5eb3c75a10aef06649085155dc5cf0d13920902c54c88c5** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=22c86976-9657-4dd0-8fff-0c3f3f08357c&version=3) (`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide DailyMed SPL version 3." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v3-v1 SHA-256: 8f699532edfd2210c31f7090bc0616510e93861d7f0de380e94062cbe86734b4.

---

<a id="dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-v1"></a>

## Liraglutide DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-14
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-v1
- Content SHA-256: `cc36caed0217aeeb9a1b91b1c554e407c28092e0655c533a6fdfe60da7e5d084`

### Claims and source pins

#### Headline

Liraglutide DailyMed SPL version 6 ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history`](#source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history))

### Sources

<a id="source-dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history"></a>
- **DailyMed SPL SET ID 22c86976-9657-4dd0-8fff-0c3f3f08357c · SPL version 6 · published 2026-07-14 · retained ZIP SHA-256 48d493b4dc6af7d7574aedf0a2f7ab6235a9ed62875baffe6c484b5433647541** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=22c86976-9657-4dd0-8fff-0c3f3f08357c&version=6) (`dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#dailymed-label-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6-v1 SHA-256: cc36caed0217aeeb9a1b91b1c554e407c28092e0655c533a6fdfe60da7e5d084.

---

<a id="fda-drugs-anda212552-v1"></a>

## Drugs@FDA application ANDA212552

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212552:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-30
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212552/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda212552-v1
- Content SHA-256: `071c39e27649c5650d30cef2f9aa71f3759ff91a3ddb51ce281de448824904a2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212552 ([`fda-drugs-anda212552-2026-03-30-70ff65d6f379`](#source-fda-drugs-anda212552-2026-03-30-70ff65d6f379))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda212552-2026-03-30-70ff65d6f379`](#source-fda-drugs-anda212552-2026-03-30-70ff65d6f379))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda212552-2026-03-30-70ff65d6f379`](#source-fda-drugs-anda212552-2026-03-30-70ff65d6f379))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212552-2026-03-30-70ff65d6f379`](#source-fda-drugs-anda212552-2026-03-30-70ff65d6f379))

### Sources

<a id="source-fda-drugs-anda212552-2026-03-30-70ff65d6f379"></a>
- **Drugs@FDA application ANDA212552 · original submission status AP · 2026-03-30 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212552%22&limit=1) (`fda-drugs-anda212552-2026-03-30-70ff65d6f379`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212552." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda212552-v1 SHA-256: 071c39e27649c5650d30cef2f9aa71f3759ff91a3ddb51ce281de448824904a2.

---

<a id="fda-drugs-anda212972-v1"></a>

## Drugs@FDA application ANDA212972

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212972:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-01
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212972/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda212972-v1
- Content SHA-256: `35c98ca5cf545c04ee145e1bec3df83490f4008761afd7cc00bed6ce40dd3cf1`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212972 ([`fda-drugs-anda212972-2026-07-01-5323e3db3f0a`](#source-fda-drugs-anda212972-2026-07-01-5323e3db3f0a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda212972-2026-07-01-5323e3db3f0a`](#source-fda-drugs-anda212972-2026-07-01-5323e3db3f0a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda212972-2026-07-01-5323e3db3f0a`](#source-fda-drugs-anda212972-2026-07-01-5323e3db3f0a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212972-2026-07-01-5323e3db3f0a`](#source-fda-drugs-anda212972-2026-07-01-5323e3db3f0a))

### Sources

<a id="source-fda-drugs-anda212972-2026-07-01-5323e3db3f0a"></a>
- **Drugs@FDA application ANDA212972 · original submission status AP · 2026-07-01 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212972%22&limit=1) (`fda-drugs-anda212972-2026-07-01-5323e3db3f0a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212972." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda212972-v1 SHA-256: 35c98ca5cf545c04ee145e1bec3df83490f4008761afd7cc00bed6ce40dd3cf1.

---

<a id="fda-drugs-anda213155-v1"></a>

## Drugs@FDA application ANDA213155

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213155:v1`
- Evidence domain: Regulatory
- Date in source: 2026-06-15
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213155/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda213155-v1
- Content SHA-256: `3f1aed4f8c5651e4052026937b99c894307ebbf697def34388682e6592a596aa`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213155 ([`fda-drugs-anda213155-2026-06-15-4e07bd462a17`](#source-fda-drugs-anda213155-2026-06-15-4e07bd462a17))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda213155-2026-06-15-4e07bd462a17`](#source-fda-drugs-anda213155-2026-06-15-4e07bd462a17))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda213155-2026-06-15-4e07bd462a17`](#source-fda-drugs-anda213155-2026-06-15-4e07bd462a17))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213155-2026-06-15-4e07bd462a17`](#source-fda-drugs-anda213155-2026-06-15-4e07bd462a17))

### Sources

<a id="source-fda-drugs-anda213155-2026-06-15-4e07bd462a17"></a>
- **Drugs@FDA application ANDA213155 · original submission status AP · 2026-06-15 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213155%22&limit=1) (`fda-drugs-anda213155-2026-06-15-4e07bd462a17`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213155." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda213155-v1 SHA-256: 3f1aed4f8c5651e4052026937b99c894307ebbf697def34388682e6592a596aa.

---

<a id="fda-drugs-anda214568-v1"></a>

## Drugs@FDA application ANDA214568

> The official Drugs@FDA dataset lists original submission 1 for ANDA 214568 with status AP dated 2025-08-27, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda214568:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-27
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda214568/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda214568-v1
- Content SHA-256: `1c5141f05c9fd701a4300fecd37b3c2a2159e5e075f3f7c0d2342f3e595913c1`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA214568 ([`fda-drugs-anda214568-2025-08-27-7205167ce886`](#source-fda-drugs-anda214568-2025-08-27-7205167ce886))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 214568 with status AP dated 2025-08-27, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda214568-2025-08-27-7205167ce886`](#source-fda-drugs-anda214568-2025-08-27-7205167ce886))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 214568 with status AP dated 2025-08-27, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda214568-2025-08-27-7205167ce886`](#source-fda-drugs-anda214568-2025-08-27-7205167ce886))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda214568-2025-08-27-7205167ce886`](#source-fda-drugs-anda214568-2025-08-27-7205167ce886))

### Sources

<a id="source-fda-drugs-anda214568-2025-08-27-7205167ce886"></a>
- **Drugs@FDA application ANDA214568 · original submission status AP · 2025-08-27 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214568%22&limit=1) (`fda-drugs-anda214568-2025-08-27-7205167ce886`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA214568." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda214568-v1 SHA-256: 1c5141f05c9fd701a4300fecd37b3c2a2159e5e075f3f7c0d2342f3e595913c1.

---

<a id="fda-drugs-anda215245-v1"></a>

## Drugs@FDA application ANDA215245

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215245:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-11
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215245/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda215245-v1
- Content SHA-256: `e1cecf3f229e2d87d9ca77be3cf0e1f2c7c854483b3bd279fe026c07ce73aa2e`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215245 ([`fda-drugs-anda215245-2026-03-11-4ef147a422e8`](#source-fda-drugs-anda215245-2026-03-11-4ef147a422e8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda215245-2026-03-11-4ef147a422e8`](#source-fda-drugs-anda215245-2026-03-11-4ef147a422e8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda215245-2026-03-11-4ef147a422e8`](#source-fda-drugs-anda215245-2026-03-11-4ef147a422e8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215245-2026-03-11-4ef147a422e8`](#source-fda-drugs-anda215245-2026-03-11-4ef147a422e8))

### Sources

<a id="source-fda-drugs-anda215245-2026-03-11-4ef147a422e8"></a>
- **Drugs@FDA application ANDA215245 · original submission status AP · 2026-03-11 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215245%22&limit=1) (`fda-drugs-anda215245-2026-03-11-4ef147a422e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215245." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda215245-v1 SHA-256: e1cecf3f229e2d87d9ca77be3cf0e1f2c7c854483b3bd279fe026c07ce73aa2e.

---

<a id="fda-drugs-anda215421-v1"></a>

## Drugs@FDA application ANDA215421

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215421 with status AP dated 2025-07-22, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215421:v1`
- Evidence domain: Regulatory
- Date in source: 2025-07-22
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215421/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda215421-v1
- Content SHA-256: `e063c07a8957f0b2095da8e8a30f92af80e884ffc9e1de78fb70a6e65d5d07be`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215421 ([`fda-drugs-anda215421-2025-07-22-82205a0657f1`](#source-fda-drugs-anda215421-2025-07-22-82205a0657f1))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215421 with status AP dated 2025-07-22, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda215421-2025-07-22-82205a0657f1`](#source-fda-drugs-anda215421-2025-07-22-82205a0657f1))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215421 with status AP dated 2025-07-22, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda215421-2025-07-22-82205a0657f1`](#source-fda-drugs-anda215421-2025-07-22-82205a0657f1))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215421-2025-07-22-82205a0657f1`](#source-fda-drugs-anda215421-2025-07-22-82205a0657f1))

### Sources

<a id="source-fda-drugs-anda215421-2025-07-22-82205a0657f1"></a>
- **Drugs@FDA application ANDA215421 · original submission status AP · 2025-07-22 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215421%22&limit=1) (`fda-drugs-anda215421-2025-07-22-82205a0657f1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215421." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda215421-v1 SHA-256: e063c07a8957f0b2095da8e8a30f92af80e884ffc9e1de78fb70a6e65d5d07be.

---

<a id="fda-drugs-anda215503-v1"></a>

## Drugs@FDA application ANDA215503

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215503 with status AP dated 2024-12-23, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215503:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-23
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215503/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda215503-v1
- Content SHA-256: `d5bc90b688000edf9e0a3df8c497b04e2b0cf69e9edff6f398909f39502d45d5`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215503 ([`fda-drugs-anda215503-2024-12-23-56b69e4fa52c`](#source-fda-drugs-anda215503-2024-12-23-56b69e4fa52c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215503 with status AP dated 2024-12-23, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda215503-2024-12-23-56b69e4fa52c`](#source-fda-drugs-anda215503-2024-12-23-56b69e4fa52c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215503 with status AP dated 2024-12-23, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda215503-2024-12-23-56b69e4fa52c`](#source-fda-drugs-anda215503-2024-12-23-56b69e4fa52c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215503-2024-12-23-56b69e4fa52c`](#source-fda-drugs-anda215503-2024-12-23-56b69e4fa52c))

### Sources

<a id="source-fda-drugs-anda215503-2024-12-23-56b69e4fa52c"></a>
- **Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215503%22&limit=1) (`fda-drugs-anda215503-2024-12-23-56b69e4fa52c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215503." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda215503-v1 SHA-256: d5bc90b688000edf9e0a3df8c497b04e2b0cf69e9edff6f398909f39502d45d5.

---

<a id="fda-drugs-anda217063-v1"></a>

## Drugs@FDA application ANDA217063

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217063:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-24
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217063/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda217063-v1
- Content SHA-256: `5df83bbcc147f0db31be66c147fdfd19bf6b8e30069904b2f8f6ed47d3f5e4e5`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217063 ([`fda-drugs-anda217063-2026-02-24-dede8f400aa6`](#source-fda-drugs-anda217063-2026-02-24-dede8f400aa6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda217063-2026-02-24-dede8f400aa6`](#source-fda-drugs-anda217063-2026-02-24-dede8f400aa6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda217063-2026-02-24-dede8f400aa6`](#source-fda-drugs-anda217063-2026-02-24-dede8f400aa6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217063-2026-02-24-dede8f400aa6`](#source-fda-drugs-anda217063-2026-02-24-dede8f400aa6))

### Sources

<a id="source-fda-drugs-anda217063-2026-02-24-dede8f400aa6"></a>
- **Drugs@FDA application ANDA217063 · original submission status AP · 2026-02-24 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217063%22&limit=1) (`fda-drugs-anda217063-2026-02-24-dede8f400aa6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217063." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda217063-v1 SHA-256: 5df83bbcc147f0db31be66c147fdfd19bf6b8e30069904b2f8f6ed47d3f5e4e5.

---

<a id="fda-drugs-anda217234-v1"></a>

## Drugs@FDA application ANDA217234

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217234:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-24
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217234/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda217234-v1
- Content SHA-256: `86ee56548cefcb942759a432b0d8b957249256bcac9865d145798d4af45b3a90`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217234 ([`fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3`](#source-fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3`](#source-fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3`](#source-fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3`](#source-fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3))

### Sources

<a id="source-fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3"></a>
- **Drugs@FDA application ANDA217234 · original submission status AP · 2026-02-24 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217234%22&limit=1) (`fda-drugs-anda217234-2026-02-24-d5d5f4ab84a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217234." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda217234-v1 SHA-256: 86ee56548cefcb942759a432b0d8b957249256bcac9865d145798d4af45b3a90.

---

<a id="fda-drugs-anda217590-v1"></a>

## Drugs@FDA application ANDA217590

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217590:v1`
- Evidence domain: Regulatory
- Date in source: 2026-01-14
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217590/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda217590-v1
- Content SHA-256: `19b9aafb866597405ddf9ef26e4ec8d69b3e266aba57de15ff3f54a8434080d2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217590 ([`fda-drugs-anda217590-2026-01-14-b3c9f3b48839`](#source-fda-drugs-anda217590-2026-01-14-b3c9f3b48839))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda217590-2026-01-14-b3c9f3b48839`](#source-fda-drugs-anda217590-2026-01-14-b3c9f3b48839))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda217590-2026-01-14-b3c9f3b48839`](#source-fda-drugs-anda217590-2026-01-14-b3c9f3b48839))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217590-2026-01-14-b3c9f3b48839`](#source-fda-drugs-anda217590-2026-01-14-b3c9f3b48839))

### Sources

<a id="source-fda-drugs-anda217590-2026-01-14-b3c9f3b48839"></a>
- **Drugs@FDA application ANDA217590 · original submission status AP · 2026-01-14 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217590%22&limit=1) (`fda-drugs-anda217590-2026-01-14-b3c9f3b48839`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217590." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda217590-v1 SHA-256: 19b9aafb866597405ddf9ef26e4ec8d69b3e266aba57de15ff3f54a8434080d2.

---

<a id="fda-drugs-anda218115-v1"></a>

## Drugs@FDA application ANDA218115

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218115 with status AP dated 2025-04-02, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218115:v1`
- Evidence domain: Regulatory
- Date in source: 2025-04-02
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218115/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda218115-v1
- Content SHA-256: `19266d46653e1e92d5b541c428e694c3533d077756fd209896ab99c1cb7cef78`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218115 ([`fda-drugs-anda218115-2025-04-02-4d294aec3dc8`](#source-fda-drugs-anda218115-2025-04-02-4d294aec3dc8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218115 with status AP dated 2025-04-02, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda218115-2025-04-02-4d294aec3dc8`](#source-fda-drugs-anda218115-2025-04-02-4d294aec3dc8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218115 with status AP dated 2025-04-02, and names liraglutide among the application record's active ingredients. ([`fda-drugs-anda218115-2025-04-02-4d294aec3dc8`](#source-fda-drugs-anda218115-2025-04-02-4d294aec3dc8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218115-2025-04-02-4d294aec3dc8`](#source-fda-drugs-anda218115-2025-04-02-4d294aec3dc8))

### Sources

<a id="source-fda-drugs-anda218115-2025-04-02-4d294aec3dc8"></a>
- **Drugs@FDA application ANDA218115 · original submission status AP · 2025-04-02 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218115%22&limit=1) (`fda-drugs-anda218115-2025-04-02-4d294aec3dc8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218115." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-anda218115-v1 SHA-256: 19266d46653e1e92d5b541c428e694c3533d077756fd209896ab99c1cb7cef78.

---

<a id="fda-drugs-nda022341-v1"></a>

## Drugs@FDA application NDA022341

> The official Drugs@FDA dataset lists original submission 1 for NDA 022341 with status AP dated 2010-01-25, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022341:v1`
- Evidence domain: Regulatory
- Date in source: 2010-01-25
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022341/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-nda022341-v1
- Content SHA-256: `6f9a1d5a28bf777e6d9b17f84e9f5f9561c14e5a711a96eac92d179cd9b434d1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022341 ([`fda-drugs-nda022341-2010-01-25-97e5fbcce57e`](#source-fda-drugs-nda022341-2010-01-25-97e5fbcce57e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022341 with status AP dated 2010-01-25, and names liraglutide among the application record's active ingredients. ([`fda-drugs-nda022341-2010-01-25-97e5fbcce57e`](#source-fda-drugs-nda022341-2010-01-25-97e5fbcce57e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022341 with status AP dated 2010-01-25, and names liraglutide among the application record's active ingredients. ([`fda-drugs-nda022341-2010-01-25-97e5fbcce57e`](#source-fda-drugs-nda022341-2010-01-25-97e5fbcce57e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022341-2010-01-25-97e5fbcce57e`](#source-fda-drugs-nda022341-2010-01-25-97e5fbcce57e))

### Sources

<a id="source-fda-drugs-nda022341-2010-01-25-97e5fbcce57e"></a>
- **Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022341%22&limit=1) (`fda-drugs-nda022341-2010-01-25-97e5fbcce57e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022341." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-nda022341-v1 SHA-256: 6f9a1d5a28bf777e6d9b17f84e9f5f9561c14e5a711a96eac92d179cd9b434d1.

---

<a id="fda-drugs-nda206321-v1"></a>

## Drugs@FDA application NDA206321

> The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda206321:v1`
- Evidence domain: Regulatory
- Date in source: 2014-12-23
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda206321/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-nda206321-v1
- Content SHA-256: `495c1995fba8b8414d518a491cb38dfea7316c369c7a9ca6f35842a87543007e`

### Claims and source pins

#### Headline

Drugs@FDA application NDA206321 ([`fda-drugs-nda206321-2014-12-23-a195c56028d5`](#source-fda-drugs-nda206321-2014-12-23-a195c56028d5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients. ([`fda-drugs-nda206321-2014-12-23-a195c56028d5`](#source-fda-drugs-nda206321-2014-12-23-a195c56028d5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients. ([`fda-drugs-nda206321-2014-12-23-a195c56028d5`](#source-fda-drugs-nda206321-2014-12-23-a195c56028d5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda206321-2014-12-23-a195c56028d5`](#source-fda-drugs-nda206321-2014-12-23-a195c56028d5))

### Sources

<a id="source-fda-drugs-nda206321-2014-12-23-a195c56028d5"></a>
- **Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA206321%22&limit=1) (`fda-drugs-nda206321-2014-12-23-a195c56028d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA206321." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-drugs-nda206321-v1 SHA-256: 495c1995fba8b8414d518a491cb38dfea7316c369c7a9ca6f35842a87543007e.

---

<a id="fda-enforcement-d-0541-2026-v1"></a>

## FDA enforcement report D-0541-2026

> FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0541-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-05-27
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0541-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-enforcement-d-0541-2026-v1
- Content SHA-256: `0545ac692bb9d498c4d989d9a6c3f75117505eeac1f6c26ab0628e40bb8119c3`

### Claims and source pins

#### Headline

FDA enforcement report D-0541-2026 ([`fda-enforcement-d-0541-2026-bc599cdc32eb`](#source-fda-enforcement-d-0541-2026-bc599cdc32eb))

#### Summary

FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations. ([`fda-enforcement-d-0541-2026-bc599cdc32eb`](#source-fda-enforcement-d-0541-2026-bc599cdc32eb))

#### Paragraph 1

FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations. ([`fda-enforcement-d-0541-2026-bc599cdc32eb`](#source-fda-enforcement-d-0541-2026-bc599cdc32eb))

#### Paragraph 2

FDA's source-reported reason is: Presence of particulate matter: a white thread-like structure in the cartridge ([`fda-enforcement-d-0541-2026-bc599cdc32eb`](#source-fda-enforcement-d-0541-2026-bc599cdc32eb))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0541-2026-bc599cdc32eb`](#source-fda-enforcement-d-0541-2026-bc599cdc32eb))

### Sources

<a id="source-fda-enforcement-d-0541-2026-bc599cdc32eb"></a>
- **FDA enforcement report D-0541-2026 · Class II · report date 2026-05-27 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0541-2026%22&limit=1) (`fda-enforcement-d-0541-2026-bc599cdc32eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0541-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-enforcement-d-0541-2026-v1 SHA-256: 0545ac692bb9d498c4d989d9a6c3f75117505eeac1f6c26ab0628e40bb8119c3.

---

<a id="fda-enforcement-d-0618-2021-v1"></a>

## FDA enforcement report D-0618-2021

> FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0618-2021:v1`
- Evidence domain: Safety
- Date in source: 2021-04-21
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0618-2021/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-enforcement-d-0618-2021-v1
- Content SHA-256: `2fc292adb9e7a7b4ee3461c8078d7633992bc4b29e91a5bce5e23c39e3bffd51`

### Claims and source pins

#### Headline

FDA enforcement report D-0618-2021 ([`fda-enforcement-d-0618-2021-3df81057b63b`](#source-fda-enforcement-d-0618-2021-3df81057b63b))

#### Summary

FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations. ([`fda-enforcement-d-0618-2021-3df81057b63b`](#source-fda-enforcement-d-0618-2021-3df81057b63b))

#### Paragraph 1

FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations. ([`fda-enforcement-d-0618-2021-3df81057b63b`](#source-fda-enforcement-d-0618-2021-3df81057b63b))

#### Paragraph 2

FDA's source-reported reason is: Temperature Abuse: product samples were stored at temperatures below 32\* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. ([`fda-enforcement-d-0618-2021-3df81057b63b`](#source-fda-enforcement-d-0618-2021-3df81057b63b))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0618-2021-3df81057b63b`](#source-fda-enforcement-d-0618-2021-3df81057b63b))

### Sources

<a id="source-fda-enforcement-d-0618-2021-3df81057b63b"></a>
- **FDA enforcement report D-0618-2021 · Class II · report date 2021-04-21 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0618-2021%22&limit=1) (`fda-enforcement-d-0618-2021-3df81057b63b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0618-2021." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-enforcement-d-0618-2021-v1 SHA-256: 2fc292adb9e7a7b4ee3461c8078d7633992bc4b29e91a5bce5e23c39e3bffd51.

---

<a id="fda-enforcement-d-0622-2021-v1"></a>

## FDA enforcement report D-0622-2021

> FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0622-2021:v1`
- Evidence domain: Safety
- Date in source: 2021-04-21
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0622-2021/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-enforcement-d-0622-2021-v1
- Content SHA-256: `991d519e47c16eb888612f2c54bd595ba86c92a964d4204dae0eaad9e14b7e16`

### Claims and source pins

#### Headline

FDA enforcement report D-0622-2021 ([`fda-enforcement-d-0622-2021-bd70eaa85ec1`](#source-fda-enforcement-d-0622-2021-bd70eaa85ec1))

#### Summary

FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations. ([`fda-enforcement-d-0622-2021-bd70eaa85ec1`](#source-fda-enforcement-d-0622-2021-bd70eaa85ec1))

#### Paragraph 1

FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations. ([`fda-enforcement-d-0622-2021-bd70eaa85ec1`](#source-fda-enforcement-d-0622-2021-bd70eaa85ec1))

#### Paragraph 2

FDA's source-reported reason is: Temperature Abuse: product samples were stored at temperatures below 32\* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. ([`fda-enforcement-d-0622-2021-bd70eaa85ec1`](#source-fda-enforcement-d-0622-2021-bd70eaa85ec1))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0622-2021-bd70eaa85ec1`](#source-fda-enforcement-d-0622-2021-bd70eaa85ec1))

### Sources

<a id="source-fda-enforcement-d-0622-2021-bd70eaa85ec1"></a>
- **FDA enforcement report D-0622-2021 · Class II · report date 2021-04-21 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0622-2021%22&limit=1) (`fda-enforcement-d-0622-2021-bd70eaa85ec1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0622-2021." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#fda-enforcement-d-0622-2021-v1 SHA-256: 991d519e47c16eb888612f2c54bd595ba86c92a964d4204dae0eaad9e14b7e16.

---

<a id="federal-register-2012-10517-v1"></a>

## Federal Register notice 2012-10517

> The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2012-10517:v1`
- Evidence domain: Regulatory
- Date in source: 2012-05-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-10517/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2012-10517-v1
- Content SHA-256: `cbe77f6aecb1aeed2f1a4f1e8b2a02c505e6611f63eb85f5d12d2ab1ca7ab621`

### Claims and source pins

#### Headline

Federal Register notice 2012-10517 ([`federal-register-2012-10517-5e562471b380`](#source-federal-register-2012-10517-5e562471b380))

#### Summary

The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2012-10517-5e562471b380`](#source-federal-register-2012-10517-5e562471b380))

#### Paragraph 1

The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2012-10517-5e562471b380`](#source-federal-register-2012-10517-5e562471b380))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-10517-5e562471b380`](#source-federal-register-2012-10517-5e562471b380))

### Sources

<a id="source-federal-register-2012-10517-5e562471b380"></a>
- **Federal Register notice 2012-10517 · published 2012-05-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10517.pdf) (`federal-register-2012-10517-5e562471b380`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-10517." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2012-10517-v1 SHA-256: cbe77f6aecb1aeed2f1a4f1e8b2a02c505e6611f63eb85f5d12d2ab1ca7ab621.

---

<a id="federal-register-2014-18304-v1"></a>

## Federal Register notice 2014-18304

> The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2014-18304:v1`
- Evidence domain: Regulatory
- Date in source: 2014-08-04
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-18304/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2014-18304-v1
- Content SHA-256: `074d145a413426d0f41f9dfae2eb262b267a5c9d4673c542125e1946412b5bde`

### Claims and source pins

#### Headline

Federal Register notice 2014-18304 ([`federal-register-2014-18304-3cf62ec91830`](#source-federal-register-2014-18304-3cf62ec91830))

#### Summary

The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2014-18304-3cf62ec91830`](#source-federal-register-2014-18304-3cf62ec91830))

#### Paragraph 1

The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2014-18304-3cf62ec91830`](#source-federal-register-2014-18304-3cf62ec91830))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-18304-3cf62ec91830`](#source-federal-register-2014-18304-3cf62ec91830))

### Sources

<a id="source-federal-register-2014-18304-3cf62ec91830"></a>
- **Federal Register notice 2014-18304 · published 2014-08-04 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-08-04/pdf/2014-18304.pdf) (`federal-register-2014-18304-3cf62ec91830`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-18304." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2014-18304-v1 SHA-256: 074d145a413426d0f41f9dfae2eb262b267a5c9d4673c542125e1946412b5bde.

---

<a id="federal-register-2016-05959-v1"></a>

## Federal Register notice 2016-05959

> The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2016-05959:v1`
- Evidence domain: Regulatory
- Date in source: 2016-03-17
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-05959/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2016-05959-v1
- Content SHA-256: `58ee23c5759ebe12af2f2df68244519f56e04dfeeb7fc90cd2adbe304c9ea24c`

### Claims and source pins

#### Headline

Federal Register notice 2016-05959 ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

#### Summary

The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

#### Paragraph 1

The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-05959-1d5042bed266`](#source-federal-register-2016-05959-1d5042bed266))

### Sources

<a id="source-federal-register-2016-05959-1d5042bed266"></a>
- **Federal Register notice 2016-05959 · published 2016-03-17 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-03-17/pdf/2016-05959.pdf) (`federal-register-2016-05959-1d5042bed266`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-05959." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2016-05959-v1 SHA-256: 58ee23c5759ebe12af2f2df68244519f56e04dfeeb7fc90cd2adbe304c9ea24c.

---

<a id="federal-register-2017-10326-v1"></a>

## Federal Register notice 2017-10326

> The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2017-10326:v1`
- Evidence domain: Regulatory
- Date in source: 2017-05-22
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2017-10326/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2017-10326-v1
- Content SHA-256: `ef5d99afd57be1d36f1ea952ccda08c475e27ea96ea3e672ffbb64444d6a1d46`

### Claims and source pins

#### Headline

Federal Register notice 2017-10326 ([`federal-register-2017-10326-1b7e96ff3dd8`](#source-federal-register-2017-10326-1b7e96ff3dd8))

#### Summary

The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2017-10326-1b7e96ff3dd8`](#source-federal-register-2017-10326-1b7e96ff3dd8))

#### Paragraph 1

The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2017-10326-1b7e96ff3dd8`](#source-federal-register-2017-10326-1b7e96ff3dd8))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2017-10326-1b7e96ff3dd8`](#source-federal-register-2017-10326-1b7e96ff3dd8))

### Sources

<a id="source-federal-register-2017-10326-1b7e96ff3dd8"></a>
- **Federal Register notice 2017-10326 · published 2017-05-22 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2017-05-22/pdf/2017-10326.pdf) (`federal-register-2017-10326-1b7e96ff3dd8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2017-10326." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2017-10326-v1 SHA-256: ef5d99afd57be1d36f1ea952ccda08c475e27ea96ea3e672ffbb64444d6a1d46.

---

<a id="federal-register-2020-04320-v1"></a>

## Federal Register notice 2020-04320

> The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide.

- Evidence object: `story:federal-register-2020-04320:v1`
- Evidence domain: Regulatory
- Date in source: 2020-03-03
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2020-04320/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2020-04320-v1
- Content SHA-256: `81f83bd59d2e6e13b6ddef6a7701d6adb8641d1c21bb28b5246c7a501f9b22d9`

### Claims and source pins

#### Headline

Federal Register notice 2020-04320 ([`federal-register-2020-04320-2147444c6790`](#source-federal-register-2020-04320-2147444c6790))

#### Summary

The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide. ([`federal-register-2020-04320-2147444c6790`](#source-federal-register-2020-04320-2147444c6790))

#### Paragraph 1

The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide. ([`federal-register-2020-04320-2147444c6790`](#source-federal-register-2020-04320-2147444c6790))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2020-04320-2147444c6790`](#source-federal-register-2020-04320-2147444c6790))

### Sources

<a id="source-federal-register-2020-04320-2147444c6790"></a>
- **Federal Register notice 2020-04320 · published 2020-03-03 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2020-03-03/pdf/2020-04320.pdf) (`federal-register-2020-04320-2147444c6790`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2020-04320." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2020-04320-v1 SHA-256: 81f83bd59d2e6e13b6ddef6a7701d6adb8641d1c21bb28b5246c7a501f9b22d9.

---

<a id="federal-register-2024-10896-v1"></a>

## Federal Register notice 2024-10896

> The Federal Register published notice 2024-10896, attributed to FDA and its parent HHS department, on 2024-05-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2024-10896:v1`
- Evidence domain: Regulatory
- Date in source: 2024-05-17
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-10896/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2024-10896-v1
- Content SHA-256: `05be89770c38698a7daf60738290cab19eccdd38ed3b7637c0b112c057913e1d`

### Claims and source pins

#### Headline

Federal Register notice 2024-10896 ([`federal-register-2024-10896-fac9b05861fd`](#source-federal-register-2024-10896-fac9b05861fd))

#### Summary

The Federal Register published notice 2024-10896, attributed to FDA and its parent HHS department, on 2024-05-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2024-10896-fac9b05861fd`](#source-federal-register-2024-10896-fac9b05861fd))

#### Paragraph 1

The Federal Register published notice 2024-10896, attributed to FDA and its parent HHS department, on 2024-05-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2024-10896-fac9b05861fd`](#source-federal-register-2024-10896-fac9b05861fd))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-10896-fac9b05861fd`](#source-federal-register-2024-10896-fac9b05861fd))

### Sources

<a id="source-federal-register-2024-10896-fac9b05861fd"></a>
- **Federal Register notice 2024-10896 · published 2024-05-17 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-05-17/pdf/2024-10896.pdf) (`federal-register-2024-10896-fac9b05861fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-10896." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2024-10896-v1 SHA-256: 05be89770c38698a7daf60738290cab19eccdd38ed3b7637c0b112c057913e1d.

---

<a id="federal-register-2024-27048-v1"></a>

## Federal Register notice 2024-27048

> The Federal Register published notice 2024-27048, attributed to FDA and its parent HHS department, on 2024-11-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-2024-27048:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-20
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-27048/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2024-27048-v1
- Content SHA-256: `f39c539cd00ba4829409ac0b31c65fb2f93e622be759f9702f65b8a6694137da`

### Claims and source pins

#### Headline

Federal Register notice 2024-27048 ([`federal-register-2024-27048-4937a5070350`](#source-federal-register-2024-27048-4937a5070350))

#### Summary

The Federal Register published notice 2024-27048, attributed to FDA and its parent HHS department, on 2024-11-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2024-27048-4937a5070350`](#source-federal-register-2024-27048-4937a5070350))

#### Paragraph 1

The Federal Register published notice 2024-27048, attributed to FDA and its parent HHS department, on 2024-11-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-2024-27048-4937a5070350`](#source-federal-register-2024-27048-4937a5070350))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-27048-4937a5070350`](#source-federal-register-2024-27048-4937a5070350))

### Sources

<a id="source-federal-register-2024-27048-4937a5070350"></a>
- **Federal Register notice 2024-27048 · published 2024-11-20 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-11-20/pdf/2024-27048.pdf) (`federal-register-2024-27048-4937a5070350`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-27048." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2024-27048-v1 SHA-256: f39c539cd00ba4829409ac0b31c65fb2f93e622be759f9702f65b8a6694137da.

---

<a id="federal-register-2026-12937-v1"></a>

## Federal Register notice 2026-12937

> The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.

- Evidence object: `story:federal-register-2026-12937:v1`
- Evidence domain: Regulatory
- Date in source: 2026-06-26
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-12937/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2026-12937-v1
- Content SHA-256: `9c24722c4f7af9ed51e4a5ee5c7a7aef9f27e000bc9ad1bc8b44afdbac13093b`

### Claims and source pins

#### Headline

Federal Register notice 2026-12937 ([`federal-register-2026-12937-2818b85377d3`](#source-federal-register-2026-12937-2818b85377d3))

#### Summary

The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide. ([`federal-register-2026-12937-2818b85377d3`](#source-federal-register-2026-12937-2818b85377d3))

#### Paragraph 1

The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide. ([`federal-register-2026-12937-2818b85377d3`](#source-federal-register-2026-12937-2818b85377d3))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-12937-2818b85377d3`](#source-federal-register-2026-12937-2818b85377d3))

### Sources

<a id="source-federal-register-2026-12937-2818b85377d3"></a>
- **Federal Register notice 2026-12937 · published 2026-06-26 · List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12937.pdf) (`federal-register-2026-12937-2818b85377d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-12937." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-2026-12937-v1 SHA-256: 9c24722c4f7af9ed51e4a5ee5c7a7aef9f27e000bc9ad1bc8b44afdbac13093b.

---

<a id="federal-register-e9-5024-v1"></a>

## Federal Register notice E9-5024

> The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

- Evidence object: `story:federal-register-e9-5024:v1`
- Evidence domain: Regulatory
- Date in source: 2009-03-10
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e9-5024/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-e9-5024-v1
- Content SHA-256: `c429b6310187a19292491bb3bf22fcd58a6c8278e64e8612871f7879e611504f`

### Claims and source pins

#### Headline

Federal Register notice E9-5024 ([`federal-register-e9-5024-958b3df3ddac`](#source-federal-register-e9-5024-958b3df3ddac))

#### Summary

The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-e9-5024-958b3df3ddac`](#source-federal-register-e9-5024-958b3df3ddac))

#### Paragraph 1

The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide. ([`federal-register-e9-5024-958b3df3ddac`](#source-federal-register-e9-5024-958b3df3ddac))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e9-5024-958b3df3ddac`](#source-federal-register-e9-5024-958b3df3ddac))

### Sources

<a id="source-federal-register-e9-5024-958b3df3ddac"></a>
- **Federal Register notice E9-5024 · published 2009-03-10 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2009-03-10/pdf/E9-5024.pdf) (`federal-register-e9-5024-958b3df3ddac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E9-5024." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#federal-register-e9-5024-v1 SHA-256: c429b6310187a19292491bb3bf22fcd58a6c8278e64e8612871f7879e611504f.

---

<a id="pubmed-pmid-20452924-liraglutide-v1"></a>

## New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.

> PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20452924-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20452924-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20452924-liraglutide-v1
- Content SHA-256: `c8a4290d9bf6fff3485f419813d6373392af7f73e18fd011ea7d465400cde54d`

### Claims and source pins

#### Headline

New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

#### Summary

PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

#### Paragraph 1

PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

### Sources

<a id="source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809"></a>
- **New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA. · retained source version 1:2015-11-19:current:f4f416513809b8ff795e0180259b166a872da260c44318fe46bba825ad5eb5f3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20452924/) (`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20452924-liraglutide-v1 SHA-256: c8a4290d9bf6fff3485f419813d6373392af7f73e18fd011ea7d465400cde54d.

---

<a id="pubmed-pmid-20456108-liraglutide-v1"></a>

## Liraglutide in islet transplantation: from bench to bedside.

> PubMed lists PMID 20456108 in Transplant international : official journal of the European Society for Organ Transplantation as Comment, Journal Article, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20456108-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20456108-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20456108-liraglutide-v1
- Content SHA-256: `6b309a58d69ab934dcc919a77079ffb77f5f3b0b0685886be1555b54bbd6f775`

### Claims and source pins

#### Headline

Liraglutide in islet transplantation: from bench to bedside. ([`pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed`](#source-pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed))

#### Summary

PubMed lists PMID 20456108 in Transplant international : official journal of the European Society for Organ Transplantation as Comment, Journal Article, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed`](#source-pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed))

#### Paragraph 1

PubMed lists PMID 20456108 in Transplant international : official journal of the European Society for Organ Transplantation as Comment, Journal Article, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed`](#source-pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed`](#source-pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed))

### Sources

<a id="source-pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed"></a>
- **Liraglutide in islet transplantation: from bench to bedside. · retained source version 1:2015-11-19:current:8142065e14ed33ad920e2ba824a59e23c12d17c933d9842d0de062fdada0050b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20456108/) (`pubmed-observation-pmid-20456108-2015-11-19-8142065e14ed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide in islet transplantation: from bench to bedside." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20456108-liraglutide-v1 SHA-256: 6b309a58d69ab934dcc919a77079ffb77f5f3b0b0685886be1555b54bbd6f775.

---

<a id="pubmed-pmid-20610447-liraglutide-v1"></a>

## PubMed record PMID 20610447

> PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-20610447-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-02-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20610447-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20610447-liraglutide-v1
- Content SHA-256: `432d7519e3d570e2a98d97837fc780ac4d66eba4c3080063da0716726d8331eb`

### Claims and source pins

#### Headline

PubMed record PMID 20610447 ([`pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d`](#source-pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d`](#source-pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d`](#source-pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d`](#source-pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d))

### Sources

<a id="source-pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d"></a>
- **PubMed record PMID 20610447 · retained source version 1:2012-02-09:current:8fa44394872de62bf52a390b1374fd33b0faaa9d6fff3def0fec62b1b9ed189f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20610447/) (`pubmed-observation-pmid-20610447-2012-02-09-8fa44394872d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 20610447." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20610447-liraglutide-v1 SHA-256: 432d7519e3d570e2a98d97837fc780ac4d66eba4c3080063da0716726d8331eb.

---

<a id="pubmed-pmid-20861602-liraglutide-v1"></a>

## PubMed record PMID 20861602

> PeptideScanner retained PubMed bibliographic metadata for PMID 20861602 at 2026-07-30T22:26:16.803Z. PubMed recorded a metadata revision date of 2010-09-23 and an Entrez history date of 2010-09-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-20861602-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2010-09-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20861602-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20861602-liraglutide-v1
- Content SHA-256: `5c1a7ecc20f49e005a2ac79940d1322b0cf698cea7b6494d6134b8679012618c`

### Claims and source pins

#### Headline

PubMed record PMID 20861602 ([`pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5`](#source-pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 20861602 at 2026-07-30T22:26:16.803Z. PubMed recorded a metadata revision date of 2010-09-23 and an Entrez history date of 2010-09-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5`](#source-pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 20861602 at 2026-07-30T22:26:16.803Z. PubMed recorded a metadata revision date of 2010-09-23 and an Entrez history date of 2010-09-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5`](#source-pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5`](#source-pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5))

### Sources

<a id="source-pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5"></a>
- **PubMed record PMID 20861602 · retained source version 1:2010-09-23:current:d1e773eb02f5009c0097be718aad382a942acbc2bbf24b4315418424e0d4aac4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20861602/) (`pubmed-observation-pmid-20861602-2010-09-23-d1e773eb02f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 20861602." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-20861602-liraglutide-v1 SHA-256: 5c1a7ecc20f49e005a2ac79940d1322b0cf698cea7b6494d6134b8679012618c.

---

<a id="pubmed-pmid-21388446-liraglutide-v1"></a>

## Liraglutide therapy in Prader-Willi syndrome.

> PubMed lists PMID 21388446 in Diabetic medicine : a journal of the British Diabetic Association as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-06 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21388446-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21388446-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-21388446-liraglutide-v1
- Content SHA-256: `4b193c36a4de777bc62458cc5dd75758158fafe67220dd235c56142e13b49d5d`

### Claims and source pins

#### Headline

Liraglutide therapy in Prader-Willi syndrome. ([`pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0`](#source-pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0))

#### Summary

PubMed lists PMID 21388446 in Diabetic medicine : a journal of the British Diabetic Association as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-06 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0`](#source-pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0))

#### Paragraph 1

PubMed lists PMID 21388446 in Diabetic medicine : a journal of the British Diabetic Association as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-06 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0`](#source-pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0`](#source-pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0))

### Sources

<a id="source-pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0"></a>
- **Liraglutide therapy in Prader-Willi syndrome. · retained source version 1:2015-11-19:current:1232b8b426a0ff580b53335d34627df51c90550d0ef41cf194abe802491a2a83** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21388446/) (`pubmed-observation-pmid-21388446-2015-11-19-1232b8b426a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide therapy in Prader-Willi syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-21388446-liraglutide-v1 SHA-256: 4b193c36a4de777bc62458cc5dd75758158fafe67220dd235c56142e13b49d5d.

---

<a id="pubmed-pmid-21595276-liraglutide-v1"></a>

## \[Liraglutide\].

> PubMed lists PMID 21595276 in Nihon rinsho. Japanese journal of clinical medicine as English Abstract, Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21595276-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21595276-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-21595276-liraglutide-v1
- Content SHA-256: `a8d89d51812c8729fe40aa6b609aa3c937df2c7ba6b28ab8ac89ca8935ccee80`

### Claims and source pins

#### Headline

\[Liraglutide\]. ([`pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e`](#source-pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e))

#### Summary

PubMed lists PMID 21595276 in Nihon rinsho. Japanese journal of clinical medicine as English Abstract, Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e`](#source-pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e))

#### Paragraph 1

PubMed lists PMID 21595276 in Nihon rinsho. Japanese journal of clinical medicine as English Abstract, Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e`](#source-pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e`](#source-pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e))

### Sources

<a id="source-pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e"></a>
- **\[Liraglutide\]. · retained source version 1:2015-11-19:current:c1791105c76ecdfdf08ef6cf97018db62aa1518b3bfb100cbf5cc4536b464073** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21595276/) (`pubmed-observation-pmid-21595276-2015-11-19-c1791105c76e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Liraglutide\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-21595276-liraglutide-v1 SHA-256: a8d89d51812c8729fe40aa6b609aa3c937df2c7ba6b28ab8ac89ca8935ccee80.

---

<a id="pubmed-pmid-22165195-liraglutide-v1"></a>

## \[Liraglutide in the treatment of diabetes type 2\].

> PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22165195-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22165195-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-22165195-liraglutide-v1
- Content SHA-256: `596b83313a83a2a6ef56d4701dfb9ea5c238a5db0b0761ea354061a787c28f68`

### Claims and source pins

#### Headline

\[Liraglutide in the treatment of diabetes type 2\]. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

#### Summary

PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

#### Paragraph 1

PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

### Sources

<a id="source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2"></a>
- **\[Liraglutide in the treatment of diabetes type 2\]. · retained source version 1:2015-11-19:current:3958cd82efe2e6a7fd0a2bbe05d386371cde63b9da5d0e8ce82659fc55a258cb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22165195/) (`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Liraglutide in the treatment of diabetes type 2\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-22165195-liraglutide-v1 SHA-256: 596b83313a83a2a6ef56d4701dfb9ea5c238a5db0b0761ea354061a787c28f68.

---

<a id="pubmed-pmid-22257418-liraglutide-v1"></a>

## Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.

> PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22257418-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22257418-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-22257418-liraglutide-v1
- Content SHA-256: `0b8ac65a5ce3ad890116259c3690754f11391957d9f2a862dc893c6d20f8b8e3`

### Claims and source pins

#### Headline

Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. ([`pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400`](#source-pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400))

#### Summary

PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400`](#source-pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400))

#### Paragraph 1

PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400`](#source-pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400`](#source-pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400))

### Sources

<a id="source-pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400"></a>
- **Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. · retained source version 1:2015-11-19:current:c9e08ae18400076736e5728ca858ed27de28df2c784180ba210c9261903a801c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22257418/) (`pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-22257418-liraglutide-v1 SHA-256: 0b8ac65a5ce3ad890116259c3690754f11391957d9f2a862dc893c6d20f8b8e3.

---

<a id="pubmed-pmid-23507272-liraglutide-v1"></a>

## \[Acute pancreatitis in a patient treated with liraglutide\].

> PubMed lists PMID 23507272 in Medicina clinica as Case Reports, Letter, with publication-date metadata of 2013-03-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23507272-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23507272-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-23507272-liraglutide-v1
- Content SHA-256: `a4b5d9bea7b0d18b1658efc9069f4a0e9141adcbe4a068d1cb493b414526c283`

### Claims and source pins

#### Headline

\[Acute pancreatitis in a patient treated with liraglutide\]. ([`pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d`](#source-pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d))

#### Summary

PubMed lists PMID 23507272 in Medicina clinica as Case Reports, Letter, with publication-date metadata of 2013-03-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d`](#source-pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d))

#### Paragraph 1

PubMed lists PMID 23507272 in Medicina clinica as Case Reports, Letter, with publication-date metadata of 2013-03-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d`](#source-pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d`](#source-pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d))

### Sources

<a id="source-pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d"></a>
- **\[Acute pancreatitis in a patient treated with liraglutide\]. · retained source version 1:2015-11-19:current:b466a0bccd6de52af29b161d3217c75ad1655d705b8927cc066f3e45d5233d76** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23507272/) (`pubmed-observation-pmid-23507272-2015-11-19-b466a0bccd6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Acute pancreatitis in a patient treated with liraglutide\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-23507272-liraglutide-v1 SHA-256: a4b5d9bea7b0d18b1658efc9069f4a0e9141adcbe4a068d1cb493b414526c283.

---

<a id="pubmed-pmid-23834125-liraglutide-v1"></a>

## Liraglutide in combination with acitretin for severe recalcitrant psoriasis.

> PubMed lists PMID 23834125 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2013-07 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23834125-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23834125-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-23834125-liraglutide-v1
- Content SHA-256: `f920e8b87a2034f0669c6fca7675301e064394fcbf7f253c654d566d51e139c6`

### Claims and source pins

#### Headline

Liraglutide in combination with acitretin for severe recalcitrant psoriasis. ([`pubmed-observation-pmid-23834125-2015-11-19-686be5368e14`](#source-pubmed-observation-pmid-23834125-2015-11-19-686be5368e14))

#### Summary

PubMed lists PMID 23834125 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2013-07 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23834125-2015-11-19-686be5368e14`](#source-pubmed-observation-pmid-23834125-2015-11-19-686be5368e14))

#### Paragraph 1

PubMed lists PMID 23834125 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2013-07 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23834125-2015-11-19-686be5368e14`](#source-pubmed-observation-pmid-23834125-2015-11-19-686be5368e14))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23834125-2015-11-19-686be5368e14`](#source-pubmed-observation-pmid-23834125-2015-11-19-686be5368e14))

### Sources

<a id="source-pubmed-observation-pmid-23834125-2015-11-19-686be5368e14"></a>
- **Liraglutide in combination with acitretin for severe recalcitrant psoriasis. · retained source version 1:2015-11-19:current:686be5368e1441205956250f65365f1eb55f525397adb11a92b3dd88508fcd6a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23834125/) (`pubmed-observation-pmid-23834125-2015-11-19-686be5368e14`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide in combination with acitretin for severe recalcitrant psoriasis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-23834125-liraglutide-v1 SHA-256: f920e8b87a2034f0669c6fca7675301e064394fcbf7f253c654d566d51e139c6.

---

<a id="pubmed-pmid-24315766-liraglutide-v1"></a>

## Acute interstitial nephritis after treatment with liraglutide.

> PubMed lists PMID 24315766 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Case Reports, Letter, with publication-date metadata of 2013-12-04 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24315766-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24315766-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-24315766-liraglutide-v1
- Content SHA-256: `88cb5694550d60951a985dbb7599f1a67ef39215700ebf08f561b03d7366b164`

### Claims and source pins

#### Headline

Acute interstitial nephritis after treatment with liraglutide. ([`pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4`](#source-pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4))

#### Summary

PubMed lists PMID 24315766 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Case Reports, Letter, with publication-date metadata of 2013-12-04 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4`](#source-pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4))

#### Paragraph 1

PubMed lists PMID 24315766 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Case Reports, Letter, with publication-date metadata of 2013-12-04 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4`](#source-pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4`](#source-pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4))

### Sources

<a id="source-pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4"></a>
- **Acute interstitial nephritis after treatment with liraglutide. · retained source version 1:2015-11-19:current:b3cb6ccec2a4e3d3e43a9f6774c982a35d9b131b16442c42fa837b2cc4dc1573** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24315766/) (`pubmed-observation-pmid-24315766-2015-11-19-b3cb6ccec2a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Acute interstitial nephritis after treatment with liraglutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-24315766-liraglutide-v1 SHA-256: 88cb5694550d60951a985dbb7599f1a67ef39215700ebf08f561b03d7366b164.

---

<a id="pubmed-pmid-25455831-liraglutide-v1"></a>

## Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.

> PubMed lists PMID 25455831 in Diabetes & metabolism as Case Reports, Letter, with publication-date metadata of 2014-11-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25455831-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25455831-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-25455831-liraglutide-v1
- Content SHA-256: `8107a9027649afc4c728f9596993bfd3e909b116b5b5ba2699f622657b74671a`

### Claims and source pins

#### Headline

Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. ([`pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8`](#source-pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8))

#### Summary

PubMed lists PMID 25455831 in Diabetes & metabolism as Case Reports, Letter, with publication-date metadata of 2014-11-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8`](#source-pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8))

#### Paragraph 1

PubMed lists PMID 25455831 in Diabetes & metabolism as Case Reports, Letter, with publication-date metadata of 2014-11-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8`](#source-pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8`](#source-pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8))

### Sources

<a id="source-pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8"></a>
- **Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. · retained source version 1:2015-11-19:current:8d002470f2a8ce9e677961788c4b1e6340884c480f8b2ef6c6564e45ed2f6ffa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25455831/) (`pubmed-observation-pmid-25455831-2015-11-19-8d002470f2a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-25455831-liraglutide-v1 SHA-256: 8107a9027649afc4c728f9596993bfd3e909b116b5b5ba2699f622657b74671a.

---

<a id="pubmed-pmid-26364391-liraglutide-v1"></a>

## \[Basal insulin and liraglutide combined in a pen\].

> PubMed lists PMID 26364391 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2015-04 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26364391-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26364391-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-26364391-liraglutide-v1
- Content SHA-256: `1868d1d3f3d551aa2abc659932a0eb9acd28a2052cbdec73dedddf817d7211c9`

### Claims and source pins

#### Headline

\[Basal insulin and liraglutide combined in a pen\]. ([`pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685`](#source-pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685))

#### Summary

PubMed lists PMID 26364391 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2015-04 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685`](#source-pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685))

#### Paragraph 1

PubMed lists PMID 26364391 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2015-04 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685`](#source-pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685`](#source-pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685))

### Sources

<a id="source-pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685"></a>
- **\[Basal insulin and liraglutide combined in a pen\]. · retained source version 1:2015-11-19:current:a33bdf9c768553aae6047203a35f623f0b64e0ac38b92908eba07bd7c63ecaa5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26364391/) (`pubmed-observation-pmid-26364391-2015-11-19-a33bdf9c7685`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Basal insulin and liraglutide combined in a pen\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-26364391-liraglutide-v1 SHA-256: 1868d1d3f3d551aa2abc659932a0eb9acd28a2052cbdec73dedddf817d7211c9.

---

<a id="pubmed-pmid-30515941-liraglutide-v1"></a>

## Liraglutide and systolic blood pressure.

> PubMed lists PMID 30515941 in Journal of clinical hypertension (Greenwich, Conn.) as Letter, with publication-date metadata of 2018-12-05 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30515941-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30515941-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-30515941-liraglutide-v1
- Content SHA-256: `b49b3a54c9ac8a13c3ad72538fa9acb7786fdfd2b24338f6ff309d9fe1f0a9b0`

### Claims and source pins

#### Headline

Liraglutide and systolic blood pressure. ([`pubmed-observation-pmid-30515941-2026-07-07-36a1024df791`](#source-pubmed-observation-pmid-30515941-2026-07-07-36a1024df791))

#### Summary

PubMed lists PMID 30515941 in Journal of clinical hypertension (Greenwich, Conn.) as Letter, with publication-date metadata of 2018-12-05 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30515941-2026-07-07-36a1024df791`](#source-pubmed-observation-pmid-30515941-2026-07-07-36a1024df791))

#### Paragraph 1

PubMed lists PMID 30515941 in Journal of clinical hypertension (Greenwich, Conn.) as Letter, with publication-date metadata of 2018-12-05 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30515941-2026-07-07-36a1024df791`](#source-pubmed-observation-pmid-30515941-2026-07-07-36a1024df791))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30515941-2026-07-07-36a1024df791`](#source-pubmed-observation-pmid-30515941-2026-07-07-36a1024df791))

### Sources

<a id="source-pubmed-observation-pmid-30515941-2026-07-07-36a1024df791"></a>
- **Liraglutide and systolic blood pressure. · retained source version 1:2026-07-07:current:36a1024df7911df730d9ba60c06db474cdbe8042b84931c61a16c137e3bc736c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30515941/) (`pubmed-observation-pmid-30515941-2026-07-07-36a1024df791`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide and systolic blood pressure." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-30515941-liraglutide-v1 SHA-256: b49b3a54c9ac8a13c3ad72538fa9acb7786fdfd2b24338f6ff309d9fe1f0a9b0.

---

<a id="pubmed-pmid-31034184-liraglutide-v1"></a>

## Liraglutide in Children and Adolescents with Type 2 Diabetes.

> PubMed lists PMID 31034184 in The New England journal of medicine as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-04-28 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31034184-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31034184-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-31034184-liraglutide-v1
- Content SHA-256: `4d419f8fbab049304bc8dcca9a79578ccd2b586534dd979aabf97e09e11bef55`

### Claims and source pins

#### Headline

Liraglutide in Children and Adolescents with Type 2 Diabetes. ([`pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e`](#source-pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e))

#### Summary

PubMed lists PMID 31034184 in The New England journal of medicine as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-04-28 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e`](#source-pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e))

#### Paragraph 1

PubMed lists PMID 31034184 in The New England journal of medicine as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-04-28 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e`](#source-pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e`](#source-pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e))

### Sources

<a id="source-pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e"></a>
- **Liraglutide in Children and Adolescents with Type 2 Diabetes. · retained source version 1:2026-05-18:current:8b5c4909931ec813fd57aac5d5b380f79883e8998bd183435e267948e20bebd2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31034184/) (`pubmed-observation-pmid-31034184-2026-05-18-8b5c4909931e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide in Children and Adolescents with Type 2 Diabetes." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-31034184-liraglutide-v1 SHA-256: 4d419f8fbab049304bc8dcca9a79578ccd2b586534dd979aabf97e09e11bef55.

---

<a id="pubmed-pmid-35936066-liraglutide-v1"></a>

## PubMed record PMID 35936066

> PeptideScanner retained PubMed bibliographic metadata for PMID 35936066 at 2026-08-10T18:13:32.320Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2022-08-08. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-35936066-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35936066-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-35936066-liraglutide-v1
- Content SHA-256: `fc0d76ba4c933efdff562679e6a40491496294924abc4072349ffbbe2ca98887`

### Claims and source pins

#### Headline

PubMed record PMID 35936066 ([`pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f`](#source-pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 35936066 at 2026-08-10T18:13:32.320Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2022-08-08. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f`](#source-pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 35936066 at 2026-08-10T18:13:32.320Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2022-08-08. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f`](#source-pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f`](#source-pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f))

### Sources

<a id="source-pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f"></a>
- **PubMed record PMID 35936066 · retained source version 1:2026-07-28:current:979bad36e09f75808c6b28fe8837d256ab2ca39d54127b0faaf2c481c375450c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35936066/) (`pubmed-observation-pmid-35936066-2026-07-28-979bad36e09f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 35936066." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-35936066-liraglutide-v1 SHA-256: fc0d76ba4c933efdff562679e6a40491496294924abc4072349ffbbe2ca98887.

---

<a id="pubmed-pmid-37967247-liraglutide-v1"></a>

## Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.

> PubMed lists PMID 37967247 in The Journal of clinical endocrinology and metabolism as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2024-04-19 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37967247-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37967247-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-37967247-liraglutide-v1
- Content SHA-256: `8991fe997ee45999c7fed55ddbc1c14f37aca9ec122dcb7ba2222aa9e998d452`

### Claims and source pins

#### Headline

Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. ([`pubmed-observation-pmid-37967247-2026-07-05-721e704c2479`](#source-pubmed-observation-pmid-37967247-2026-07-05-721e704c2479))

#### Summary

PubMed lists PMID 37967247 in The Journal of clinical endocrinology and metabolism as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2024-04-19 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37967247-2026-07-05-721e704c2479`](#source-pubmed-observation-pmid-37967247-2026-07-05-721e704c2479))

#### Paragraph 1

PubMed lists PMID 37967247 in The Journal of clinical endocrinology and metabolism as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2024-04-19 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37967247-2026-07-05-721e704c2479`](#source-pubmed-observation-pmid-37967247-2026-07-05-721e704c2479))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37967247-2026-07-05-721e704c2479`](#source-pubmed-observation-pmid-37967247-2026-07-05-721e704c2479))

### Sources

<a id="source-pubmed-observation-pmid-37967247-2026-07-05-721e704c2479"></a>
- **Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. · retained source version 1:2026-07-05:current:721e704c2479a2ef8e4598406e370bca1bdc213d4d113f7be93155585fef2736** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37967247/) (`pubmed-observation-pmid-37967247-2026-07-05-721e704c2479`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-37967247-liraglutide-v1 SHA-256: 8991fe997ee45999c7fed55ddbc1c14f37aca9ec122dcb7ba2222aa9e998d452.

---

<a id="pubmed-pmid-38092710-liraglutide-v1"></a>

## PubMed record PMID 38092710

> PeptideScanner retained PubMed bibliographic metadata for PMID 38092710 at 2026-08-10T10:49:06.858Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-13. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38092710-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38092710-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38092710-liraglutide-v1
- Content SHA-256: `226dd75dc7901c367785c39a2640419629420fe03171a2c78f2616150c925fdf`

### Claims and source pins

#### Headline

PubMed record PMID 38092710 ([`pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac`](#source-pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38092710 at 2026-08-10T10:49:06.858Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-13. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac`](#source-pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38092710 at 2026-08-10T10:49:06.858Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-13. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac`](#source-pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac`](#source-pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac))

### Sources

<a id="source-pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac"></a>
- **PubMed record PMID 38092710 · retained source version 1:2026-08-05:current:8bcc5ef54bace80a0485eba6c0711e0792889332bda618c6cea8f839f7d5f0c8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38092710/) (`pubmed-observation-pmid-38092710-2026-08-05-8bcc5ef54bac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38092710." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38092710-liraglutide-v1 SHA-256: 226dd75dc7901c367785c39a2640419629420fe03171a2c78f2616150c925fdf.

---

<a id="pubmed-pmid-38240127-liraglutide-v1"></a>

## PubMed record PMID 38240127

> PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38240127-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38240127-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38240127-liraglutide-v1
- Content SHA-256: `9b7a3599972723fd4d8cc41d164db34a2f6efa35bf653b1d35d60ab734c80a50`

### Claims and source pins

#### Headline

PubMed record PMID 38240127 ([`pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438`](#source-pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438`](#source-pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438`](#source-pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438`](#source-pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438))

### Sources

<a id="source-pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438"></a>
- **PubMed record PMID 38240127 · retained source version 1:2026-08-07:current:4ae11eb55438f0b09d4534f7a0b338b5656c3e5ee2cc2f9d128dc7bc839ce301** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38240127/) (`pubmed-observation-pmid-38240127-2026-08-07-4ae11eb55438`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38240127." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38240127-liraglutide-v1 SHA-256: 9b7a3599972723fd4d8cc41d164db34a2f6efa35bf653b1d35d60ab734c80a50.

---

<a id="pubmed-pmid-38619705-liraglutide-v1"></a>

## Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.

> PubMed lists PMID 38619705 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38619705-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38619705-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38619705-liraglutide-v1
- Content SHA-256: `c8799aa5e3ed65a9429856b69c65b718303927b693b09d352fd77fbd0668af1f`

### Claims and source pins

#### Headline

Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs. ([`pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121`](#source-pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121))

#### Summary

PubMed lists PMID 38619705 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121`](#source-pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121))

#### Paragraph 1

PubMed lists PMID 38619705 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121`](#source-pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121`](#source-pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121))

### Sources

<a id="source-pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121"></a>
- **Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs. · retained source version 1:2026-05-20:current:a2078f3bf121c3a8f0f9a7485946820d1ed94d4de26087ed02cbd615709e5d40** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38619705/) (`pubmed-observation-pmid-38619705-2026-05-20-a2078f3bf121`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38619705-liraglutide-v1 SHA-256: c8799aa5e3ed65a9429856b69c65b718303927b693b09d352fd77fbd0668af1f.

---

<a id="pubmed-pmid-38757729-liraglutide-v1"></a>

## Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.

> PubMed lists PMID 38757729 in Diabetes, obesity & metabolism as Journal Article, Clinical Trial, with publication-date metadata of 2024-05-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38757729-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38757729-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38757729-liraglutide-v1
- Content SHA-256: `00e0a845e08c25f80c0d0e6ba04ac0a9e3290a75954f8df5f62fcd4a4770f59a`

### Claims and source pins

#### Headline

Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration. ([`pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2`](#source-pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2))

#### Summary

PubMed lists PMID 38757729 in Diabetes, obesity & metabolism as Journal Article, Clinical Trial, with publication-date metadata of 2024-05-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2`](#source-pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2))

#### Paragraph 1

PubMed lists PMID 38757729 in Diabetes, obesity & metabolism as Journal Article, Clinical Trial, with publication-date metadata of 2024-05-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2`](#source-pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2`](#source-pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2))

### Sources

<a id="source-pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2"></a>
- **Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration. · retained source version 1:2026-06-17:current:0af0096608e26ee1c91dc42ccbddb478e5b130c0bbcf3b7f2b649bc406458578** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38757729/) (`pubmed-observation-pmid-38757729-2026-06-17-0af0096608e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-38757729-liraglutide-v1 SHA-256: 00e0a845e08c25f80c0d0e6ba04ac0a9e3290a75954f8df5f62fcd4a4770f59a.

---

<a id="pubmed-pmid-39949066-liraglutide-v1"></a>

## Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.

> PubMed lists PMID 39949066 in Annals of clinical and translational neurology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-02-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39949066-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39949066-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-39949066-liraglutide-v1
- Content SHA-256: `e5c87b0ef6d6134fd16b3ca193db1c69266b7e189ebdcdd5f325416af78195a1`

### Claims and source pins

#### Headline

Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study. ([`pubmed-observation-pmid-39949066-2026-06-30-83710087b060`](#source-pubmed-observation-pmid-39949066-2026-06-30-83710087b060))

#### Summary

PubMed lists PMID 39949066 in Annals of clinical and translational neurology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-02-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39949066-2026-06-30-83710087b060`](#source-pubmed-observation-pmid-39949066-2026-06-30-83710087b060))

#### Paragraph 1

PubMed lists PMID 39949066 in Annals of clinical and translational neurology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-02-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39949066-2026-06-30-83710087b060`](#source-pubmed-observation-pmid-39949066-2026-06-30-83710087b060))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39949066-2026-06-30-83710087b060`](#source-pubmed-observation-pmid-39949066-2026-06-30-83710087b060))

### Sources

<a id="source-pubmed-observation-pmid-39949066-2026-06-30-83710087b060"></a>
- **Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study. · retained source version 1:2026-06-30:current:83710087b0606d2a6b85176c170b86893e6f3504669105057bb5b2030b06c51b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39949066/) (`pubmed-observation-pmid-39949066-2026-06-30-83710087b060`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-39949066-liraglutide-v1 SHA-256: e5c87b0ef6d6134fd16b3ca193db1c69266b7e189ebdcdd5f325416af78195a1.

---

<a id="pubmed-pmid-40429612-liraglutide-v1"></a>

## PubMed record PMID 40429612

> PeptideScanner retained PubMed bibliographic metadata for PMID 40429612 at 2026-08-10T10:49:06.946Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-05-28. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40429612-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40429612-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40429612-liraglutide-v1
- Content SHA-256: `6f3011ae9721d9507cd93ddb40100b5d1d1bdcd573b8c28c60d4a2431b6549ca`

### Claims and source pins

#### Headline

PubMed record PMID 40429612 ([`pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c`](#source-pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40429612 at 2026-08-10T10:49:06.946Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-05-28. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c`](#source-pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40429612 at 2026-08-10T10:49:06.946Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-05-28. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c`](#source-pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c`](#source-pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c))

### Sources

<a id="source-pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c"></a>
- **PubMed record PMID 40429612 · retained source version 1:2026-08-06:current:7ad8af10b60ce495ab2800319a1be326f1fb331208a4e91a5b63f0ae3ca89eef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40429612/) (`pubmed-observation-pmid-40429612-2026-08-06-7ad8af10b60c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40429612." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40429612-liraglutide-v1 SHA-256: 6f3011ae9721d9507cd93ddb40100b5d1d1bdcd573b8c28c60d4a2431b6549ca.

---

<a id="pubmed-pmid-40521838-liraglutide-v1"></a>

## PubMed record PMID 40521838

> PeptideScanner retained PubMed bibliographic metadata for PMID 40521838 at 2026-08-10T18:13:37.865Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2025-06-16. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40521838-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-23
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40521838-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40521838-liraglutide-v1
- Content SHA-256: `7c99eaf3fd312a0fc7685963f6653d8393645649b41b1322e6b6e7beacc951bb`

### Claims and source pins

#### Headline

PubMed record PMID 40521838 ([`pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71`](#source-pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40521838 at 2026-08-10T18:13:37.865Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2025-06-16. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71`](#source-pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40521838 at 2026-08-10T18:13:37.865Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2025-06-16. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71`](#source-pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71`](#source-pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71))

### Sources

<a id="source-pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71"></a>
- **PubMed record PMID 40521838 · retained source version 1:2026-07-23:current:846c80a0fa7192a6e5e32ca6666ea4ba7ed951dc0b0057649a9b270b03494a3b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40521838/) (`pubmed-observation-pmid-40521838-2026-07-23-846c80a0fa71`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40521838." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40521838-liraglutide-v1 SHA-256: 7c99eaf3fd312a0fc7685963f6653d8393645649b41b1322e6b6e7beacc951bb.

---

<a id="pubmed-pmid-40646278-liraglutide-v1"></a>

## Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.

> PubMed lists PMID 40646278 in Journal of neural transmission (Vienna, Austria : 1996) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-12 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40646278-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40646278-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40646278-liraglutide-v1
- Content SHA-256: `40d31f46340fb763bf2fd7097d9899d19ab80083f7ee4f16acbec71960b9ac78`

### Claims and source pins

#### Headline

Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats. ([`pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce`](#source-pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce))

#### Summary

PubMed lists PMID 40646278 in Journal of neural transmission (Vienna, Austria : 1996) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-12 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce`](#source-pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce))

#### Paragraph 1

PubMed lists PMID 40646278 in Journal of neural transmission (Vienna, Austria : 1996) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-12 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce`](#source-pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce`](#source-pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce))

### Sources

<a id="source-pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce"></a>
- **Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats. · retained source version 1:2026-06-04:current:d7efec2d77ce1a57e4ca9be2bccc87105908333fff9733dda63847a8d0c6ffc0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40646278/) (`pubmed-observation-pmid-40646278-2026-06-04-d7efec2d77ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40646278-liraglutide-v1 SHA-256: 40d31f46340fb763bf2fd7097d9899d19ab80083f7ee4f16acbec71960b9ac78.

---

<a id="pubmed-pmid-40913889-liraglutide-v1"></a>

## PubMed record PMID 40913889

> PeptideScanner retained PubMed bibliographic metadata for PMID 40913889 at 2026-08-10T10:49:06.966Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-09-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40913889-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40913889-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40913889-liraglutide-v1
- Content SHA-256: `a6ccf8989617e288e0a30e095a048053f36c8a1c33c6d6a81a520c8020f54b37`

### Claims and source pins

#### Headline

PubMed record PMID 40913889 ([`pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a`](#source-pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40913889 at 2026-08-10T10:49:06.966Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-09-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a`](#source-pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40913889 at 2026-08-10T10:49:06.966Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-09-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a`](#source-pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a`](#source-pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a))

### Sources

<a id="source-pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a"></a>
- **PubMed record PMID 40913889 · retained source version 1:2026-08-06:current:94ad0f064e5ad8b4d8ee895e747088c8c8dfa6a9da3957f9de240874f993b9d8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40913889/) (`pubmed-observation-pmid-40913889-2026-08-06-94ad0f064e5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40913889." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40913889-liraglutide-v1 SHA-256: a6ccf8989617e288e0a30e095a048053f36c8a1c33c6d6a81a520c8020f54b37.

---

<a id="pubmed-pmid-40914786-liraglutide-v1"></a>

## Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.

> PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40914786-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40914786-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40914786-liraglutide-v1
- Content SHA-256: `8d3c3e74ed6d275c41bdb0335ed3cbfea6f3c5aa39accf27a5882612ff3e639f`

### Claims and source pins

#### Headline

Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

#### Summary

PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

#### Paragraph 1

PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`](#source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e))

### Sources

<a id="source-pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e"></a>
- **Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus. · retained source version 1:2026-06-01:current:f95fdb4a332ee95ea94f2c23147f3f1f7d79a65c8f745764c6dcc3ce021a9bb3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40914786/) (`pubmed-observation-pmid-40914786-2026-06-01-f95fdb4a332e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-40914786-liraglutide-v1 SHA-256: 8d3c3e74ed6d275c41bdb0335ed3cbfea6f3c5aa39accf27a5882612ff3e639f.

---

<a id="pubmed-pmid-41160027-liraglutide-v1"></a>

## PubMed record PMID 41160027

> PeptideScanner retained PubMed bibliographic metadata for PMID 41160027 at 2026-08-10T18:13:37.970Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2025-10-29. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41160027-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41160027-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41160027-liraglutide-v1
- Content SHA-256: `b3f52772050299ebf82ef3c2748d9daa8fce8891f9c6ff607da301b57338182d`

### Claims and source pins

#### Headline

PubMed record PMID 41160027 ([`pubmed-observation-pmid-41160027-2026-07-21-18ea72144978`](#source-pubmed-observation-pmid-41160027-2026-07-21-18ea72144978))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41160027 at 2026-08-10T18:13:37.970Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2025-10-29. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41160027-2026-07-21-18ea72144978`](#source-pubmed-observation-pmid-41160027-2026-07-21-18ea72144978))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41160027 at 2026-08-10T18:13:37.970Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2025-10-29. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41160027-2026-07-21-18ea72144978`](#source-pubmed-observation-pmid-41160027-2026-07-21-18ea72144978))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41160027-2026-07-21-18ea72144978`](#source-pubmed-observation-pmid-41160027-2026-07-21-18ea72144978))

### Sources

<a id="source-pubmed-observation-pmid-41160027-2026-07-21-18ea72144978"></a>
- **PubMed record PMID 41160027 · retained source version 1:2026-07-21:current:18ea72144978d1defb52f96190dc8bcfeca5d2d61435412e9ec1feeadce356eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41160027/) (`pubmed-observation-pmid-41160027-2026-07-21-18ea72144978`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41160027." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41160027-liraglutide-v1 SHA-256: b3f52772050299ebf82ef3c2748d9daa8fce8891f9c6ff607da301b57338182d.

---

<a id="pubmed-pmid-41321175-liraglutide-v1"></a>

## PubMed record PMID 41321175

> PeptideScanner retained PubMed bibliographic metadata for PMID 41321175 at 2026-08-10T10:49:07.012Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-12-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41321175-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41321175-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41321175-liraglutide-v1
- Content SHA-256: `64269ad1c69e0510d9a465a8ba0960b84405f6d1dcc9a57f571f9909407436aa`

### Claims and source pins

#### Headline

PubMed record PMID 41321175 ([`pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11`](#source-pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41321175 at 2026-08-10T10:49:07.012Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-12-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11`](#source-pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41321175 at 2026-08-10T10:49:07.012Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-12-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11`](#source-pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11`](#source-pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11))

### Sources

<a id="source-pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11"></a>
- **PubMed record PMID 41321175 · retained source version 1:2026-08-06:current:5aa761500b110dc97602bd8f79840d767c2b5a9195fc623b79553620da1d5ec6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41321175/) (`pubmed-observation-pmid-41321175-2026-08-06-5aa761500b11`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41321175." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41321175-liraglutide-v1 SHA-256: 64269ad1c69e0510d9a465a8ba0960b84405f6d1dcc9a57f571f9909407436aa.

---

<a id="pubmed-pmid-41508932-liraglutide-v1"></a>

## PubMed record PMID 41508932

> PeptideScanner retained PubMed bibliographic metadata for PMID 41508932 at 2026-08-10T10:49:08.740Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41508932-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41508932-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41508932-liraglutide-v1
- Content SHA-256: `036443f1a99117bd3d322fbccdc1fd08617bad8b5aaf75c349f23244e2ca6414`

### Claims and source pins

#### Headline

PubMed record PMID 41508932 ([`pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f`](#source-pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41508932 at 2026-08-10T10:49:08.740Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f`](#source-pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41508932 at 2026-08-10T10:49:08.740Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f`](#source-pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f`](#source-pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f))

### Sources

<a id="source-pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f"></a>
- **PubMed record PMID 41508932 · retained source version 1:2026-07-30:current:54e2c2055d6fe173e44ed7fafbba5d0cf62c98d0286355a432456cfd6c74edd4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41508932/) (`pubmed-observation-pmid-41508932-2026-07-30-54e2c2055d6f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41508932." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41508932-liraglutide-v1 SHA-256: 036443f1a99117bd3d322fbccdc1fd08617bad8b5aaf75c349f23244e2ca6414.

---

<a id="pubmed-pmid-41604908-liraglutide-v1"></a>

## Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.

> PubMed lists PMID 41604908 in Biomaterials advances as Journal Article, with publication-date metadata of 2026-01-14 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41604908-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41604908-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41604908-liraglutide-v1
- Content SHA-256: `db60215db4988718edad709afd5cdf38adf3a78da0c4edf72b6d35dc477de891`

### Claims and source pins

#### Headline

Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption. ([`pubmed-observation-pmid-41604908-2026-07-01-0269d960839c`](#source-pubmed-observation-pmid-41604908-2026-07-01-0269d960839c))

#### Summary

PubMed lists PMID 41604908 in Biomaterials advances as Journal Article, with publication-date metadata of 2026-01-14 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41604908-2026-07-01-0269d960839c`](#source-pubmed-observation-pmid-41604908-2026-07-01-0269d960839c))

#### Paragraph 1

PubMed lists PMID 41604908 in Biomaterials advances as Journal Article, with publication-date metadata of 2026-01-14 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41604908-2026-07-01-0269d960839c`](#source-pubmed-observation-pmid-41604908-2026-07-01-0269d960839c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41604908-2026-07-01-0269d960839c`](#source-pubmed-observation-pmid-41604908-2026-07-01-0269d960839c))

### Sources

<a id="source-pubmed-observation-pmid-41604908-2026-07-01-0269d960839c"></a>
- **Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption. · retained source version 1:2026-07-01:current:0269d960839cd7616fd270144fbde33cb4c37aeaccd65d50cff3af66fc847c1a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41604908/) (`pubmed-observation-pmid-41604908-2026-07-01-0269d960839c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41604908-liraglutide-v1 SHA-256: db60215db4988718edad709afd5cdf38adf3a78da0c4edf72b6d35dc477de891.

---

<a id="pubmed-pmid-41651380-liraglutide-v1"></a>

## PubMed record PMID 41651380

> PeptideScanner retained PubMed bibliographic metadata for PMID 41651380 at 2026-08-10T10:49:08.761Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-02-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41651380-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-04
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41651380-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41651380-liraglutide-v1
- Content SHA-256: `81eda862acfad2f4f8066dcfc4321c9a7665da9dc441b9f3afb9cb87d5451620`

### Claims and source pins

#### Headline

PubMed record PMID 41651380 ([`pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7`](#source-pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41651380 at 2026-08-10T10:49:08.761Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-02-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7`](#source-pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41651380 at 2026-08-10T10:49:08.761Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-02-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7`](#source-pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7`](#source-pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7))

### Sources

<a id="source-pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7"></a>
- **PubMed record PMID 41651380 · retained source version 1:2026-08-04:current:ed611766d2a7946e23c8a1fb4d52c334713fd548f26f8b23e8d80b9c5b812d6f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41651380/) (`pubmed-observation-pmid-41651380-2026-08-04-ed611766d2a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41651380." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41651380-liraglutide-v1 SHA-256: 81eda862acfad2f4f8066dcfc4321c9a7665da9dc441b9f3afb9cb87d5451620.

---

<a id="pubmed-pmid-41736232-liraglutide-v1"></a>

## PubMed record PMID 41736232

> PeptideScanner retained PubMed bibliographic metadata for PMID 41736232 at 2026-08-10T10:49:08.773Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41736232-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41736232-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41736232-liraglutide-v1
- Content SHA-256: `73f901756cd29e99ff30d1833167c127e05e39a8aecf218e221bf87c2c302e5d`

### Claims and source pins

#### Headline

PubMed record PMID 41736232 ([`pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876`](#source-pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41736232 at 2026-08-10T10:49:08.773Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876`](#source-pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41736232 at 2026-08-10T10:49:08.773Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876`](#source-pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876`](#source-pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876))

### Sources

<a id="source-pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876"></a>
- **PubMed record PMID 41736232 · retained source version 1:2026-08-03:current:d6756b0c38760baa93165b766d479a2c86ef01854be69adf4f091f141d33495b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41736232/) (`pubmed-observation-pmid-41736232-2026-08-03-d6756b0c3876`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41736232." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41736232-liraglutide-v1 SHA-256: 73f901756cd29e99ff30d1833167c127e05e39a8aecf218e221bf87c2c302e5d.

---

<a id="pubmed-pmid-41966799-liraglutide-v1"></a>

## Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions.

> PubMed lists PMID 41966799 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41966799-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-15
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41966799-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41966799-liraglutide-v1
- Content SHA-256: `385e54a60eb97455688649cacf47eeed86b46f32fdd6ab345e3139af1dea9824`

### Claims and source pins

#### Headline

Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions. ([`pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1`](#source-pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1))

#### Summary

PubMed lists PMID 41966799 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1`](#source-pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1))

#### Paragraph 1

PubMed lists PMID 41966799 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1`](#source-pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1`](#source-pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1))

### Sources

<a id="source-pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1"></a>
- **Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions. · retained source version 1:2026-07-15:current:05276097d6c1a00a2d540b0a434104a9edea158261ba2ba03cb2e439cc9ec1c5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41966799/) (`pubmed-observation-pmid-41966799-2026-07-15-05276097d6c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41966799-liraglutide-v1 SHA-256: 385e54a60eb97455688649cacf47eeed86b46f32fdd6ab345e3139af1dea9824.

---

<a id="pubmed-pmid-41970854-liraglutide-v1"></a>

## Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study.

> PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41970854-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41970854-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41970854-liraglutide-v1
- Content SHA-256: `79c3459b580c5fe7444c9a6c10f168ec6f705eaed34f9007903fec788b189d29`

### Claims and source pins

#### Headline

Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study. ([`pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d`](#source-pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d))

#### Summary

PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d`](#source-pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d))

#### Paragraph 1

PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d`](#source-pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d`](#source-pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d))

### Sources

<a id="source-pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d"></a>
- **Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study. · retained source version 1:2026-08-13:current:14ef80bd3f6dbd2d868a2eeda0f54537d048cd191df3a01f00239635ff664772** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41970854/) (`pubmed-observation-pmid-41970854-2026-08-13-14ef80bd3f6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-41970854-liraglutide-v1 SHA-256: 79c3459b580c5fe7444c9a6c10f168ec6f705eaed34f9007903fec788b189d29.

---

<a id="pubmed-pmid-42015323-liraglutide-v1"></a>

## A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study.

> PubMed lists PMID 42015323 in Journal of pharmaceutical health care and sciences as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42015323-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42015323-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42015323-liraglutide-v1
- Content SHA-256: `2b0e9dc3ef9f6e47f6d23bff9413c2633a7ac21c63e270a1f4b2a50187930417`

### Claims and source pins

#### Headline

A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study. ([`pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34`](#source-pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34))

#### Summary

PubMed lists PMID 42015323 in Journal of pharmaceutical health care and sciences as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34`](#source-pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34))

#### Paragraph 1

PubMed lists PMID 42015323 in Journal of pharmaceutical health care and sciences as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34`](#source-pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34`](#source-pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34))

### Sources

<a id="source-pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34"></a>
- **A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study. · retained source version 1:2026-06-27:current:a8bf5b9b9f34f5c8f29da1ceaca0e3d9ed9d32b915a50f35c9911a885a1f5aaa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42015323/) (`pubmed-observation-pmid-42015323-2026-06-27-a8bf5b9b9f34`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42015323-liraglutide-v1 SHA-256: 2b0e9dc3ef9f6e47f6d23bff9413c2633a7ac21c63e270a1f4b2a50187930417.

---

<a id="pubmed-pmid-42203210-liraglutide-v1"></a>

## PubMed record PMID 42203210

> PeptideScanner retained PubMed bibliographic metadata for PMID 42203210 at 2026-08-10T18:13:50.682Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42203210-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42203210-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42203210-liraglutide-v1
- Content SHA-256: `fe9baad6b741cfe0359af64b78f12e4ec62eeaabdc1131074813e433f463074f`

### Claims and source pins

#### Headline

PubMed record PMID 42203210 ([`pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70`](#source-pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42203210 at 2026-08-10T18:13:50.682Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70`](#source-pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42203210 at 2026-08-10T18:13:50.682Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70`](#source-pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70`](#source-pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70))

### Sources

<a id="source-pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70"></a>
- **PubMed record PMID 42203210 · retained source version 1:2026-07-26:current:7ab556423f707a62f485869a372d24fbfe8518ac613f842258ff4d2ad11daf76** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42203210/) (`pubmed-observation-pmid-42203210-2026-07-26-7ab556423f70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42203210." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42203210-liraglutide-v1 SHA-256: fe9baad6b741cfe0359af64b78f12e4ec62eeaabdc1131074813e433f463074f.

---

<a id="pubmed-pmid-42233323-liraglutide-v1"></a>

## PubMed record PMID 42233323

> PeptideScanner retained PubMed bibliographic metadata for PMID 42233323 at 2026-08-10T18:13:50.725Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42233323-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42233323-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42233323-liraglutide-v1
- Content SHA-256: `bc80eca60bbd94278d83814ca6c42caf14536a0079dbd7a6c985ee2a2b93a477`

### Claims and source pins

#### Headline

PubMed record PMID 42233323 ([`pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1`](#source-pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42233323 at 2026-08-10T18:13:50.725Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1`](#source-pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42233323 at 2026-08-10T18:13:50.725Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1`](#source-pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1`](#source-pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1))

### Sources

<a id="source-pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1"></a>
- **PubMed record PMID 42233323 · retained source version 1:2026-07-26:current:f6d858f84df1065ec69f97e511adfcd0d0ba91a393c0e1f7ee9d531a182e8661** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42233323/) (`pubmed-observation-pmid-42233323-2026-07-26-f6d858f84df1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42233323." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42233323-liraglutide-v1 SHA-256: bc80eca60bbd94278d83814ca6c42caf14536a0079dbd7a6c985ee2a2b93a477.

---

<a id="pubmed-pmid-42286095-liraglutide-v1"></a>

## PubMed record PMID 42286095

> PeptideScanner retained PubMed bibliographic metadata for PMID 42286095 at 2026-08-10T18:13:52.266Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42286095-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42286095-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42286095-liraglutide-v1
- Content SHA-256: `3e3105c189b2096707b859725f874c3ff77be224cf7f218f11feaf5557f3ee4b`

### Claims and source pins

#### Headline

PubMed record PMID 42286095 ([`pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223`](#source-pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42286095 at 2026-08-10T18:13:52.266Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223`](#source-pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42286095 at 2026-08-10T18:13:52.266Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223`](#source-pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223`](#source-pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223))

### Sources

<a id="source-pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223"></a>
- **PubMed record PMID 42286095 · retained source version 1:2026-07-26:current:93bb03e76223e60c1824ac8a6b545667d36c5c9cfbf8b059b9d0ee839512bf2d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42286095/) (`pubmed-observation-pmid-42286095-2026-07-26-93bb03e76223`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42286095." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42286095-liraglutide-v1 SHA-256: 3e3105c189b2096707b859725f874c3ff77be224cf7f218f11feaf5557f3ee4b.

---

<a id="pubmed-pmid-42342869-liraglutide-v1"></a>

## PubMed record PMID 42342869

> PeptideScanner retained PubMed bibliographic metadata for PMID 42342869 at 2026-08-10T18:13:52.311Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42342869-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42342869-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42342869-liraglutide-v1
- Content SHA-256: `571c300fbe92e1d54205c1a46df96873ba8a1f5a87998d00da3ee6c65b443f16`

### Claims and source pins

#### Headline

PubMed record PMID 42342869 ([`pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5`](#source-pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42342869 at 2026-08-10T18:13:52.311Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5`](#source-pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42342869 at 2026-08-10T18:13:52.311Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5`](#source-pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5`](#source-pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5))

### Sources

<a id="source-pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5"></a>
- **PubMed record PMID 42342869 · retained source version 1:2026-07-27:current:35a3f8af2df5a7e0927491925d2365d7f363a70780bf337882b23bafa7b20abc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42342869/) (`pubmed-observation-pmid-42342869-2026-07-27-35a3f8af2df5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42342869." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42342869-liraglutide-v1 SHA-256: 571c300fbe92e1d54205c1a46df96873ba8a1f5a87998d00da3ee6c65b443f16.

---

<a id="pubmed-pmid-42356253-liraglutide-v1"></a>

## PubMed record PMID 42356253

> PeptideScanner retained PubMed bibliographic metadata for PMID 42356253 at 2026-08-10T18:13:53.759Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42356253-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42356253-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42356253-liraglutide-v1
- Content SHA-256: `05644ce1d4531e185f2f9cb86fef592015d62142ef10402ee0fd315c2da9fd5d`

### Claims and source pins

#### Headline

PubMed record PMID 42356253 ([`pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9`](#source-pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42356253 at 2026-08-10T18:13:53.759Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9`](#source-pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42356253 at 2026-08-10T18:13:53.759Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9`](#source-pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9`](#source-pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9))

### Sources

<a id="source-pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9"></a>
- **PubMed record PMID 42356253 · retained source version 1:2026-07-26:current:975f1ec2e9c9d7463721d3f79f6b7f08e6646b2fc72ed193d99a9c241e39dfb8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42356253/) (`pubmed-observation-pmid-42356253-2026-07-26-975f1ec2e9c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42356253." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42356253-liraglutide-v1 SHA-256: 05644ce1d4531e185f2f9cb86fef592015d62142ef10402ee0fd315c2da9fd5d.

---

<a id="pubmed-pmid-42385677-liraglutide-v1"></a>

## PubMed record PMID 42385677

> PeptideScanner retained PubMed bibliographic metadata for PMID 42385677 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42385677-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42385677-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42385677-liraglutide-v1
- Content SHA-256: `d0a09e5ba54fe82a94b76f0adf311419880e2766e3601c6bf49b83de11440a46`

### Claims and source pins

#### Headline

PubMed record PMID 42385677 ([`pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2`](#source-pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42385677 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2`](#source-pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42385677 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2`](#source-pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2`](#source-pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2))

### Sources

<a id="source-pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2"></a>
- **PubMed record PMID 42385677 · retained source version 1:2026-07-01:current:1e32efd9e5b20e126d0b2cdcfd1510580a4f73465dffb0f4a001d1ef3a17d76c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42385677/) (`pubmed-observation-pmid-42385677-2026-07-01-1e32efd9e5b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42385677." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42385677-liraglutide-v1 SHA-256: d0a09e5ba54fe82a94b76f0adf311419880e2766e3601c6bf49b83de11440a46.

---

<a id="pubmed-pmid-42392029-liraglutide-v1"></a>

## PubMed record PMID 42392029

> PeptideScanner retained PubMed bibliographic metadata for PMID 42392029 at 2026-08-10T18:13:53.799Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42392029-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42392029-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42392029-liraglutide-v1
- Content SHA-256: `953668b017a5a3f5891a1a3d73e71952170fe43b5e211906e14272e45aa7f8b7`

### Claims and source pins

#### Headline

PubMed record PMID 42392029 ([`pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a`](#source-pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42392029 at 2026-08-10T18:13:53.799Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a`](#source-pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42392029 at 2026-08-10T18:13:53.799Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a`](#source-pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a`](#source-pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a))

### Sources

<a id="source-pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a"></a>
- **PubMed record PMID 42392029 · retained source version 1:2026-07-21:current:eae3686f301adda57b73e60438b2d4b4b758fb35695d210e4f1f0550e3b41ffe** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42392029/) (`pubmed-observation-pmid-42392029-2026-07-21-eae3686f301a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42392029." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42392029-liraglutide-v1 SHA-256: 953668b017a5a3f5891a1a3d73e71952170fe43b5e211906e14272e45aa7f8b7.

---

<a id="pubmed-pmid-42394413-liraglutide-v1"></a>

## PubMed record PMID 42394413

> PeptideScanner retained PubMed bibliographic metadata for PMID 42394413 at 2026-08-10T18:13:53.810Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42394413-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42394413-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42394413-liraglutide-v1
- Content SHA-256: `cc855e2a1b0807903af05d3cf4b85a3d1639dd0e797265ace8a394e64a9172f9`

### Claims and source pins

#### Headline

PubMed record PMID 42394413 ([`pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a`](#source-pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42394413 at 2026-08-10T18:13:53.810Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a`](#source-pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42394413 at 2026-08-10T18:13:53.810Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a`](#source-pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a`](#source-pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a))

### Sources

<a id="source-pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a"></a>
- **PubMed record PMID 42394413 · retained source version 1:2026-07-26:current:071fb5332e2afb4007c94ae20373dfb3b9fc4298037d5d7f4f53e305bb25a88c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42394413/) (`pubmed-observation-pmid-42394413-2026-07-26-071fb5332e2a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42394413." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42394413-liraglutide-v1 SHA-256: cc855e2a1b0807903af05d3cf4b85a3d1639dd0e797265ace8a394e64a9172f9.

---

<a id="pubmed-pmid-42442575-liraglutide-v1"></a>

## Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio.

> PubMed lists PMID 42442575 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-07-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42442575-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-15
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42442575-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42442575-liraglutide-v1
- Content SHA-256: `8a0b86ecd0cb96a53ad4ae305437c119565325e1baeeb961e96d61e89c76a97d`

### Claims and source pins

#### Headline

Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. ([`pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93`](#source-pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93))

#### Summary

PubMed lists PMID 42442575 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-07-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93`](#source-pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93))

#### Paragraph 1

PubMed lists PMID 42442575 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-07-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93`](#source-pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93`](#source-pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93))

### Sources

<a id="source-pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93"></a>
- **Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. · retained source version 1:2026-07-15:current:62c411f64b93d33e42e64e175fc976474665bc983474a79f68d980e71ff05591** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42442575/) (`pubmed-observation-pmid-42442575-2026-07-15-62c411f64b93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42442575-liraglutide-v1 SHA-256: 8a0b86ecd0cb96a53ad4ae305437c119565325e1baeeb961e96d61e89c76a97d.

---

<a id="pubmed-pmid-42446801-liraglutide-v1"></a>

## PubMed record PMID 42446801

> PeptideScanner retained PubMed bibliographic metadata for PMID 42446801 at 2026-08-10T10:49:10.767Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42446801-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42446801-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42446801-liraglutide-v1
- Content SHA-256: `e442ad903c1c539d90b84db00adeec1c0b9cf0cebd467b68c360dd30c9d127f2`

### Claims and source pins

#### Headline

PubMed record PMID 42446801 ([`pubmed-observation-pmid-42446801-2026-08-02-63be31993aee`](#source-pubmed-observation-pmid-42446801-2026-08-02-63be31993aee))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42446801 at 2026-08-10T10:49:10.767Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42446801-2026-08-02-63be31993aee`](#source-pubmed-observation-pmid-42446801-2026-08-02-63be31993aee))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42446801 at 2026-08-10T10:49:10.767Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42446801-2026-08-02-63be31993aee`](#source-pubmed-observation-pmid-42446801-2026-08-02-63be31993aee))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42446801-2026-08-02-63be31993aee`](#source-pubmed-observation-pmid-42446801-2026-08-02-63be31993aee))

### Sources

<a id="source-pubmed-observation-pmid-42446801-2026-08-02-63be31993aee"></a>
- **PubMed record PMID 42446801 · retained source version 1:2026-08-02:current:63be31993aee8c3edff6739ffa012262157b6ad9c7fb84f8d79ac1e19ea4d746** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42446801/) (`pubmed-observation-pmid-42446801-2026-08-02-63be31993aee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42446801." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42446801-liraglutide-v1 SHA-256: e442ad903c1c539d90b84db00adeec1c0b9cf0cebd467b68c360dd30c9d127f2.

---

<a id="pubmed-pmid-42470452-liraglutide-v1"></a>

## PubMed record PMID 42470452

> PeptideScanner retained PubMed bibliographic metadata for PMID 42470452 at 2026-08-10T18:13:56.686Z. PubMed recorded a metadata revision date of 2026-07-18 and an Entrez history date of 2026-07-18. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42470452-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-18
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42470452-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42470452-liraglutide-v1
- Content SHA-256: `f7a32bae9300c34465c59fcc5441346bc39e0c77966dbc28e54999f38a5ba744`

### Claims and source pins

#### Headline

PubMed record PMID 42470452 ([`pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae`](#source-pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42470452 at 2026-08-10T18:13:56.686Z. PubMed recorded a metadata revision date of 2026-07-18 and an Entrez history date of 2026-07-18. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae`](#source-pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42470452 at 2026-08-10T18:13:56.686Z. PubMed recorded a metadata revision date of 2026-07-18 and an Entrez history date of 2026-07-18. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae`](#source-pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae`](#source-pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae))

### Sources

<a id="source-pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae"></a>
- **PubMed record PMID 42470452 · retained source version 1:2026-07-18:current:49e021a113aeaf9d25e1ade7a8642354cbf3623e621be00cccb048d6107d4c5c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42470452/) (`pubmed-observation-pmid-42470452-2026-07-18-49e021a113ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42470452." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42470452-liraglutide-v1 SHA-256: f7a32bae9300c34465c59fcc5441346bc39e0c77966dbc28e54999f38a5ba744.

---

<a id="pubmed-pmid-42491030-liraglutide-v1"></a>

## PubMed record PMID 42491030

> PeptideScanner retained PubMed bibliographic metadata for PMID 42491030 at 2026-08-10T18:13:56.726Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42491030-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-23
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42491030-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42491030-liraglutide-v1
- Content SHA-256: `5a3423a2d8b177ed1ae61e5ef3edca4e1e096ac1cb519da5ab5db2c17c0f6a2d`

### Claims and source pins

#### Headline

PubMed record PMID 42491030 ([`pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65`](#source-pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42491030 at 2026-08-10T18:13:56.726Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65`](#source-pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42491030 at 2026-08-10T18:13:56.726Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65`](#source-pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65`](#source-pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65))

### Sources

<a id="source-pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65"></a>
- **PubMed record PMID 42491030 · retained source version 1:2026-07-23:current:2164f671bb659d8d50111b5e28a5788ac7c7528f9a50139675aac999d2ae4b18** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42491030/) (`pubmed-observation-pmid-42491030-2026-07-23-2164f671bb65`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42491030." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42491030-liraglutide-v1 SHA-256: 5a3423a2d8b177ed1ae61e5ef3edca4e1e096ac1cb519da5ab5db2c17c0f6a2d.

---

<a id="pubmed-pmid-42500463-liraglutide-v1"></a>

## PubMed record PMID 42500463

> PeptideScanner retained PubMed bibliographic metadata for PMID 42500463 at 2026-08-10T18:13:56.748Z. PubMed recorded a metadata revision date of 2026-07-25 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42500463-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-25
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42500463-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42500463-liraglutide-v1
- Content SHA-256: `0035dbdfcadd2f6914fcef135f4471f8fce4f01cfdaf89541dcfd835fe48af3b`

### Claims and source pins

#### Headline

PubMed record PMID 42500463 ([`pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58`](#source-pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42500463 at 2026-08-10T18:13:56.748Z. PubMed recorded a metadata revision date of 2026-07-25 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58`](#source-pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42500463 at 2026-08-10T18:13:56.748Z. PubMed recorded a metadata revision date of 2026-07-25 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58`](#source-pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58`](#source-pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58))

### Sources

<a id="source-pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58"></a>
- **PubMed record PMID 42500463 · retained source version 1:2026-07-25:current:473d638e5d58c10056c483daf4d1157b8d00e7b3502e32a8a3c66974a1c5e2dd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42500463/) (`pubmed-observation-pmid-42500463-2026-07-25-473d638e5d58`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42500463." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42500463-liraglutide-v1 SHA-256: 0035dbdfcadd2f6914fcef135f4471f8fce4f01cfdaf89541dcfd835fe48af3b.

---

<a id="pubmed-pmid-42507607-liraglutide-v1"></a>

## PubMed record PMID 42507607

> PeptideScanner retained PubMed bibliographic metadata for PMID 42507607 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42507607-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42507607-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42507607-liraglutide-v1
- Content SHA-256: `3811833aad538762d61e88d52bbec8333bac4830c678a372aebb0e0b0b00412f`

### Claims and source pins

#### Headline

PubMed record PMID 42507607 ([`pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00`](#source-pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42507607 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00`](#source-pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42507607 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00`](#source-pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00`](#source-pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00))

### Sources

<a id="source-pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00"></a>
- **PubMed record PMID 42507607 · retained source version 1:2026-07-27:current:6d1d5472ca006494480bede38e45cc2f25a310c7754ab28665b93ae83244396b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42507607/) (`pubmed-observation-pmid-42507607-2026-07-27-6d1d5472ca00`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42507607." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42507607-liraglutide-v1 SHA-256: 3811833aad538762d61e88d52bbec8333bac4830c678a372aebb0e0b0b00412f.

---

<a id="pubmed-pmid-42538646-liraglutide-v1"></a>

## PubMed record PMID 42538646

> PeptideScanner retained PubMed bibliographic metadata for PMID 42538646 at 2026-08-10T10:49:12.953Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42538646-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42538646-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42538646-liraglutide-v1
- Content SHA-256: `b7bfddca013ba752e83fceb896d7a0823f33c20388df732843472b0f51641732`

### Claims and source pins

#### Headline

PubMed record PMID 42538646 ([`pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197`](#source-pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42538646 at 2026-08-10T10:49:12.953Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197`](#source-pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42538646 at 2026-08-10T10:49:12.953Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197`](#source-pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197`](#source-pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197))

### Sources

<a id="source-pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197"></a>
- **PubMed record PMID 42538646 · retained source version 1:2026-08-03:current:255f42d6f19711edd00d91f91bca3df60ac0623765815cac2b7a294c870c5136** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42538646/) (`pubmed-observation-pmid-42538646-2026-08-03-255f42d6f197`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42538646." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42538646-liraglutide-v1 SHA-256: b7bfddca013ba752e83fceb896d7a0823f33c20388df732843472b0f51641732.

---

<a id="pubmed-pmid-42545022-liraglutide-v1"></a>

## PubMed record PMID 42545022

> PeptideScanner retained PubMed bibliographic metadata for PMID 42545022 at 2026-08-10T10:49:12.969Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42545022-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42545022-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42545022-liraglutide-v1
- Content SHA-256: `a936dfea0b0b25cc4ac2c01ea2ecf6c85e282babbec85d1794c9a516b7ec6a24`

### Claims and source pins

#### Headline

PubMed record PMID 42545022 ([`pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0`](#source-pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42545022 at 2026-08-10T10:49:12.969Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0`](#source-pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42545022 at 2026-08-10T10:49:12.969Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0`](#source-pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0`](#source-pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0))

### Sources

<a id="source-pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0"></a>
- **PubMed record PMID 42545022 · retained source version 1:2026-08-03:current:48c55f6708b05b3d38cc442bf91234795542748f880c40c44cadd74fbb831e40** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42545022/) (`pubmed-observation-pmid-42545022-2026-08-03-48c55f6708b0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42545022." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42545022-liraglutide-v1 SHA-256: a936dfea0b0b25cc4ac2c01ea2ecf6c85e282babbec85d1794c9a516b7ec6a24.

---

<a id="pubmed-pmid-42549609-liraglutide-v1"></a>

## PubMed record PMID 42549609

> PeptideScanner retained PubMed bibliographic metadata for PMID 42549609 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42549609-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42549609-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42549609-liraglutide-v1
- Content SHA-256: `48debc1d01ed2a9ac4acdf315cf9c30304857e1a639fbaf6a7d2937f640239a2`

### Claims and source pins

#### Headline

PubMed record PMID 42549609 ([`pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6`](#source-pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42549609 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6`](#source-pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42549609 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6`](#source-pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6`](#source-pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6))

### Sources

<a id="source-pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6"></a>
- **PubMed record PMID 42549609 · retained source version 1:2026-08-06:current:84c70ac4a1a65120b6db04702d5696fb108fc0aada3a9f09af77fb589c8b4fff** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42549609/) (`pubmed-observation-pmid-42549609-2026-08-06-84c70ac4a1a6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42549609." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42549609-liraglutide-v1 SHA-256: 48debc1d01ed2a9ac4acdf315cf9c30304857e1a639fbaf6a7d2937f640239a2.

---

<a id="pubmed-pmid-42597211-liraglutide-v1"></a>

## Treatment of obesity with liraglutide in bipolar disorder: a case report.

> PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42597211-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-14
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42597211-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42597211-liraglutide-v1
- Content SHA-256: `a3c4d647e514438b0eb48a602a7c479be1adb1f1b1ad8eb3b1268b7f99d14310`

### Claims and source pins

#### Headline

Treatment of obesity with liraglutide in bipolar disorder: a case report. ([`pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3`](#source-pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3))

#### Summary

PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3`](#source-pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3))

#### Paragraph 1

PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3`](#source-pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3`](#source-pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3))

### Sources

<a id="source-pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3"></a>
- **Treatment of obesity with liraglutide in bipolar disorder: a case report. · retained source version 1:2026-08-14:current:8b4f4fd804b3ae70a564195d7a0c065bcfa0d6d6e07a9d699602764f72d5b2bd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42597211/) (`pubmed-observation-pmid-42597211-2026-08-14-8b4f4fd804b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of obesity with liraglutide in bipolar disorder: a case report." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42597211-liraglutide-v1 SHA-256: a3c4d647e514438b0eb48a602a7c479be1adb1f1b1ad8eb3b1268b7f99d14310.

---

<a id="pubmed-pmid-42708757-liraglutide-v1"></a>

## Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.

> PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42708757-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-08
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42708757-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42708757-liraglutide-v1
- Content SHA-256: `a2d5f3ddbac80ed4d5c51cf4642c1393becc48b42ae9c26b390091f05fe3f3f8`

### Claims and source pins

#### Headline

Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c))

#### Summary

PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c))

#### Paragraph 1

PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c))

### Sources

<a id="source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c"></a>
- **Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. · retained source version 1:2026-09-08:current:e64e298b159c447ce0472b3b62186d2af017cd709de6aa78faf5179bf245268b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42708757/) (`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42708757-liraglutide-v1 SHA-256: a2d5f3ddbac80ed4d5c51cf4642c1393becc48b42ae9c26b390091f05fe3f3f8.

---

<a id="pubmed-pmid-42708757-liraglutide-v2"></a>

## Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.

> PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42708757-liraglutide:v2`
- Evidence domain: Literature metadata
- Date in source: 2026-09-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42708757-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42708757-liraglutide-v2
- Content SHA-256: `4e7f5670cd311afbc594b5dcbcd9345e9f85b94aa702147459ee0843f5137879`

### Claims and source pins

#### Headline

Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2))

#### Summary

PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2))

#### Paragraph 1

PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2))

### Sources

<a id="source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2"></a>
- **Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. · retained source version 1:2026-09-11:current:a4405118e69c18fd7676a5adc73926cd72749635bf29479ba78bd1275d2c9098** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42708757/) (`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2`)

### Correction lineage

updated on 2026-11-16: PubMed revised the bibliographic metadata of PMID 42708757, with a metadata revision date of 2026-09-11. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2`](#source-pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2)

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42708757-liraglutide-v2 SHA-256: 4e7f5670cd311afbc594b5dcbcd9345e9f85b94aa702147459ee0843f5137879.

---

<a id="pubmed-pmid-42723672-liraglutide-v1"></a>

## Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.

> PubMed lists PMID 42723672 in F1000Research as Journal Article, Review, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42723672-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42723672-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42723672-liraglutide-v1
- Content SHA-256: `2a74bc773e8346e43c3162fae0efeb3ccbe781f6fc32be5aaead7b8c455de416`

### Claims and source pins

#### Headline

Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence. ([`pubmed-observation-pmid-42723672-2026-09-12-254709a8d378`](#source-pubmed-observation-pmid-42723672-2026-09-12-254709a8d378))

#### Summary

PubMed lists PMID 42723672 in F1000Research as Journal Article, Review, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42723672-2026-09-12-254709a8d378`](#source-pubmed-observation-pmid-42723672-2026-09-12-254709a8d378))

#### Paragraph 1

PubMed lists PMID 42723672 in F1000Research as Journal Article, Review, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42723672-2026-09-12-254709a8d378`](#source-pubmed-observation-pmid-42723672-2026-09-12-254709a8d378))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42723672-2026-09-12-254709a8d378`](#source-pubmed-observation-pmid-42723672-2026-09-12-254709a8d378))

### Sources

<a id="source-pubmed-observation-pmid-42723672-2026-09-12-254709a8d378"></a>
- **Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence. · retained source version 1:2026-09-12:current:254709a8d37878eaaaaac4170c327ef18852d08634032232516965f9b259a11e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42723672/) (`pubmed-observation-pmid-42723672-2026-09-12-254709a8d378`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42723672-liraglutide-v1 SHA-256: 2a74bc773e8346e43c3162fae0efeb3ccbe781f6fc32be5aaead7b8c455de416.

---

<a id="pubmed-pmid-42762462-liraglutide-v1"></a>

## Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.

> PubMed lists PMID 42762462 in Endocrinology, diabetes & metabolism as Journal Article, Multicenter Study, with publication-date metadata of 2026-09 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42762462-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-23
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42762462-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42762462-liraglutide-v1
- Content SHA-256: `1a8a04e07069b1d93e4b072b6e5d1797d46d6e2ebd7057f631ca2d9ba14307d7`

### Claims and source pins

#### Headline

Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan. ([`pubmed-observation-pmid-42762462-2026-09-23-91f134f20722`](#source-pubmed-observation-pmid-42762462-2026-09-23-91f134f20722))

#### Summary

PubMed lists PMID 42762462 in Endocrinology, diabetes & metabolism as Journal Article, Multicenter Study, with publication-date metadata of 2026-09 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42762462-2026-09-23-91f134f20722`](#source-pubmed-observation-pmid-42762462-2026-09-23-91f134f20722))

#### Paragraph 1

PubMed lists PMID 42762462 in Endocrinology, diabetes & metabolism as Journal Article, Multicenter Study, with publication-date metadata of 2026-09 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42762462-2026-09-23-91f134f20722`](#source-pubmed-observation-pmid-42762462-2026-09-23-91f134f20722))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42762462-2026-09-23-91f134f20722`](#source-pubmed-observation-pmid-42762462-2026-09-23-91f134f20722))

### Sources

<a id="source-pubmed-observation-pmid-42762462-2026-09-23-91f134f20722"></a>
- **Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan. · retained source version 1:2026-09-23:current:91f134f20722b2335e384dcb605ca99455ecdfa0ae54e33544a0b25b0bacb04d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42762462/) (`pubmed-observation-pmid-42762462-2026-09-23-91f134f20722`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42762462-liraglutide-v1 SHA-256: 1a8a04e07069b1d93e4b072b6e5d1797d46d6e2ebd7057f631ca2d9ba14307d7.

---

<a id="pubmed-pmid-42891862-liraglutide-v1"></a>

## Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.

> PubMed lists PMID 42891862 in Cardiovascular drugs and therapy as Letter, with publication-date metadata of 2026-10-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42891862-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-18
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42891862-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42891862-liraglutide-v1
- Content SHA-256: `db0c51504c770f0c98a3471dcd0f81b47db04f7306cb8d381a420c7210ce7b7a`

### Claims and source pins

#### Headline

Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism. ([`pubmed-observation-pmid-42891862-2026-10-18-48555e396c17`](#source-pubmed-observation-pmid-42891862-2026-10-18-48555e396c17))

#### Summary

PubMed lists PMID 42891862 in Cardiovascular drugs and therapy as Letter, with publication-date metadata of 2026-10-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42891862-2026-10-18-48555e396c17`](#source-pubmed-observation-pmid-42891862-2026-10-18-48555e396c17))

#### Paragraph 1

PubMed lists PMID 42891862 in Cardiovascular drugs and therapy as Letter, with publication-date metadata of 2026-10-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42891862-2026-10-18-48555e396c17`](#source-pubmed-observation-pmid-42891862-2026-10-18-48555e396c17))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42891862-2026-10-18-48555e396c17`](#source-pubmed-observation-pmid-42891862-2026-10-18-48555e396c17))

### Sources

<a id="source-pubmed-observation-pmid-42891862-2026-10-18-48555e396c17"></a>
- **Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism. · retained source version 1:2026-10-18:current:48555e396c177bead4fa78434a134e69b539884ee99dc21cb75f1752d16a406d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42891862/) (`pubmed-observation-pmid-42891862-2026-10-18-48555e396c17`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/liraglutide.json#pubmed-pmid-42891862-liraglutide-v1 SHA-256: db0c51504c770f0c98a3471dcd0f81b47db04f7306cb8d381a420c7210ce7b7a.

